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ABSTRACT 
 Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu 
opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer 
negative side-effects (respiratory depression, constipation, tolerance, and dependence).  The 
KOP receptor has also been implicated in several abuse-related effects in the central nervous 
system (CNS).  KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP 
agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate 
the self-administration of cocaine in a variety of species, and KOP antagonists have potential in 
the treatment of relapse.  One drawback of current opioid ligand investigation is that many 
compounds are based on the morphine scaffold and thus have similar properties, both positive 
and negative, to the parent molecule.  Thus there is increasing need to discover new chemical 
scaffolds with opioid receptor activity. 
 The flavonoid class of natural products has been identified as a potential source of novel 
opioid ligands.  In particular, dioclein (86) and dioflorin (87) have been reported to have an 
antinociceptive effect in rodent models of pain, although there has been no in vitro 
pharmacological evaluation to date.  Dioclein and several simplified analogs of dioflorin were 
synthesized in order to develop structure activity relationships (SAR) for the flavonoid scaffold 
at opioid receptors.  The analogs were pharmacologically evaluated in several cell-based assays 
(radioligand binding, fluorescent calcium mobilization, and luminescent PathHunter™ -
arrestin) and found to be inactive at both opioid and cannabinoid receptors. 
 The novel KOP receptor agonist and neoclerodane diterpene salvinorin A was also 
investigated.  Salvinorin A is the main active component of the hallucinogenic plant Salvia 
iv 
 
divinorum and is the first opioid ligand reported that lacks a basic nitrogen atom in the structure. 
Ether analogs at the C-2 position of salvinorin A have been reported to have improved affinity 
and potency over the parent molecule.  As alkyl chain ethers have a high degree of flexibility and 
the oxygen atom may allow for extra hydrogen bonding interactions in the receptor, 
modifications were made at the C-2 position in order to develop analogs to elucidate the 
molecular basis for this improved affinity and potency.  Tetrahydropyranyl ether 220, ether 223a, 
and methyltetrahydropyranyl ether 231 were found to have similar KOP affinity and potency to 
salvinorin A in radioligand binding, [35S]GTP--S functional, and fluorescent calcium 
mobilization assays.  Tetrahydropyranyl ether 220 was further evaluated for its effects on the 
cocaine-primed reinstatement of extinguished cocaine self-administration in rats; 220 (1 mg/kg) 
was found to attenuate cocaine self-administration comparably to salvinorin A (0.3 mg/kg), 
previously reported to be effective in this animal model.  This represents the first report of a 
salvinorin A derivative with demonstrated anti-addictive capability. 
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CHAPTER 1: INTRODUCTION 
A Historical Perspective on Natural Products and Traditional Medicine 
 Throughout recorded history, humans have consumed natural products for medicinal, 
spiritual, and recreational purposes.  In fact, several prominent ancient civilizations developed 
extensive ethnomedicinal traditions.  Documents in the form of cuneiform clay tablets that date 
to 668–626 BC indicate that the ancient Mesopotamian pharmacopeia included approximately 
250 medicines of plant origin and 120 of mineral origin.1  Additionally, many of these cuneiform 
tablets are actually copies of much older texts from 3000–2000 BC.  The Rigveda sacred text 
from ancient India contains multiple references to a plant derived inebriant called soma that was 
used ritualistically.2-3 The practice of Chinese traditional medicine began as early as 4,000 years 
ago with the Shang dynasty.4  Perhaps the best known Chinese traditional ethnomedicinals are 
ginseng and ephedra, which have been in use for thousands of years and are still in current use to 
treat a rather large variety of ailments from incontinence to asthma.  A number of ancient 
Chinese traditional drug formularies still exist, detailing more than 10,000 medicinal substances 
as well as common drug formulations.4  In pre–Columbian Central America, the Toltecs 
recorded their ritualistic use of two mind-altering natural substances known to them as 
teonanácatl and the more familiar peyote.5 Finally, a well-known documented example of 
medicinal natural products is De materia medica, a detailed record of the medicinal uses of 
hundreds of plants throughout the then “known world,” written in his native Greek by 
Dioscorides, a military physician under the Roman Empire during the 1st century AD.6 The five 
volume codex was one of very few classical works that did not fall out of circulation between the 
decline of the Roman Empire (5th century AD) and the Renaissance (14th century AD), and 
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continued to be the primary authority for pharmacology, medicine, and herbal writing until the 
16th century AD.   
Although modern medicine has changed the face of healthcare for many people, currently 
the World Health Organization (WHO) estimates that in some developing countries as much as 
80% of the population still depends on traditional medicine as the primary form of healthcare.7  
Even in some developed nations, 70% to 80% of the population has used some form of 
traditional medicine.  In a survey conducted by the Centers for Disease Control and Prevention 
(CDC) in 2007, 17.7% of adult respondents reported using nonvitamin, nonmineral natural 
products, such as fish oil, glucosamine, echinacea, or ginseng, as part of a 
complementary/alternative medicine (CAM) regime to promote overall health.8 
Natural Products and Modern Medicine 
Using current terminology and definitions, the phrase “natural products” typically refers 
to secondary metabolites that are produced by organisms in response to external changes in their 
environment from nutrient deficiencies, infection, competition, etc.9  Historically, natural 
products have been used therapeutically by humans in the form of crude extracts.10 For example, 
extracts of willow bark, Salix alba L. (Salicaceae), were used by the ancient Egyptians to treat 
inflammation.11  However, it was not until 1897 while working for Friedrich Bayer & Co. that 
Felix Hoffmann synthesized acetylsalicylic acid from the salicylic acid isolated from willow 
bark, thus creating aspirin.12-13  Similarly, extracts of the opium poppy, Papaver somniferum L. 
(Papaveraceae), were used to treat pain and induce sleep throughout the 19th century and for 
millennia prior.14-16  The principle agent responsible for the effects of the opium poppy, 
morphine, was isolated by Surtürner in the first decade of the 19th century.  However, the correct 
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structure for morphine was not proposed until 1925, by Gulland and Robinson,17-19 and their 
proposal was not confirmed until 1953 when the total synthesis was published by Gates and 
Tschudi.20-21  Although the discoveries of morphine from opium poppies, aspirin from willow 
bark, and penicillin from mold (1928) occurred during the 19th and 20th centuries, these dates 
belie the millennia of ethnomedicinal use that inspired scientific investigation.  The use of these 
natural products as single chemical entities rather than as extracts created the modern 
pharmaceutical industry.9, 13  From 2000–2010, natural products or their semi-synthetic 
derivatives made up approximately one third of all small molecule new chemical entity (NCE) 
applications filed.22  In 2010 alone, 50% of the 20 small molecule NCE applications filed were 
natural products. 
Arguably, one of the most important medical advances made in the 20th century is the 
discovery of antibacterial agents that could be systemically administered (Figure 1).23  The story 
of the discovery of the antibacterial penicillin by Sir Alexander Flemming in 1928 is well-
known.24  It was over a decade before penicillin was introduced into the clinic in 1941, and 
following its success, a large number of penicillins (1), cephalosporins (2), aminoglycosides like 
streptomycin (3)25, chloramphenicol (4)25, tetracycline (5)26, macrolides like erythromycin (6)27, 
and glycopeptides like vancomycin (7) (all natural products or natural product derivatives) were 
introduced into clinical practice.23  In 1900, pneumonia, tuberculosis, diarrhea/enteritis, and 
diphtheria caused one third of all deaths in the United States.28  In 1997, just 4.5% of all deaths 
could be attributed to infectious diseases, and life-expectancy had increased by 29.2 years. 
Nearly a century of research has provided a wide variety of natural product antibacterial agents, 
and new products continue to be produced.  Just from 1981 through 2010, 104 new antibacterial 
agents were introduced, and of these, just under 75% are natural products.22 
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Another area of medicine for which natural products have been a boon is cancer 
chemotherapy (Figure 2).  Of the 175 approved small molecule anti-cancer agents world-wide, 
131 (75%) were derived from research into natural products.22  The first small molecules to be 
used clinically against cancer were the vinca alkaloids, the natural products vinblastine (8) and  
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vincristine (9), isolated from the Madagascar periwinkle, Catharanthus roseus G. Don 
(Apocynaceae), in 1958 and 1961, respectively.29-30  These agents are still in current clinical use, 
primarily as part of combination therapies to treat a variety of cancers.  Podophyllotoxin (10) 
was isolated from the Mayapple, Podophyllum peltatum L. (Podophyllaceae) in 1880,31-32 
however the structure was not determined until 1951.33  Extensive attempts to optimize the 
efficacy and toxicity profiles of podophyllotoxin led to two clinically useful semisynthetic 
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derivatives, etoposide (11) and teniposide (12).31-32  Another addition to the arsenal of anti-
cancer agents is camptothecin (13), isolated from the Chinese ornamental tree, Camptotheca 
acuminate Decne (Nyssaceae).34  This agent was dropped from clinical trials in the 1970s due to 
unacceptable toxicity,32 but continued attempts to optimize the scaffold produced topotecan35 
(14) and irinotecan36 (15) in the early 1990s.  Finally, one of the most important classes of anti-
cancer agents is the taxanes.  Paclitaxel (16), known by the trade name Taxol®, was initially 
isolated from the bark of the Pacific Yew tree, Taxus brevifolia Nutt. (Taxaceae), in 1971.37  
Despite intense interest and promising anti-cancer capabilities, paclitaxel and its semisynthetic 
derivative docetaxel (17) were beset by supply problems and were not able to enter clinical usage 
until the early 1990s.31-32  These agents are still in current clinical use against a variety of 
cancers.  Additionally there are currently 23 members of the taxane structural class in preclinical 
development as potential cancer chemotherapeutics.32 
Although in the United States rapid progress in medical interventions against bacterial 
infection has resulted in decreased deaths due to infectious disease and an increase in life 
expectancy, malaria, a parasitic infection, remains one of the most significant health issues faced 
worldwide, with 250 million cases and over 800,000 deaths annually.38  Symptoms of malaria-
like disease are found in the Nei Ching (The Canon of Medicine), a document from China dated 
to 2700 BC, as well as in other ancient texts.39 The history of antimalarial chemotherapy can be 
traced to herbal medicinal products (Figure 3).  Quinine (18), a natural product and the first 
single chemical entity antimalarial treatment, was isolated and purified from cinchona tree bark, 
Cinchona succiruba L. (Rubiaceae), in 1820.38  The use of the plant source itself against malaria, 
however, had been known for centuries.39-40  Attempts to produce quinine synthetically led to the 
development of the classical 4-aminoquinolines, such as chloroquine (19), which have been  
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mainstays of antimalarial chemotherapy through the last century.38 In 1972, artemisinin (20) was 
isolated from Artemisia annua L. (Asteraceae) as the result of research efforts to find new 
treatments to combat the malaria parasite’s developing resistance to chloroquine and similar 
drugs.41  The unusual endoperoxide motif of artemisinin has inspired the production of many 
fully synthetic analogs with tailored pharmacokinetic and pharmacodynamic properties that are 
currently in clinical development.38, 42  However, artemisinin-resistant strains of malaria already 
exist, and the continual threat of such drug resistance means that it is likely that it will always be 
necessary to continue the search for new molecular scaffolds. 
Finally pain is currently, and likely always has been, one of the most common reasons 
that individuals seek medical intervention.43  As previously stated, the use of salicylic acid (21), 
a natural product, can be traced back to ancient Egypt where extracts of willow bark were used to 
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treat pain and inflammation (Figure 3).11, 44  Since then, one significant landmark in the history 
of medicine was the discovery of aspirin (22), or acetylsalicylic acid, which alone stimulated the 
development of an entire family of drugs known as the non-steroidal anti-inflammatory drugs 
(NSAIDs).11  Aspirin was first synthesized in the pharmaceutical laboratory of the German dye 
manufacturer Friedrich Bayer & Co. in 1897 in an effort to produce pain medication that lacked 
the negative side effects of both morphine and salicylate salts.12  NSAIDs such as aspirin, 
acetaminophen (23), ibuprofen (24), and naproxen (25), all three instigated by natural product 
investigation, have been invaluable drugs for the treatment of pain, inflammation, and fever. 
Opioids: Natural Products used in Modern Medicine 
Another family of drugs commonly prescribed for the treatment of pain is the opioid 
analgesics; morphine (26) is a member of this family (Figure 4).  The term “analgesia” refers to a 
drug’s ability to diminish pain.43  Drugs that accomplish this are called analgesics, analgetics, or 
antinociceptives.  In the modern clinical setting, NSAIDs are generally used as an initial 
treatment for mild to moderate pain, but an opioid analgesic may be added if pain persists; if pain 
progresses from moderate to severe, an opioid may be used as the sole treatment.16  However, as 
previously stated, opioids in the form of extracts from the opium poppy have been used for 
millennia for the treatment of pain.  One of the earliest written references to the medicinal use of 
such extracts is from the Eber Papyrus dated to 1552 BC, which describes the Egyptian goddess 
Isis giving the juice of the poppy to the sun god Ra to treat his headache.45 
Use of opioid analgesics to treat cancer pain and severe, chronic non-cancer pain 
continues to be a controversial practice in medicine.16, 45  In the 1960s physicians actually 
attempted to discontinue opioid use to treat chronic pain.45  In the 1970s, the work of researchers  
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at Sloan-Kettering in New York and St. Christopher’s Hospice in London re-established opioid 
analgesics as an important part of treatment plans for patients suffering from cancer pain.45  In 
2009, the American Geriatric Society (AGS) published clinical practice guidelines 
recommending that patients with moderate to severe pain and diminished quality of life be 
considered for chronic opioid therapy.46  Also in 2009, Chou et al., in conjunction with the 
American Pain Society and the American Academy of Pain, concluded that opioid therapy 
should be used for patients with chronic, non-cancer pain under careful supervision.47 
The controversy over the chronic use of opioids analgesics stems from the fact that their 
use includes the risk of several clinically important and potentially severe side-effects, namely 
respiratory depression, constipation, tolerance, and dependence.14-16  Even so, opioid analgesics 
are a mainstay of prescription drug therapy for the treatment of pain.  The most common 
clinically used opioids are morphine, codeine (27), hydromorphone (28), oxycodone (29), 
meperidine (30), fentanyl (31), methadone (32), and until recently, propoxyphene (33), which 
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was withdrawn from the U.S. market in November 2010 due to patient deaths associated with 
cadiotoxicity (Figure 4).16, 48 
Identification of the Opioid Receptors 
The opioid drugs exert their effects through the opioid receptors of which there are three 
types:  (MOP), named for its best known agonist, morphine;  (KOP) named for the agonist 
first used to characterize it, ketocyclazocine (34); and  (DOP), named for the mouse vas 
deferens tissue preparation.49  Although it was not until the 1990’s that these individual receptor 
types were cloned and characterized, the concept of specific receptors for opioid compounds was 
first detailed by Beckett and Casy as early as 1954.50  In 1971, Goldstein et al. proposed that 
radiolabeled compounds could be used to interrogate the existence of these receptors as well as 
characterize them.51  Following this hypothesis, three different research groups simultaneously 
and independently demonstrated the existence of stereospecific opioid binding sites in 
mammalian brain.52-54  The first convincing evidence of multiple types of opioid receptors came 
from Martin et al. in 1976.55 They observed behavioral and neurophysiological differences in the 
chronic spinal dog model that led them to propose the existence of three different types of opioid 
receptors.  In 1977, Lord et al. observed differences in rank order potency of opioid compounds 
between electrically induced twitches of guinea pig ileum and mouse vas deferens tissue, 
bolstering the hypothesis of multiple opioid receptor types.56  
While researchers were teasing out the pharmacological differences between the opioid 
receptors, putative endogenous ligands for each receptor were identified (Figure 5).  In 1975, the 
DOP receptor agonists methionine-enkephalin (35, Met-enkephalin) and leucine-enkephalin (36, 
Leu-enkephalin) were isolated from pig brains and demonstrated to have activity that could be  
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inhibited by naloxone (37), an opioid antagonist.57  Also in 1975, the endogenous ligand for KOP 
receptors, dynorphin A (38), was isolated from bovine pituitary glands. 58-59  Finally, in 1976, the 
endogenous ligand for the MOP receptor, -endorphin (39), was isolated from camel pituitary 
glands.60 
The DOP receptors were the first of the three opioid receptors to be cloned and 
expressed.  This was accomplished in 1992 simultaneously and independently by Keiffer et al.61 
at École Supérieure de Biotechnologie in Strasbourg, France and by Evans et al.62 at the 
University of California at Los Angeles.  Next in 1993, Meng et al.63 at the University of 
Michigan isolated and cloned the KOP receptors, and finally in 1994, the MOP receptors were 
cloned by Wang et al. at the National Institute on Drug Abuse (NIDA).64  
SAR of the Endogenous Opioid Peptides 
 All of the endogenous opioid peptides are derived from one of three precursor peptides; 
proenkephalin (enkephalins), proopiomelanocortin (endorphins), or prodynorphin 
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(dynorphins).65  The cleavage products of these precursor peptides all contain the pentapeptide 
sequence of either Met-enkephalin or Leu-enkephalin at the N-terminus (Tyr-Gly-Gly-Phe-X, 
where X = Met or Leu), but differ in their C-terminal sequence.16  The differences in C-terminal 
sequences produce differences in preferred receptor interactions.  As previously mentioned, the 
enkephalins exhibit preference for DOP receptors, the dynorphins interact selectively with KOP 
receptors, and -endorphin possesses affinity for MOP receptors. 
 SAR development of the enkephalins produced a peptide with the sequence Tyr-D-Arg-
Gly-Phe-D-Leu which came to be known as D-Ala-D-Leu-enkephalin (DADLE) and is a 
selective DOP receptor agonist.66  Further changes to the enkephalin sequence led to Tyr-D-Ala-
Gly-MePhe-Gly-ol-enkephalin (DAMGO), a selective MOP agonist.67  Tritiated versions of 
DADLE and DAMGO are the standard agonists used in radioligand binding studies for DOP and 
MOP receptors, respectively.68  From collective studies, the general SAR of the enkephalin 
peptides is: 1) alteration of either Tyr1 or Gly3 results in a loss of opioid activity,69-70 2) 
replacement of Phe4 is not well tolerated, but the para position on the ring may be substituted,70 
3) adding rigidity to the peptide via a dehydrophenylalanine residue in place of Phe4 is 
tolerated.71  The SAR for -endorphin is very similar to that of the enkephalins, and replacement 
or deletion of the C-terminal residues is not well tolerated.72  Finally, in SAR studies of 
dynorphin it has been published that Arg7 and Lys11 are critical for KOP receptor selectivity, 
while Tyr1 is required for biological activity.73  However, relatively recent work has shown that, 
for opioid peptides in general, modification of Tyr1 such that the amino-terminus is no longer 
basic or removal of the phenolic hydroxyl (replacement with Phe residue) can convert opioid 
agonists to antagonists.14, 74-75  
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SAR of Non-Peptidic Opioid Ligands 
 While much research has focused on the development of peptidic ligands for the opioid 
receptors, there is an even larger body of research concerning the development of morphine-
based small molecule ligands.  Although compounds with opioid activity appear structurally 
diverse, ranging from fused multi-cyclic scaffolds to acyclic scaffolds, conceptually these 
differing molecules can be related to each other by envisioning a systematic dismantling of 
morphine, the prototypical opioid ligand (Figure 6).16  With this in mind, non-peptide opioids fall 
into one of five structural categories: 1) 4,5-epoxymorphinans, 2) morphinans, 3) 
benzomorphans, 4) phenyl piperidines, and 5) acyclic or other opioids. 
  
 
 
 
 
 
 
4,5-Epoxymorphinans 
 The largest class of opioid ligands is the 4,5-epoxymorphinan class, which includes 
several natural products found in the opium poppy; morphine (26), codeine (27), and thebaine  
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(40), which is an important precursor for the synthesis of many therapeutically important 
morphine-based derivatives (Figure 7).16  The first synthetic derivative of morphine to be 
produced was 3,6-diacetylmorphine (41, heroin) in the late 19th century.76  Masking the 3- and 6-
hydroxyl groups of morphine increases the lipophilicity of the molecule, increasing penetration 
of the blood-brain barrier.14  Once absorbed, esterases rapidly hydrolyze the 3-acetyl group to 
produce 6-acetylmorphine, which has MOP agonist activity greater than morphine.14, 77  Another 
well-known derivative is codeine, in which the 3-hydroxyl of morphine has been methylated.  
Codeine has less activity as an analgesic than morphine, but is used as an antitussive due to its 
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oral bioavailability and low risk of physical dependence.78-80  The general SAR for 4,5-
epoxymorphinans is summarized in Table 1.14  One important feature to note is that alteration of 
the N-alkyl substitutent dramatically effects functionality; N-Me and N-phenethyl are agonists, 
while N-allyl (37, naloxone) and N-cycloropylmethyl (42, naltrexone) are antagonists. 
Table 1.14  Structure, numbering, and selected SAR summary for morphine. 
 
Substituent Alteration Analgesic Activity Change 
3-OH to 3-H 10× decrease 
6-OH to 6-keto Decrease 
or increase with 7,8-dihydro 
6-OH to 6-H Increase 
7,8-dihydro Increase 
14--OH Increase 
3-OH to 3-OMe Decrease 
3-OH to 3-OAc Decrease 
6-OH to 6-OAc Increase 
N-Me to N-phenethyl 10× increase 
N-Me to N-allyl Becomes MOP antagonist 
 
 While thebaine does not produce an analgesic effect, it is a very important precursor in 
the preparation of codeine as well as the Diels–Alder products etorphine (43), diprenorphine 
(44), and buprenorphine (45).  Etorphine is 8,600 times more potent than morphine as an 
analgesic and is used for large animal veterinary procedures.81  Diprenorphine is an antagonist 
and is used to reverse the effects of etorphine.16, 72  Interestingly, buprenorphine appears to be a 
partial MOP agonist, showing a greater analgesic effect than morphine, but with a longer 
duration of action as well as some KOP antagonist properties.82  Consequently, buprenorphine 
has been approved for the treatment of heroin addiction.83 
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Morphinans 
 Morphinans differ structurally from the 4,5-epoxymorphinans in that they lack the 
4,5-ether bridge (Figure 8).  The best known compounds in the morphinan class are 
levorphanol (46) and dextrorphan (47).  Levorphanol, the levo isomer, has the same 
configuration as morphine, but is about four times as potent as an analgesic.84  Dextrorphan, the 
dextro isomer, and particularly its 3-methyl ether dextromethorphan (48), are powerful 
antitussives used in over-the-counter medications.85  The general SAR for the morphinans is 
otherwise very similar to the SAR of the 4,5-epoxymorphinans.  
 
 
Benzomorphans 
 Since the structural simplification of the 4,5-epoxymorphinans to the morphinans 
successfully yielded compounds with biological activity, further simplification was explored 
through removal of the C-ring, producing the benzomorphan core (Figure 9).  Ketocyclazocine 
(34), a selective KOP ligand, is an important member of this class which, as previously 
described, was used to pharmacologically differentiate the KOP receptor.  The majority of 
analogs made in this structural class are alkyl substitutions at the 5- or 9-positions, as well as at 
the nitrogen.  Substituents at the 9-position that have the -orientation tend to have higher  
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analgesic potency than those with the -orientation,86 and compounds with a dual -methyl/-
alkanone substitution at this position, such as WIN 44,441 (49), tend to be very potent ligands 
with functionalities ranging from agonist to antagonist.87  SAR for N-substituents is generally 
similar to that of the 4,5-epoxymorphinans and the morphinans; N-Me and N-phenethyl are 
agonists however, N-allyl or N-cyclopropylmethyl can lead to either antagonists or mixed 
agonist/antagonists.16  One unique example is bremazocine (50), which is a KOP agonist, but a 
MOP/DOP antagonist.88  
Piperidine Derivatives 
 Further simplification of the benzomorphan scaffold through removal of the B-ring yields 
the 4-phenylpiperidines.  This results in more flexible compounds and therefore more complex 
SAR, which can be explained through different conformations (e.g. axial or equatorial) of the 
phenyl ring.16  The prototypical 4-phenylpiperidine is meperidine (30), which is clinically used 
for the relief of labor pain.89  A large number of meperidine analogs have been reported; the 
general SAR is: 1) alterations to the 4-position reduce analgesic activity;16  2) incorporation of a 
m-hydroxyl on the phenyl ring enhances activity and can be either an agonist or antagonist 
depending on the N-substituent;16, 90 3) while N-phenethyl is an agonist, N-allyl and N-
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cyclopropylmethyl do not necessarily produce antagonism;91 4) reversed esters of meperidine are 
more potent.14 
 The 4-anilidopiperdines, fentanyl (31) being the best known example, are potent 
analgesics; fentanyl is 200 times more potent than morphine.92-94  Because of its rapid onset and 
short duration of action, fentanyl is used almost exclusively for anesthesia.16  The SAR for 4-
anilidopiperdines and 4-phenylpiperidines is very similar, leading to the hypothesis that the two 
classes of compounds interact with the opioid receptor in a very similar fashion.95 
Other Classes of Opioids 
 Methadone (32) and its derivatives can be considered as “ring-opened” derivatives of the 
4-phenylpiperidine class.16 Currently, methadone is used clinically as replacement therapy for 
opioid addiction. This is because it has a similar analgesic effect to morphine but a much longer 
duration of action; methadone can be more easily dosed to achieve steady blood concentrations 
and alleviate withdrawal symptoms.96  In general, alteration of the N-substitutent leads to 
derivatives with reduced analgesic efficacy.97 
 Discovered in 1982 by the Upjohn Company, the arylacetamides are a relatively recently 
developed class of opioid ligands (Figure 10).98  The selective KOP agonists U50,488 (51) and 
U69,593 (52) are members of this class and tritiated versions of these are the standard agonists of 
choice for KOP radioligand binding assays.99-100  In 1994, SNC 80 (53) was reported as a 
selective DOP receptor agonist; it is a member of the benzhydrylic piperazine class.101  Another 
recently developed (2001) class of opioid ligand is the tetrahydroisoquinolines, of which JDTic 
(54) is a member.102  The development of JDTic was inspired by the 4-phenylpiperidine class, 
and it is a highly potent and selective KOP antagonist.  In 2010, the 8-azabicyclo[3.2.1]octan-3- 
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yloxy-benzamide structural class was reported to produce selective KOP antagonists.103-104  From 
this initial in vitro work, AZ-MTAB (55) and AZ-ECPC (56) were found to be short acting 
antagonists in vivo compared to standard KOP antagonists.105  Eli Lilly has reported similar 
compounds (57, LY-DMPF) that have similar activity.106  Also in 2010 (with a follow-up in 
2012), Frankowski et al. reported a high through-put screening (HTS) strategy that identified N-
alkyl-octahydroisoquinolin-1-one-8-carboxamides (58) as nonbasic, selective KOP ligands.107-108  
Finally, in 2011, Pfizer reported PF-4455242 (59) as a selective KOP antagonist.109  This  
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Figure 10. Other examples of opioid receptor ligands.
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Table 2.  Summary of selected opioid receptor ligands. 
Structural Class Ligand 
Selective 
Receptor 
Agonist (+) / 
Antagonist (-) 
Peptidic Met-enkephalin (35) DOP + 
 Leu-enkephalin (36) DOP + 
 -Endorphin (39) MOP + 
 Dynorphin (38) KOP + 
 DADLE DOP + 
 DAMGO MOP + 
4,5-Epoxymorphinan Morphine (26) MOP + 
 Codeine (27) MOP + 
 Heroin (41) MOP + 
 Naloxone (37) MOP - 
 Naltrexone (42) MOP - 
 Etorphine (43) MOP + 
 Diprenorphine (44) MOP - 
 Buprenorphine (45) MOP + MOP, - KOP 
Morphinan Levorphanol (46) MOP + 
 Dextrorphan(47) MOP + 
 Dextromethorphan (48) MOP + 
Benzomorphan Ketocyclazocine (34) KOP + 
 WIN 44,441 (49) KOP - KOP/MOP 
 Bremazocine (50) KOP + KOP, - MOP/DOP
4-Phenylpiperidine Meperidine (30) MOP + 
4-Anilidopiperidine Fentanyl (31) MOP + 
Acyclic Methadone (32) MOP + 
Arylacetamide U50,488 (51) KOP + 
 U69,593 (52) KOP + 
Benzhydric Piperazine SNC 80 (53) DOP + 
Tetrahydroisoquinoline JDTic (54) KOP - 
Benzamides AZ-MTAB (55) KOP - 
 AZ-ECPC (56) KOP - 
 LY-DMPF (57) KOP - 
Isoquinolone carboxamide 58 KOP + 
Biphenylsulfonamide PF-4455242 (59) KOP - 
 
compound is a biphenylsulfonamide, the core structure of which was identified from a HTS 
campaign, and has entered Phase 1 clinical trials for depression.   
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 Since the 19th century the morphine scaffold has been explored as a source of molecules 
with opioid receptor activity, and there exists a wide variety of derivatives, only a few of which 
have been mentioned here, that span different potencies, functionalities, and receptor selectivities 
(Table 2).  Even so, the utility of ligands related to the morphine scaffold is limited due to the 
associated negative side effects that seem to follow through even with simplification and 
derivatization.  Therefore the identification of non-morphine-like scaffolds is important for new 
ligand development.  
G-Protein Coupled Receptors 
As previously stated, all of the opioid ligands exert their effects through the opioid 
receptor system.  There is substantial evidence that the opioid receptors are members of the G-
protein coupled receptor (GPCR) superfamily, one of the largest and most diverse protein 
families in the mammalian genome with more than 800 unique receptors.16, 110-111  In fact, all of 
the opioid receptor isolation and cloning studies noted that the receptors shared significant 
sequence homology with known GPCRs.  Despite their large array of functional diversity, all 
GPCRs share a similar structure consisting of 7 transmembrane domains connected by 
alternating intra- and extra-cellular loops (Figure 11).110  Extra-cellular loops, which differ 
among the different types of GPCRs, apparently contribute to ligand recognition and binding, 
whereas coupling to particular G-proteins is determined by the intra-cellular loops.112-113  When 
an agonist binds to the extra-cellular loop of a GPCR, it induces a conformational change in the 
receptor structure which leads to intra-cellular coupling to and activation of one or more G-
proteins.110 
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G-proteins are heterotrimeric, consisting of 3 subunits named , , and , and bind 
guanine nucleotides to their -subunit, catalyzing the hydrolysis of guanosine triphosphate 
(GTP) to guanosine diphosphate (GDP) upon agonist binding.16, 110  A variety of different genes 
have been identified which encode each of these subunits.  Coupling of the GPCR to the G-
protein results in dissociation of the -subunit from the -subunit, and the -subunit can then 
activate a number of different effectors, such as enzymes or ion channels.110, 114-115  The -
subunit has a role in determining receptor specificity and can also influence the efficiency of 
interactions of the -subunit.110  On the basis of G-protein coupling preference, GPCRs can be 
classified into 4 major categories: Gs-, Gi/o-, Gq/11-, and G12/13-coupled receptors.114  
Almost all agonists that have an analgesic action are coupled to Gi/o proteins.110  The Gi and 
Go proteins inhibit adenylate cyclase, while Gs stimulates production, and of the effectors 
implicated in signaling mechanisms for opioid receptors, inhibition of adenylate cyclase and  
Figure 11. GPCR signal cascade. 
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subsequent decrease in intra-cellular cyclic adenosine monophosphate (cAMP) concentrations is 
the best studied.16 
GPCRs can also signal through G-protein independent mechanisms, the best 
characterized of which is the GPCR kinase (GRK)/-arrestin pathway.116  Mammals express 
seven GRK isoforms.  Isoforms GRK1 and GRK7 are confined to the retina, GRK4 has limited 
cellular distribution with high expression localized in the testes, and GRK2, GRK3, GRK5, and 
GRK6 are ubiquitously expressed.116-117  In the first step of the pathway, serine and threonine 
residues of the third intra-cellular loop and the carboxy terminus region of the agonist-bound 
receptor are phosphorylated by a GRK (Figure 12).  For some GPCRs, agonist activation and 
Figure 12.  GRK/-arrestin mechanism. 
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phosphorylation by a GRK are enough to cause the G-protein to become decoupled from the 
receptor itself, leading to receptor desensitization, however many GPCRs require the additional 
step of recruitment of proteins called arrestins.116-117   
There are four members in the arrestin family.  Arrestin 1 (visual arrestin) and arrestin 4 
(cone arrestin) are localized to retinal rods and cones, whereas arrestin 2 (-arrestin 1) and 
arrestin 3 (-arrestin 2) are ubiquitous.117  Recruitment of a -arrestin protein to an agonist-
activated, GRK-phosphorylated receptor sterically hinders further G-protein coupling of the 
receptor, causing desensitization.118  Further, -arrestins are known to interact with and serve as 
adaptors for components of the endocytotic machinery, thus their recruitment to the receptor 
promotes receptor internalization from the cell surface and sequestration from G-proteins, 
followed by either eventual degradation or recycling back to the cell surface.116-117, 119   In order 
to signal through the GRK/-arrestin pathway, -arrestin that has been recruited to an agonist-
activated, GRK-phosphorylated receptor also promotes association of the receptor with other 
signaling proteins, such as kinases, furthering intracellular signal cascades completely 
independently of the G-protein.117  Thus, even as -arrestin interferes with G-protein signaling, it 
also promotes a second, parallel signaling pathway.   
Until recently, a ligand’s efficacy for -arrestin recruitment/signaling was thought to be 
proportional to its efficacy for G-protein signaling; the signaling paradigm for receptors and their 
ligands was completely linear in nature.  However, it is now known that “biased ligands” can 
selectively activate either the -arrestin or the G-protein signaling pathway, indicating a more 
complicated, non-linear paradigm for ligand-GPCR signaling.119  This also implies that there are 
novel biological consequences to be discovered, even for well-studied GPCRs.  Furthermore, this 
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suggests that molecules can be discovered or even designed to selectively activate either 
pathway, possibly resulting in either novel biological probes or more therapeutically beneficial 
drugs. 
Opioids, Receptors, and the Treatment of Pain 
One area of medicine that would benefit greatly from the elucidation of novel biological 
mechanisms or the development of improved therapeutics is the area of pain management.  
Acute pain, postoperative pain, and types of chronic pain are initiated by the activation of a 
nociceptor, a peripheral sensory receptor that responds to noxious stimuli.43, 120  Nociceptors are 
present in all tissues and can respond to different stimuli such as thermal, mechanical, or 
chemical mediators released from surrounding tissues (e.g. histamine or lactic acid).120  The 
manifestation of pain, however, is a complex experience that is not only governed by the central 
nervous system (CNS), but is informed by such cognitive input as environment (e.g. society and 
culture), life experience, and gender.43   As previously stated, pain is one of the most common 
reasons that individuals seek medical intervention.  This phenomenon results in around 40 
million physician visits annually and is estimated to cost $100 billion each year in health care 
and lost productivity.43  The opium alkaloids, such as morphine and its derivatives, are among 
the most potent analgesics used in the clinic.  Clinically used opioid analgesics are a popular 
choice for the treatment of severe pain, however their negative side effects—respiratory 
depression, constipation, tolerance, and dependence—decrease their appeal.16  The opium 
alkaloids and many of their synthetic derivatives are selective agonists at MOP receptors, and it 
is MOP receptor activation that is linked to these agents’ negative effects. 
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The most common side effect of opioid use is constipation in addition to a collection of 
other gastrointestinal (GI) effects termed opioid bowl dysfunction.16  The frequency of opioid-
related GI effects is quite high, 40-50% or more in patients receiving opioid therapy.121-123 The 
constipation is mediated by MOP receptors in the bowel; delayed food digestion and a decrease 
in peristaltic waves in the intestines results in retention of contents.89  Tolerance does not usually 
develop to this side effect, and patients receiving chronic opioid therapy are chronically 
constipated.  Fortunately, this side effect can be diminished with prophylactic administration of a 
laxative and/or a stool softener.124-125 
The slowed breathing associated with opioid analgesics is termed respiratory depression, 
and constitutes the most severe side effect of opioid use.124  The interaction of opioid analgesics 
with the respiratory center in the brain causes a decreased response to carbon dioxide 
concentration in the blood and thus a decrease in breathing rate.89  Such an effect occurs at drug 
doses much lower than those that affect consciousness and increases in a dose-dependent 
manner.  Death from opioid overdose is nearly always a result of respiratory depression.  The 
severity of this side effect can be diminished by careful titration of opioid drug dose.124 
Chronic use of opioids often results in tolerance and physical dependence.16  Tolerance is 
a phenomenon that results when continuous drug exposure leads to decreased effectiveness, and 
larger doses are required to achieve the previous therapeutic effect.126  It is hypothesized that 
tolerance to opioid analgesics may be caused physiologically by the receptor desensitization and 
internalization processes described previously that take place in the GRK/-arrestin signaling 
pathway.  Physical dependence is a physiologically adaptive state that is characterized by the 
appearance of withdrawal symptoms specific to the opioid family of drugs upon abrupt cessation 
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or significant reduction in dose, or upon administration of an opioid antagonist.126  It is important 
to note that physical dependence is distinct from addiction.  Physical dependence is defined only 
by the appearance of withdrawal symptoms at decreased drug concentrations in blood (or when 
an antagonist is administered). Addiction is defined by chronic, uncontrolled and/or compulsive 
drug use, and continued drug use despite grievous harm to health and well-being.126 
Therapeutic Potential of KOP Receptor Selective Agents 
In part because of the side effect liabilities of MOP receptor ligands, opioid ligands that 
are selective for other types of opioid receptors show promise as clinical agents to treat a variety 
of conditions.  One example is KOP receptor selective ligands; selective KOP agonists are 
capable of producing clinically useful analgesia, but lack the constipation, respiratory depression, 
and tolerance and physical dependence properties associated with MOP agonists.14-16  Still, there 
is an important negative side effect associated with KOP receptor activation in the CNS, and that 
is dysphoria, a hallucinogenic-like, aversive effect that is the opposite of euphoria.127  In spite of 
this, KOP agonists are targets for pain relief absent the negative side effects of MOP agonists.  
Although some KOP agonists are known to produce a dysphoric effect, there is still some hope 
that a clinically useful analgesic may be found.  KOP agonists whose action is restricted to the 
peripheral nervous system (PNS) have been shown to be effective in relieving inflammatory and 
visceral pain, and due to the PNS restriction, this analgesia occurs without dysphoria.16, 120  
Another important indication for KOP-selective ligands is mood regulation.  The 
endogenous opioid systems in the brain are certainly involved in the regulation of mood, 
although they have received far less research interest than the monoamine systems such as 
dopamine, norepinephrine, and serotonin.128  Work focused on the effects of stimulant drugs on 
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cAMP response element binding protein (CREB), a transcription factor, found that repeated 
administration of stimulants such as amphetamine increased the function of CREB in the nucleus 
accumbens (NAc) region of rodent brains.129   Stress was also found to activate CREB in the 
rodent NAc.130  Continued study of these phenomena lead to the observation that elevated CREB 
function in the NAc, whether by drug administration or stress, produces the rodent equivalent of 
symptoms of major depression: dysphoria, anhedonia, and despair.130  Further, disruption of 
CREB function in the NAc leads to opposite effects and has anti-depressant-like qualities.  
Because CREB is a transcription factor that regulates gene expression, it is logical that 
the effects of elevated CREB function are caused by target genes, and recent work indicates that 
the same stress that activates CREB in the NAc also increases the expression of prodynorphin 
(PDYN), the precursor to the endogenous KOP agonist, dynorphin (DYN).131  In fact, elevations 
in CREB function in the NAc increase PDYN expression, whereas disruptions in CREB function 
reduce expression.132  Taken together, these observations suggest the idea that depression could 
be attributed in part to increased DYN and subsequent elevations in KOP receptor activation in 
the NAc.128  Therefore, a KOP antagonist, whose action would decrease KOP receptor 
activation, could be a useful target for the treatment of depression.   
The KOP receptor antagonists nor-binaltorphimine (norBNI, 60), GNTI (61), ANTI (62), 
and JDTic have all been investigated for anti-depressant effects in various rodent behavioral 
models and found to be effective (Figure 13).130, 133-134  However, study of the effects of selective 
KOP antagonists in rodents, non-human primates, and humans is hindered by the abnormally 
long half-life of these agents: a single injection can block the effects of a KOP agonist for as long 
as 56 days.135  The cause of this extremely long duration of action is not fully understood,  
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although it does not seem to be an inevitable consequence of KOP receptor inactivation; non-
selective opioid antagonists do not produce this complication.136  Work from the Chavkin group 
indicates that the long duration of selective KOP antagonists is not caused by antagonist 
deposition in lipid membranes, or by antagonist-mediated changes in the KOP receptor 
population, or by the antagonist covalently binding to the receptor.  The Chavkin group did find 
that the long duration of selective antagonist action is positively correlated to activation of c-Jun 
N-terminal kinase (JNK), although how JNK activation leads to long-term KOP receptor 
inactivation remains unclear.136-137  Thus, the search for selective KOP antagonists with 
improved pharmacokinetic and pharmacodynamic properties continues. 
Despite their documented dysphoric effect, selective KOP agonists have been suggested 
as anti-manic agents based on studies that found that clinically used anti-manic agents increase 
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the activity of dynorphinergic neurons, implying that these drugs may increase DYN and 
therefore KOP receptor activation, eliciting a mood lowering effect.128, 138  This idea is bolstered 
by the fact that known selective KOP agonists such as U69,593 and U50,488 produce pro-
depressive-like behaviors in rodent models, identical to behavior caused by CREB elevation in 
the NAc.130, 133  While many selective KOP agonists reported in the literature are full agonists, 
partial agonists may have a decreased propensity to cause dysphoria while retaining mood 
lowering capabilities, and this type of effect might be useful in the treatment of mania or bi-polar 
disorder.128 
Finally, KOP-selective ligands have also been implicated as pharmacotherapies for drug 
addiction.139-142  Addiction is a chronic, relapsing disease characterized by compulsive drug-
seeking and drug-taking behavior that persists despite severe adverse consequences.143  Addicts 
typically demonstrate diminished motivation for the natural rewards that drive behavior (e.g. 
food, sex), and the abrupt cessation of drug use produces withdrawal symptoms.144-146  While 
there are currently FDA-approved treatments for opioid (methadone), nicotine (varenicline), and 
alcohol (naltrexone) abuse, at present there are no FDA-approved therapies for the abuse of 
stimulants such as cocaine and methamphetamine.139 
A wealth of research has established that the DYN/KOP receptor system has an 
inhibitory influence on brain reward function by suppressing dopamine (DA) release from the 
mesolimbic and nigrostriatal pathways.147-151  These brain regions are intimately associated with 
the development of drug dependence.142  Additionally, several studies in both rodents and non-
human primates have demonstrated that selective KOP agonists functionally attenuate many 
behavioral effects of cocaine including locomotor activity,152 sensitization and place 
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preference,152-154 and self-administration.155-158  Place preference studies in animals provide a 
measurement of the conditioned, reinforcing effects of drugs on behavior; in rodents, conditioned 
place aversions are observed upon systemic administration of KOP receptor agonists.140, 159  KOP 
selective agonists also attenuate the reinstatement of extinguished drug-taking behavior in animal 
models of relapse.158, 160  This collection of inhibitory effects on cocaine-induced, abuse-related 
behavior is possibly accomplished through direct inhibition of DA release from dopaminergic 
neurons,150-151, 161 modulation of DA uptake in the NAc,162 and alterations in the synaptic 
concentration of the dopamine transporter (DAT).163-164  Frustratingly, while consistent data are 
produced that find that KOP stimulation antagonizes the rewarding and reinforcing effects of 
drugs of abuse, KOP antagonists show no consistent results.141  Still, these observations 
implicate selective KOP agonists as candidates for pharmacotherapies for drug abuse in that such 
therapies could diminish the rewarding effects associated with stimulant use and thus the 
resultant negative behavioral changes.   
Despite these seemingly positive effects, KOP agonists are still known still precipitate 
pro-depression-like behaviors (dysphoria) in rodents, which is not an ideal side-effect for a 
potential pharmacotherapy for drug addiction.133  Paradoxically, KOP agonists can themselves 
also potentiate the rewarding effects of cocaine under stress conditions and stress-induced 
reinstatement.149, 165-166  Previously mentioned behavioral studies were performed with animals 
otherwise naive to KOP ligands (drug administered ≤15 min before challenge), but animals with 
a history of exposure to KOP agonists (continuous exposure or drug administered 60 min before 
challenge) demonstrated this phenomenon.141, 166  In these animals, KOP receptor antagonists 
were found to be effective in decreasing the increased intake of cocaine.167  This observation is 
likely due to persistent KOP receptor activation producing a stress-like effect in the animal.141  
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Consequently, in a state of addiction/drug-dependence, KOP receptor antagonists, which would 
suppress the KOP receptor system, may be a potential target for diminishing compulsive drug 
use and relapse. 
Finally, while several selective full KOP receptor agonists have been evaluated for their 
usefulness in treating addiction in animal models, no such data have been reported for selective 
partial KOP receptor agonists.  This type of compound has the potential to block the rewarding 
effects of CNS stimulants such as cocaine as a full KOP agonist does, but without the dysphoric 
effect and such persistent KOP receptor activation that it produces a stress-like effect and then 
subsequently promotes relapse.139 
Interactions between the Opioid and Cannabinoid Receptor Systems 
An alternative way in which selective KOP ligands could be of use both as clinical agents 
and as biological probes is in conjunction with the cannabinoid receptor system.  The 
cannabinoid receptor system is another type of GPCR system, and compounds from the cannabis 
plant, Cannabis sativa L. (Cannabaceae), have been ingested for centuries for medicinal, 
spiritual, and recreational purposes.  SAR development of known cannabinoid ligands and 
research into their biological targets eventually resulted in the isolation and cloning of the 
cannabinoid receptors, CB1 in 1988 and CB2 in 1993.168-170 
Cannabinoids and opioids share many pharmacological properties including 
antinociception and sedation.171  In fact, there is a known synergistic antinociceptive effect upon 
activation of both cannabinoid and opioid receptor systems.172-175  A plausible hypothesis for this 
observation is that drugs that activate these receptors reciprocally influence the synthesis and/or 
release of the endogenous ligands.171  In the spinal cord, cannabinoid induced antinociception 
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can be reversed by KOP antagonists.176-177  Also, an increase in extra-cellular levels of 
endogenous DYN can be measured after acute administration of cannabinoid agonists.176-178  
These findings suggest that the DYN/KOP receptor system is involved in the mechanism of 
cannabinoid induced antinociception.   
The benefits of simultaneous opioid and cannabinoid receptor activation have not been 
fully exploited or investigated for use in the clinic.  Since the KOP receptor system has been 
implicated in a variety of conditions as described previously, study of the interactions between 
the cannabinoid and opioid receptor systems would provide a clearer view of the underlying 
neurobiology and possibly offer new therapeutic targets.  In order to conduct these studies, 
existing KOP and cannabinoid ligands need to be characterized at the reciprocal receptors, and 
new ligands need to be developed. 
Alternative Chemical Scaffolds for Opioid Ligands 
 In summary, since the 19th century the morphine scaffold has been intensively explored 
as a source of molecules with opioid receptor activity.  However, the utility of ligands related to 
the morphine scaffold is limited due to the associated negative side effects that seem to follow 
through, despite extensive scaffold simplification and derivatization.  The identification of novel, 
diverse, non-morphine-like chemical scaffolds with opioid receptor activity is important because 
scaffolds different from known opioids have the potential to have different side effect profiles 
and different and useful pharmacological profiles.  Recent research has shown that flavonoids 
possess some opioid activity, making them a novel class of non-nitrogenous opioid receptor 
ligands.179  Another non-nitrogenous structural class that bears investigation is the neoclerodane 
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diterpenes, a subclass of the terpene class of natural products.  The neoclerodane diterpene 
salvinorin A has been identified as a selective KOP receptor agonist.180 
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CHAPTER 2: INVESTIGATION OF FLAVONOIDS AS OPIOID LIGANDS 
Introduction to Flavonoids 
The flavonoids are part of a family of polyphenolic natural products that are produced in 
high quantities by a variety of plants.181-183  They are recognized for their anti-cancer, anti-
oxidant, anti-inflammatory, and free-radical scavenging activities. The flavonoid class is known 
to chelate bivalent metals and prevent redox cycling, inhibit enzymes involved in prostaglandin 
biosynthesis (e.g. lipoxygenase, phospholipase, and cyclooxygenase), inhibit a variety of kinases, 
inhibit topoisomerase I and II, and bind to the estrogen receptor.182  The major source of 
flavonoids is fruits and fruit products, vegetables, tea leaves, soybeans, and herbs.182  Because 
they are produced by so many plants, flavonoids are widely distributed in foods and other 
consumable plant products, and are thus more likely than other scaffolds to have acceptable side 
effect and toxicity profiles.184  This makes them an attractive investigational target for molecules 
with biological activity. 
The basic structure of a flavonoid is the flavan core (63) which consists of 15 carbon 
atoms arranged in three rings, called A, B, and C.185  The biosynthesis of flavonoids begins with 
the condensation of one molecule of 4-coumaroyl CoA (66) with three molecules of malonyl 
CoA to yield a chalcone, a precursor for all flavonoids (Scheme 1).182  To produce 4-coumaroyl 
CoA, phenylalanine is deaminated by phenylalanine ammonialyase (PAL), and the trans-
cinnamate (64) product is then hydroxylated to 4-coumarate (65) by cinnamate 4-hydroxylase 
(C4H), a cytochrome P450 (CYP450) enzyme.186  Activation of 4-coumarate to the CoA 
thioester is catalyzed by 4-coumarate:CoA ligase (4CL), giving the necessary precursor 4-
coumaroyl CoA.  This precursor can be further hydroxylated at the 3 position by 4-coumaroyl  
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CoA 3-hydroxylase (CC3H) to give caffeoyl CoA (67), an alternative flavonoid precursor in 
some plant species.  Malonyl CoA is derived from the condensation of acetyl CoA and CO2, 
facilitated by acetyl CoA carboxylase.  Next, the step-wise condensation of 4-coumaroyl CoA 
and three molecules of malonyl CoA is catalyzed by the enzyme chalcone synthase (CHS) to 
produce 2’,4’,6’,4-tetrahydroxychalcone (68).  An alternative chalcone precursor in some plant  
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species is isoliquiritigenin (69), also synthesized from 4-coumaroyl CoA and malonyl CoA, but 
in conjunction with a NADPH-dependent reductase.  The stereospecific cyclization of the 
chalcone precursor, catalyzed by chalcone isomerase (CHI), yields a 2S-flavonone (e.g. 
naringenin (70), liquiritigenin (71)), which has the typical flavonoid skeletal core.  These 
relatively simple scaffolds can then be extensively modified by many different types of enzymes, 
producing an overwhelming diversity of unique structures with a wide array of biological 
activities. 
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Based on structural details of their carbon skeletons, flavonoids are classified into eight 
groups (Figure 14): flavans (72), flavanones (73), isoflavanones (74), flavones (75), isoflavones 
(76), anthocyanidines (77), chalcones (78), and flavonolignans (part flavonoid, part lignan).182  
Since the chemical structures and sometimes also the biological activities of several flavonoids 
are similar to those of naturally occurring estrogens, flavonoids are frequently assigned as 
phytoestrogens.187  More than 8,000 compounds that conform to the flavonoid structural 
definition have been discovered.185  Because of their ubiquity, wide range of biological activity, 
and relative ease of synthesis, flavonoids as a structural class continue to be an investigational 
target for new disease pharmacotherapies. 
The Identification of Flavonoids as Potential Opioid Receptor Ligands 
 Flavonoids from Hypericum perforatum L. (Hypericaceae), commonly called St. John’s 
Wort, have been recently investigated for their biological activities.  Published work indicates 
that H. perforatum may have antiaddictive potential.179   In rat models of alcohol dependence, 
extracts of H. perforatum have been observed to attenuate alcohol self-administration.188-189  
They have also been shown to work synergistically with opioid antagonists in the attenuation of 
rodent alcohol intake.190  As opioid antagonists such as naltrexone are used clinically to treat 
alcohol abuse, these findings indicate that the attenuation of alcohol self-administration in rats 
caused by H. perforatum extracts may be opioid receptor mediated.179  Extracts of H. perforatum 
have also been evaluated for anti-inflammatory and antinociceptive potential in different rodent 
models and found to be effective.191-194  Such effects are mediated in part by opioid receptors.195-
196  Furthermore, in vitro receptor screens have shown that H. perforatum extracts inhibited the 
binding of [3H]naloxone and [3H]deltorphin to opioid receptors.197-198  Finally, amentoflavone  
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(79), a biflavone found in H. perforatum extracts is known to compete for binding to opioid 
receptors and in fact has relatively high affinity for the DOP receptor (Ki = 36 nM)
199 and is an 
antagonist at both DOP (weak, Ke = 6000 nM) and KOP receptors (Ke = 490 ± 150 nM).
179  
These findings further support the hypothesis that the actions of H. perforatum extracts are 
opioid receptor mediated.  Amentoflavone is the first reported flavonoid with KOP receptor 
antagonist activity, opening the possibility of a new structural scaffold for the development of 
opioid antagonists, and opioid ligands in general. 
OHO
OH O
HO OH
O
O
OH
OH
79
Amentoflavone
O
O
OH
OH
HO
80
Apigenin
O
O
OH
OH
HO
O
OH
O
OH
OH
OH
HO
81
Hyperoside
O
OH
O
82
4'-Hydroxyflavonone
O
OH
OH
OH
OH
HO
83
(+)-Catechin
O
OH
OH
O
OH
HO
O
OH
OH
OH
84
(-)-Catechin gallate
O
OH
OH
OH
OH
HO
OH
85
(-)-Epigallocatechin
Figure 15. Selected f lavonoids evaluated in [35S]GTP- -S functional assay.
40 
 
 Following the success with amentoflavone, efforts began to investigate structural 
modification of its flavonoid core.179  A small library of flavonoid natural products (Figure 15) 
was submitted to screening in the [35S]GTP--S functional assay, including apigenin (80), 
hyperoside (81), 4’-hydroxyflavonone (82), (+)-catechin (83), (-)-catechin gallate (84), and (-)-
epigallocatechin (85).  All of these flavonoids had potency at KOP receptors in the range of Ke = 
220–550 nM, with potencies at the MOP receptor ranging from Ke = 210–10,000 nM; their DOP 
receptor potencies were negligible.179  These findings indicate that flavonoids are a potential 
source of molecules with both opioid receptor activity and low structural similarity to known 
opioid ligands.  Furthermore, given the range of potencies between the different opioid receptor 
subtypes, these findings also suggest that flavonoid ligands may be designed and manipulated for 
optimal receptor selectivity. 
Dioclea Grandiflora Background 
Dioclea grandiflora Mart. ex Benth. (Leguminosae) is a vine that is native to 
northeastern Brazil.200 Commonly called “Mucunã”, the plant is well known locally for its 
medicinal value, and an infusion of the roots is used in traditional medicine to treat kidney stones 
and prostate gland disorders.200-201  Prior to 1995, D. grandiflora had never been screened 
pharmacologically.  Subsequently, observations of the antinociceptive actions of extracts of this 
plant were undertaken by collaborating groups at Universidade Federal da Paraiba, Brazil and 
University of Georgia, Athens, GA.  The flavonoid natural products dioclein (86)202 and dioflorin 
(87),203 obtained from the chloroform fraction of the ethanolic extract of D. grandiflora root 
bark, are two minor constituents that have been isolated and characterized from this plant and 
found to have antinociceptive properties (Figure 16).   
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Antinociceptive Effects of Dioclea Grandiflora Extracts 
The crude,  90% ethanolic extract of D. grandiflora root bark was found to dose 
dependently reduce the number of writhes in the acetic acid induced writhing test in mice; this 
effect was naloxone reversible.200  The same extract was also found to significantly increase 
reaction time in the tail-flick assay in rats.200    The crude, 70% ethanolic extract of D. 
grandiflora seeds significantly increased reaction time in the tail-flick test in rats, as well as in 
the hot-plate test in mice; the increased reaction times in the hot-plate were reversed by pre-
treatment with naloxone.204  In the same study, a daily dose of 500 mg/kg of seed extract not 
only failed to produce any signs of toxicity, but also maintained an antinociceptive effect through 
30 days, whereas morphine (6 mg/kg daily) lost effectiveness after 21 days.  In a recent study, 
the crude, 70% ethanolic extract of D. grandiflora seed pods was found to significantly decrease 
the number of writhes in the acetic acid induced writhing test in mice.205  However, the seed pod 
extract had only a numerical, but not statistically significant effect in the hot plate test.  In the 
formalin test, treatment with the seed pod extract significantly reduced formalin-induced licking 
in both the neurogenic (first phase) and inflammatory (second phase) phases; interestingly, this 
attenuation was actually enhanced in both phases by naloxone pretreatment.205   These collective 
findings suggest that the antinociceptive effects of D. grandiflora extracts may in part be opioid 
receptor mediated.  
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Preliminary Pharmacological Studies of Dioclea Grandiflora Flavonoids 
 The antinociceptive effects of dioclein were assessed by the acetic acid induced writhing 
test in male Swiss mice and by the tail-flick assay in male Wistar rats.200  In the acetic acid 
induced writhing test, 50 and 100 mg/kg dioclein significantly, although not dose dependently, 
reduced the number of writhes.  This effect was reversed by pretreatment with naloxone.  In the 
tail-flick test, a single dose (50 mg/kg) of dioclein produced a significant increase in reaction 
time and had a longer duration of action than morphine (6 mg/kg), maintaining significant 
antinociceptive activity through 2 h post administration.  These results indicate that dioclein may 
act centrally, involving an opioid-like mechanism. 
 The antinociceptive effects of dioflorin were assessed by the acetic acid induced writhing 
test and by the tail-immersion test, both in male Swiss mice.201  A single dose of 10 mg/kg of 
dioflorin was found to produce near maximal reduction of the writhing response, very similar to 
morphine (6 mg/kg).  In the tail immersion test, the same single dose of dioflorin significantly 
increased reaction times.  The effects of naxolone pretreatment were not reported for this 
particular study.  However, these results still demonstrate that dioflorin exhibits a central 
antinociceptive effect in mice. 
Rationale and Specific Aims 
 Dioclein and dioflorin are flavonoid natural products that demonstrate antinociceptive 
properties in rodent models of pain that are reversible by pretreatment with an opioid antagonist.  
Although these observations indicate that the mechanism of action of these flavonoids proceeds 
through opioid receptors, this information has not been investigated in vitro and no SAR studies 
of these molecules have been published.  This is significant because the flavonoid structural class 
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represents a novel chemical scaffold for the discovery of new opioid receptor ligands.  
Furthermore, the opioid receptors themselves have been linked to a variety of conditions 
including pain, mood disorders, and drug abuse.  Exploration of the SAR of dioclein and 
dioflorin has the potential to yield novel opioid ligands with altered pharmacological profiles that 
may be of use both in the clinic and as probes for biological evaluation. 
Specific Aim 1: Prepare dioclein and simplified dioflorin analogs for biological evaluation 
through total synthesis. 
 Dioclein and dioflorin are not commercially available, nor are there any published reports 
of large-scale, high-yielding extractions of these constituents from D. grandiflora plant material.  
Furthermore, even with the advent of the Convention on Biological Diversity,206 since D. 
grandiflora is not native to the United States it is likely to be difficult and very expensive to 
obtain the significant quantities of plant material that would be required to investigate and 
accomplish a successful extraction procedure.  Since flavonoids as a structural class are 
relatively simple molecules, the most reliable and economical way to produce analogs for 
biological evaluation is through total synthesis.   
There is a previously published total synthesis of dioclein that obtains the desired product 
in three steps from commercially available material and 43% over all yield.207  Simplified 
analogs of dioflorin may be made racemically from commercially available starting materials 
using well known synthetic organic methods.208-212  The initial hypothesis in the design of these 
simplified analogs of dioflorin is that the 8-methoxy group of the A-ring is not required for 
opioid activity of the flavonoid scaffold as dioclein itself lacks a methoxy in the analogous 
position (Figure 17).  Removal of this moiety from the structural scaffold of dioflorin is also  
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desirable as the 8-methoxy group is difficult to install relative to the other synthetic steps 
required to build the flavonoid core.  To this end, a series of dioflorin analogs were synthesized 
in which the 8-methoxy group has been removed from the A-ring.  Additionally, the tolerance of 
the C-ring to changes in the position of the hydroxyl group will be investigated.  Finally, these 
analogs will first be synthesized and evaluated in a racemic fashion as the absolute configuration 
of dioclein is not reported,202 making comparison to dioflorin for initial determinations of the 
stereochemical preferences of the target receptors difficult.  These modifications are intended to 
develop preliminary SAR for these flavonoids at opioid receptors and demonstrate that these 
scaffolds may be manipulated and retain or improve opioid receptor affinity and efficacy.  
Specific Aim 2: Evaluate dioclein and simplified dioflorin analog opioid receptor affinity 
through radioligand binding assays, and opioid and cannabinoid receptor efficacy through 
calcium mobilization fluorescent and -arrestin luminescent assays. 
 Using known methodology, compounds generated from Specific Aim 1 will be evaluated 
in vitro for affinity at MOP and KOP receptors through displacement of the radioligands 
[3H]DAMGO (MOP) and [3H]U69,593 (KOP).213  In order to determine the efficacy of these 
compounds at all three subtypes of opioid receptors, they will also be evaluated in a fluorescent 
calcium mobilization assay using a known protocol.214  This assay uses chimeric G-proteins 
Figure 17. Design rationale for simplified dioflorin analogs. 
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coupled to opioid receptors in order to measure changes in intracellular calcium concentration 
using a fluorescent, calcium-sensitive dye.215  The calcium assay format as an efficacy evaluation 
has an advantage over the [35S]GTP--S assay format as it requires less time and special training 
because it excludes the use of radiolabeled ligands.  Further, the compounds generated from 
Specific Aim 1 will also evaluated for efficacy at CB1 cannabinoid receptors using the same 
calcium mobilization assay format.  As previously described, cannabinoid ligands are able to 
produce an antinociceptive effect that is reversed by opioid antagonists and can upregulate 
endogenous opioids.    Thus, the purpose of this assay is to determine if these compounds are 
exerting their opioid-like antinociceptive effect through cannabinoid receptors.   
Finally, the compounds will also be evaluated for both opioid receptor and GPR-55 (a 
GPCR and novel, putative cannabinoid receptor216-217) efficacy in the PathHunter™ -arrestin 
luminescence assay format. As previously mentioned, some GPCR signaling can be 
accomplished through the G-protein independent GRK/-arrestin pathway.  If the ligands being 
tested do not operate through a G-protein mediated pathway, they will not be detected in either 
the [35S]GTP--S assay or the calcium mobilization assay.  Thus, the PathHunter™ -arrestin 
assay format will investigate if the antinociceptive effects previously seen in animal models are 
operating through the GRK/-arrestin signaling pathway.  These proposed assays are intended to 
thoroughly investigate mechanism of action behind the observed antinociceptive effects of 
dioclein and dioflorin.  Identification of a specific mechanism of action will be a boon to further 
SAR development, and speed the eventual discovery of a new ligand for the clinic or biological 
probe. 
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 These specific aims are intended to investigate the hypothesis that dioclein and dioflorin 
can be simplified and/or altered and that these derivatives will serve as novel opioid receptor 
ligands. The ability to synthesize novel opioid analogues inspired by these molecules would 
further demonstrate the utility of flavonoids as lead molecules as well as provide evidence that 
they can be employed as structural scaffolds for the construction of biologically relevant 
compounds that interact at opioid receptors. The results of these studies will be presented and 
discussed. 
Results and Discussion 
Synthesis 
 In an effort to generate SAR and elucidate the pharmacophore of flavonoids at opioid 
receptors, dioclein and several simplified analogs of dioflorin were synthesized.  The racemic 
synthesis of dioclein from commercially available materials was accomplished following the 
published procedure of Spearing et al. (Scheme 2).207  First, 2-hydroxy-4,5,6-
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trimethoxyacetophenone was condensed with 2,5-bis(benzyloxy)benzaldehyde in the presence of 
50% aqueous KOH to give chalcone 88. Treatment of chalcone 88 with KF in methanol at reflux  
afforded flavonone 89, which was globally deprotected with BCl3 to reveal the desired product, 
dioclein (86).  
The racemic synthesis of simplified dioflorin analogs (Scheme 3) began with the partial 
protection of commercially available 2’,4’,6’-trihydroxyacetophenone monohydrate as the 
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methoxymethyl (MOM) ether 90 in 66% yield using N,N-diisopropylethylamine (DIPEA) and 
chloromethyl methyl ether (MOM-Cl).208 A prenyl group was installed by refluxing 90 and 3,3-
dimethylallyl bromide in acetone/K2CO3
 to afford 91 in 92% yield.210  A thermal Claisen 
rearrangement of 91 in N,N-dimethylaniline (N,N-DMA) produced the desired prenylated 
acetophenone 92 in 46% yield.208, 210  Chalcones 97–100 were generated in 52–83% yield via 
coupling to the appropriately protected benzaldehydes (93–96, prepared in 92–95% yield from 
commercially available hydroxybenzaldehydes208-209) in the presence of NaOH in a mixture of 
water and ethanol.211  Chalcones 97–100 were then cyclized to afford flavonones 101–104 in 73–
78% yield using NaOAc in refluxing ethanol.212  Finally, flavonones 101–104 were subjected to 
acidic conditions in a global deprotection of the MOM-ether groups to afford flavonoids 105–
108 in 24–47% yield.212 
Radioligand Binding Results 
Compounds 86, 102, and 105–108 were evaluated for affinity at human opioid receptors 
using methodology previously described (Table 3).213  The results of this assay revealed that 
these flavonoid compounds have very little affinity for opioid receptors.  This was unexpected 
given that preliminary work in rodent models showed that the antinociceptive effect of dioclein 
(86) could be attenuated with the antagonist naloxone, suggesting a mechanism of action directly 
involving opioid receptors.200  However, our finding is consistent with a recent report in which it 
was found that naloxone was unable to reverse to antinociceptive effects of D. grandiflora seed 
pod extract in the formalin test in mice.205   
The flat SAR suggests that the initial hypothesis in the design of compounds 102 and 
105–108 may have been incorrect, and that the 8-methoxy group present in the parent compound 
dioflorin may be required for affinity at opioid receptors.  Also, these flavonoid compounds were  
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Table 3.  Opioid receptor binding affinity for 
compounds dioclein (86), 102, and 105–108. 
 Ki nM
a 
Compound
[3H]DAMGO 
(MOP) 
[3H]U69,593 
(KOP) 
86 >2,500 >8,700 
102 >2,500 >8,700 
105 >2,500 >8,700 
106 >2,500 >3,200 
107 >2,500 >8,700 
108 >2,500 >8,700 
aReceptor binding was performed in CHO 
cells expressing the human MOP or KOP 
receptors. 
 
synthesized in a racemic fashion, while dioflorin is a chiral molecule.  The racemic nature of the 
compounds evaluated may contribute to their apparent lack of opioid receptor affinity.  Finally, it 
is possible that the reported flavonoids dioclein and dioflorin are exerting their effects through a 
mechanism that only indirectly involves opioid receptors; this would account for both the 
apparent lack of opioid receptor affinity of dioclein, as well as the previously observed naloxone-
reversible, antinociceptive effects.  This means that the mechanism of action of the 
antinociceptive effects of the flavonoid scaffold requires further study. 
Calcium Mobilization Results 
 One drawback of the radioligand binding assay format is that it assumes that the 
compounds being scrutinized bind in such a way that would compete with or displace the 
radioligand.  However, since flavonoids are structurally distinct from other known opioid 
ligands, it may be the case that they bind to opioid receptors in an entirely different manner that 
does not lead to the displacement of the radioligand being used in the assay.  In order to 
determine this, flavonoids 86 and 105–108 were screened at all three opioid receptor subtypes in 
the calcium mobilization assay format.214  This assay format is not binding-and-displacement,  
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Table 4.  Opioid receptor potency for compounds 
dioclein (86) and 105–108 in the calcium mobilization 
assay format. 
 EC50 ± SEM nM
a 
Compound MOP KOP DOP 
DAMGO 22.6 ± 1.8   
U69,593  6.4 ± 1.4  
DPDPE   5.2 ± 3.8 
86 >10,000 >10,000 >10,000 
105 >10,000 >10,000 >10,000 
106 >10,000 >10,000 >10,000 
107 >10,000 >10,000 >10,000 
108 >10,000 >10,000 >10,000 
aReceptor binding was performed in CHO cells 
expressing the human MOP, KOP, or DOP receptors. 
 
but functional.  Thus, no matter how the ligands being investigated bind to the receptor, as long 
as they lead to activation of the traditional GPCR signal cascade, they will be detected.  Human 
Gq16 is a relatively promiscuous G-protein with regards to the number of GPCR interactions it is 
known to have.  Opioid receptors are intrinsically Gi-coupled, so for these assays each receptor 
is cotransfected with Gq16 in order to stimulate the Gq pathway.
215 When an agonist binds to the 
chimeric Gq16-opioid receptor and activates the Gq GPCR signal cascade, intracellular calcium 
is mobilized and changes in calcium concentration can be detected with a calcium-sensitive 
fluorescent dye and a fluorimetric plate reader.   
 Unfortunately, while the standard agonists behaved as expected, none of the flavonoid 
ligands generated a dose-response curve to indicate that the EC50 would be less than 10 M 
(Table 4).  The same possibilities to explain the lack of affinity of these ligands in the 
radioligand binding assays apply to these opioid receptor calcium mobilization assays as well. 
 In an attempt to determine if flavonoids 86 and 105–108 were interacting indirectly with 
opioid receptors via the stimulation of cannabinoid receptors, these compounds were screened at 
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CB1 cannabinoid receptors in the calcium mobilization assay format.  And again, unfortunately, 
while the standard agonist behaved as expected, none of the flavonoid ligands generated a dose-
response curve to indicate that the EC50 would be less than 10 M (Table 5). 
Table 5.  CB1 receptor potency for 
compounds dioclein (86) and 105–108 in the 
calcium mobilization assay format. 
Compound CB1 EC50 nM
a ± SEM 
CP55,940 26.3 ± 14 
86 >10,000 
105 >10,000 
106 >10,000 
107 >10,000 
108 >10,000 
aReceptor binding was performed in CHO 
cells expressing the human CB1 receptor. 
 
-Arrestin Luminescence Results 
 Finally, in an attempt to determine if flavonoids 86 and 105–108 were interacting with 
opioid receptors in a G-protein independent manner, these compounds were screened at both 
KOP receptors and GPR-55 receptors in the PathHunter™ -arrestin luminescence assay format.  
This assay platform uses an enzyme fragment complementation technique in which 
complementing fragments of the -galactosidase enzyme are expressed in different 
compartments of a stably transfected cell; one enzyme fragment is localized within the cell and 
the other fragment is fused to an extra-cellular portion of the GPCR of interest.218  When an 
agonist binds to the GPCR and activates signaling, -arrestin is recruited and the fused receptor 
is internalized.  Upon receptor internalization, the two fragments of the enzyme meet, forming a 
functional -galactosidase enzyme that hydrolyzes a proprietary substrate and generates a 
chemiluminescent signal that can be detected with a microplate reader.    
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Table 6.  Receptor potency for compounds 
dioclein (86) and 105–108 in the -arrestin 
assay format. 
 EC50 nM
a ± SEM 
Compound KOP GPR-55 
U69,593 152 ± 79  
LPI  2.1 ± 1.1 (M) 
86 >10,000 >10,000 
105 >10,000 >10,000 
106 >10,000 >10,000 
107 >10,000 >10,000 
108 >10,000 >10,000 
aReceptor binding was performed in CHO 
cells expressing the human KOP or GPR-55 
receptors. 
 
Unfortunately, not only did the test ligands once again fail to generate a dose-response 
curve to indicate that the EC50 would be less than 10 M while the standard agonist ligands 
behaved as expected (Table 6), but in the GPR-55 assay, the test compounds appeared to be toxic 
to the cells at concentrations above 100 nM.  Additionally, the flavonoid ligands were screened 
at KOP receptors at 10 M for antagonist ability against 1 M U69,593, and at GPR-55 
receptors at 10 M for antagonist ability against 3 M LPI.  While 10 M naltrexone completely 
knocked down U69,593 receptor activation, none of the test ligands appeared to have any effect.  
Similarly, none of the test ligands were able to knock down LPI receptor activation either.  Once 
again, these results mean that the mechanism of action of the antinociceptive effects of the 
flavonoid scaffold requires further study. 
Conclusions 
 Given the collective findings, it is apparent that the mechanism of action that underlies 
the antinociceptive effects of dioclein and dioflorin is more complex than simple opioid receptor 
activation.  While dioclein itself and five simplified analogs of dioflorin were successfully 
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generated through organic synthetic methods, none of the tested flavonoids appeared to activate 
opioid receptors through the traditional G-protein coupled pathway or through the GRK/-
arrestin pathway.  Further, none of the tested flavonoids appeared to activate CB1 cannabinoid 
receptors either, which would indicate an indirect opioid-activation mechanism.  The reasons for 
these failures may be because the initial hypothesis was incorrect, and that the 8-methoxy group 
present in the parent compound dioflorin may be required for affinity at opioid receptors.  Also, 
these flavonoid compounds were synthesized in a racemic fashion, while dioflorin is a chiral 
molecule.  The racemic nature of the compounds evaluated may contribute to their apparent lack 
of activity.  Additionally, in the rodent studies reported in the literature, the flavonoids being 
tested were isolated from D. grandiflora plant material, not generated synthetically.  It is 
possible that the molecules identified as the constituents responsible for antinociceptive activity 
were inactive, yet the samples contained a small amount of unidentified impurity that was the 
active compound.  Finally, it is also possible that these compounds exert their effects through a 
receptor system not examined in this report.     
Future Directions 
 One in vitro experiment that may be worth performing is an assay to determine if these 
flavonoids have any effect on the dopamine transporter (DAT).  In the synapse, dopamine is 
inactivated mainly by reuptake into the neuron by DAT.219  Because changes in dopamine 
concentration have been linked to many CNS disorders, a compound that modulates the activity 
of DAT (and therefore dopamine concentration) is potentially useful as both a drug and an 
experimental probe.  Flavonoids that modulate the DAT have been reported.219 
Finally, in order to make progress in determining the mechanism, if any, of the 
antinociceptive effects of the flavonoid scaffold, the previously reported rodent studies need to 
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be repeated.  Confirming that these flavonoids have antinociceptive effects in rodents would 
make it more worthwhile to keep performing in vitro experiments to determine the mechanism of 
action behind such activity.  Furthermore, these rodent studies should ideally be revisited with 
both plant-extracted and synthetic compound, especially for dioclein, whose antinociceptive 
effects were found to be naloxone-reversible.  This would determine whether or not the reported 
flavonoids are actually responsible for the observed effects, or if the responsible constituent is an 
unidentified impurity in the plant extract. 
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CHAPTER 3: EXPERIMENTAL PROCEDURES FOR FLAVONOID ANALOGS 
Chemistry 
General Procedures.  Unless otherwise indicated, all reagents were purchased from 
commercial suppliers and are used without further purification.  All melting points were 
determined on a Thomas–Hoover capillary melting apparatus and are uncorrected.  NMR spectra 
were recorded on a Bruker Avance-300 spectrometer, Bruker DRX-400 with qnp probe or a 
Bruker AV-500 with cryoprobe using  values in ppm (TMS as internal standard) and J (Hz) 
assignments of 1H resonance coupling. High resolution mass spectrometry data was collected on 
a LCT Premier (Waters Corp., Milford, MA) time of flight mass spectrometer or an Agilent 6890 
N gas chromatograph in conjunction with a Quatro Micro GC mass spectrometer (Micromass 
Ltd, Manchester UK).  Thin-layer chromatography (TLC) was performed on 0.25 mm plates 
Analtech GHLF silica gel plates using mixtures of EtOAc/n-hexanes as the solvent system.  
Spots on TLC were visualized when appropriate with 254 nm UV light, phosphomolybdic acid 
in ethanol, or vanillin in ethanol.  Column chromatography was performed with Silica Gel (32–
63  particle size) from MP Biomedicals (Solon, OH).  Analytical HPLC was carried out on an 
Agilent 1100 Series Capillary HPLC system with diode array detection at 209 nm, 214 nm, and 
235 nm on a Phenomenex Luna C18 column (250 × 10.0 mm, 5 m) with isocratic elution in 
mixtures of CH3CN/H2O as noted at a flow rate of 5.0 mL/min. 
General Procedure A: MOM Protection.208-209  Chloromethyl methyl ether (3.0 equiv.) 
was added in a dropwise manner to a solution of the appropriate substrate (1.0 equiv.) and N,N-
diisopropylethylamine (3.0 equiv.) in anhydrous methylene chloride at 0 °C under an argon 
atmosphere.  The reaction mixture was allowed to reach room temperature and stirred for 4 h – 6 
h, until complete or no additional progress as observed by TLC.  The reaction was quenched by 
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the addition of a solution of saturated aqueous NH4Cl.  This mixture was then extracted three 
times with 1:1 DCM/H2O.  The organic layers were combined, dried over Na2SO4, filtered, and 
the solvent removed in vacuo.  The resulting residue was purified by flash column 
chromatography using EtOAC/n-hexanes (1:5) to yield the known MOM protected products. 
 
1-(2-hydroxy-4,6-bis(methoxymethoxy)phenyl)ethanone (90). Synthesized following 
general procedure A to afford 4.4393 g (66% yield) as a colorless oil that solidified upon 
standing overnight at room temperature, Rf = 0.45 (EtOAc/n-hexanes 1:5).  Spectral data in 
agreement with reported.208  
 
2-(Methoxymethoxy)benzaldehyde (94).  Synthesized following general procedure A to 
afford 1.5024 g (92% yield) as a light red-brown oil, Rf = 0.47 (EtOAc/n-hexanes 1:5).  Spectral 
data in agreement with reported.209  
H
O
OMOM  
3-(Methoxymethoxy)benzaldehyde (95).  Synthesized following general procedure A to 
afford 1.5100 g (91% yield) as a light yellow oil, Rf = 0.42 (EtOAc/n-hexanes 1:5).  Spectral data 
in agreement with reported.209  
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4-(Methoxymethoxy)benzaldehyde (96).  Synthesized following general procedure A to 
afford 1.5867 g (95% yield) as a light yellow oil, Rf = 0.40 (EtOAc/n-hexanes 1:5).  Spectral data 
in agreement with reported.209  
 
1-(2,4-bis(methoxymethoxy)-6-((3-methylbut-2-en-1-yl)oxy)phenyl)ethanone (91).  
Synthesized following the procedures of Vogel et al.210  3,3-dimethylallyl bromide (1.47 mL, 
11.7 mmol, 1.5 equiv.), K2CO3 (4.31 g, 31.2 mmol, 4 equiv.), and acetophenone 90 (2.00 g, 37.8 
mmol) were refluxed in acetone (30 mL) for 24 h.  The reaction mixture was allowed to cool to 
room temperature and the solids were filtered off and the filtrate evaporated.  The resulting 
residue was purified by flash column chromatography using EtOAc/n-hexanes (1:5) to afford 
2.3504 g (92% yield) of the known prenylated product as a colorless oil, Rf = 0.37 (EtOAc/n-
hexanes 1:5).  Spectral data in agreement with reported.210  
 
1-(6-hydroxy-2,4-bis(methoxymethoxy)-3-(3-methylbut-2-en-1-yl)phenyl)ethanone 
(92).  Synthesized following the procedures of Vogel at al.210  Acetophenone 91 was refluxed in 
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N,N-dimethylaniline (10 mL) for 4 h.  The reaction mixture was allowed to cool to room 
temperature and diluted with 50 mL of EtOAc.  The organic layer was washed with 1 N HCl (3 × 
50 mL), dried over Na2SO4, filtered, and the solvent removed in vacuo. The resulting residue 
was purified by flash column chromatography using a gradient of EtOAc/n-hexanes (1:20 to 1:5) 
to afford 0.2103 g (46 % yield) of the rearranged product as a yellow-orange oil, Rf = 0.60 
(EtOAc/n-hexanes 1:5).  Spectral data in agreement with reported.210  
General Procedure B: Synthesis of Chalcones (97–100).211  The appropriate MOM 
protected benzaldehyde (93–96, 1.1 equiv.) was added in a dropwise manner to a solution of 
acetophenone 92 (1 equiv.) in 2 mL of absolute EtOH and 3.25 mL of 2.75 M NaOH.  The 
mixture was allowed to warm to room temperature and stirred overnight.  The reaction was 
quenched by the addition of saturated aqueous NH4Cl (10 mL), and extracted into diethyl ether 
(3 × 10 mL).  The combined organic layers were dried over Na2SO4, filtered, and the solvent 
removed in vacuo.  The resulting residue was purified by flash column chromatography using a 
gradient of EtOAc/n-hexanes (1:20 to 1:10) to yield the chalcones as yellow-orange oils. 
 
(E)-1-(6-Hydroxy-2,4-bis(methoxymethoxy)-3-(3-methylbut-2-enyl)phenyl)-3-
phenylprop-2-en-1-one (97).  Synthesized using general procedure B to afford 0.3507 g (83% 
yield) as a yellow oil, Rf = 0.35 (EtOAc/n-hexanes 1:20).  
1H NMR (500 MHz, CDCl3)  12.82 
(s, 1H), 7.84 (s, 2H), 7.68 – 7.62 (m, 2H), 7.46 – 7.38 (m, 3H), 6.51 (s, 1H), 5.23 (s, 2H), 5.21 – 
5.16 (m, 1H), 4.89 (s, 2H), 3.46 (d, 6H), 3.37 (d, 2H), 1.79 (s, 3H), 1.70 (s, 3H).  13C NMR (126 
MHz, CDCl3)  193.00, 163.79, 161.65, 156.96, 143.03, 135.10, 131.50, 130.40, 128.96, 128.56, 
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126.60, 123.03, 116.66, 111.01, 101.82, 98.80, 93.92, 58.41, 56.34, 25.76, 22.95, 17.92.  HRMS 
(m/z): [M-H] calcd for C24H27O6, 411.1808; found 411.1639.   
 
(E)-1-(6-Hydroxy-2,4-bis(methoxymethoxy)-3-(3-methylbut-2-enyl)phenyl)-3-(2-
(methoxymethoxy)phenyl)prop-2-en-1-one (98).  Synthesized using general procedure B to 
afford 0.3440 g (52% yield) as a yellow oil, Rf = 0.27 (EtOAc/n-hexanes 1:10).  
1H NMR (500 
MHz, CDCl3)  12.86 (s, 1H), 8.24 (d, 1H), 7.86 (d, 1H), 7.70 (dd, 1H), 7.37 – 7.32 (m, 1H), 
7.20 – 7.16 (m, 1H), 7.04 (t, 1H), 6.50 (s, 1H), 5.28 (s, 2H), 5.23 (s, 2H), 5.21 – 5.17 (m, 1H), 
4.90 (s, 2H), 3.52 (s, 3H), 3.46 (d, 6H), 3.37 (d, 2H), 1.79 (s, 3H), 1.69 (s, 3H).  13C NMR (126 
MHz, CDCl3)  193.32, 163.72, 161.49, 157.07, 156.46, 138.05, 131.70, 131.43, 128.30, 126.92, 
124.71, 123.09, 121.94, 116.57, 114.80, 111.06, 101.86, 98.75, 94.55, 93.92, 58.36, 56.37, 56.33, 
25.77, 22.95, 17.91.  HRMS (m/z): [M-H] calcd for C26H31O8, 471.2019; found 471.1839.   
 
(E)-1-(6-Hydroxy-2,4-bis(methoxymethoxy)-3-(3-methylbut-2-enyl)phenyl)-3-(3-
(methoxymethoxy)phenyl)prop-2-en-1-one (99).  Synthesized using general procedure B to 
afford 0.3278 g (71% yield) as a yellow oil, Rf = 0.33 (EtOAc/n-hexanes 1:10).  
1H NMR (500 
MHz, CDCl3)  12.83 (s, 1H), 7.84 – 7.77 (m, 2H), 7.36 – 7.28 (m, 3H), 7.11 – 7.07 (m, 1H), 
6.51 (s, 1H), 5.23 (s, 2H), 5.22 (s, 2H), 5.21 – 5.16 (m, 1H), 4.89 (s, 2H), 3.50 (s, 3H), 3.48 (s, 
3H), 3.46 (s, 3H), 3.37 (d, 2H), 1.79 (s, 3H), 1.70 (s, 3H).  13C NMR (126 MHz, CDCl3)  
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192.94, 163.83, 161.68, 157.65, 156.95, 142.76, 136.60, 131.51, 129.97, 127.01, 123.03, 122.25, 
118.19, 116.67, 116.14, 111.00, 101.78, 98.80, 94.47, 93.93, 58.39, 56.34, 56.10, 25.76, 22.96, 
17.92.  HRMS (m/z): [M-H] calcd for C26H31O8, 471.2019; found 471.1840.    
 
(E)-1-(6-Hydroxy-2,4-bis(methoxymethoxy)-3-(3-methylbut-2-enyl)phenyl)-3-(4-
(methoxymethoxy)phenyl)prop-2-en-1-one (100).  Synthesized using general procedure B to 
afford 0.3030 g (77% yield) as a yellow oil, Rf = 0.34 (EtOAc/n-hexanes 1:10).  Spectral data in 
agreement with reported.220   
General Procedure C: Synthesis of Flavonones (101–104).221  A mixture of the 
appropriate chalcone (97–100, 1 equiv.) and NaOAc (5 equiv.) in 5 mL of EtOH with 3 drops of 
water was refluxed for 24 hours.  The mixture was poured into 10 mL of ice-cold water and 
extracted with EtOAc (3 × 15 mL).  The combined organic layers were dried over Na2SO4, 
filtered, and the solvent removed in vacuo.  The resulting residue was purified by flash column 
chromatography using EtOAc/n-hexanes (1:10) to yield the flavonones as yellow oils.  
 
5,7-bis(methoxymethoxy)-6-(3-methylbut-2-enyl)-2-phenylchroman-4-one (101).  
Synthesized using general procedure C to afford 0.2116 g (73% yield) as a light yellow oil.  Rf = 
0.20 (EtOAc/n-hexanes 1:10).  1H NMR (500 MHz, CDCl3)  7.48 – 7.35 (m, 5H), 6.56 (s, 1H), 
5.41 (dd, J = 2.8, 13.4, 1H), 5.24 – 5.17 (m, 4H), 5.07 (d, J = 6.7, 1H), 3.61 (s, 3H), 3.45 (s, 3H), 
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3.39 (d, J = 6.7, 2H), 3.00 (dd, J = 13.4, 16.8, 1H), 2.77 (dd, J = 2.8, 16.8, 1H), 1.78 (s, 3H), 1.66 
(d, J = 1.0, 3H).  13C NMR (126 MHz, CDCl3)  189.33, 162.68, 161.57, 156.91, 138.62, 131.34, 
128.80, 128.71, 126.11, 122.80, 118.93, 108.82, 101.66, 98.39, 93.85, 78.86, 57.69, 56.31, 45.42, 
25.75, 22.70, 17.89.  HRMS (m/z): [M+Na] calcd for C24H28O6Na, 435.1748; found 435.1776.   
 
5,7-bis(methoxymethoxy)-2-(2-(methoxymethoxy)phenyl)-6-(3-methylbut-2-
enyl)chroman-4-one (102).  Synthesized using general procedure C to afford 0.2925 g (73% 
yield) as a yellow oil.  Rf = 0.17 (EtOAc/n-hexanes 1:10).  
1H NMR (500 MHz, CDCl3)  7.63 – 
7.59 (m, 1H), 7.33 – 7.28 (m, 1H), 7.18 – 7.13 (m, 1H), 7.12 – 7.07 (m, 1H), 6.57 (s, 1H), 5.79 
(dd, 1H), 5.25 – 5.18 (m, 6H), 5.09 (d, 1H), 3.63 (s, 3H), 3.47 (s, 3H), 3.45 (s, 3H), 3.42 – 3.38 
(m, 2H), 2.87 – 2.83 (m, 2H), 1.78 (s, 3H), 1.67 (s, 3H).  13C NMR (126 MHz, CDCl3)  189.95, 
163.10, 161.45, 156.95, 153.55, 131.31, 129.41, 127.88, 126.45, 122.86, 122.03, 118.78, 113.88, 
108.84, 101.65, 98.37, 94.27, 93.85, 73.90, 57.68, 56.31, 56.24, 44.65, 25.75, 22.70, 17.89.  
HRMS (m/z): [M+Na] calcd for C26H32O8Na, 495.1995; found 495.1937.  HPLC in 60% 
MeCN/40% H2O, tR = 28.902 min; purity = 99.1%. 
 
5,7-bis(methoxymethoxy)-2-(3-(methoxymethoxy)phenyl)-6-(3-methylbut-2-
enyl)chroman-4-one (103).  Synthesized using general procedure C to afford 0.2975 g (78% 
yield) as a yellow oil.  Rf = 0.13 (EtOAc/n-hexanes 1:10).  
1H NMR (400 MHz, CDCl3)  7.34 (t, 
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1H), 7.15 – 7.12 (m, 1H), 7.10 – 7.02 (m, 2H), 6.56 (s, 1H), 5.38 (dd, 1H), 5.25 – 5.16 (m, 6H), 
5.06 (d, 1H), 3.62 (s, 3H), 3.50 (s, 3H), 3.45 (s, 3H), 3.40 (d, 2H), 2.98 (dd, 1H), 2.77 (dd, 1H), 
1.78 (s, 3H), 1.66 (s, 3H).  13C NMR (126 MHz, CDCl3)  189.24, 162.61, 161.59, 157.63, 
156.91, 140.27, 131.32, 129.93, 122.83, 119.48, 118.99, 116.33, 114.16, 108.87, 101.65, 98.43, 
94.48, 93.89, 78.68, 57.68, 56.31, 56.09, 45.45, 25.73, 22.71, 17.88.  HRMS (m/z): [M+Na] 
calcd for C26H32O8Na, 495.1995; found 495.1713.     
 
5,7-bis(methoxymethoxy)-2-(4-(methoxymethoxy)phenyl)-6-(3-methylbut-2-
enyl)chroman-4-one (104).  Synthesized using general procedure C to afford 0.2800 g (74% 
yield) as a yellow oil.  Rf = 0.14 (EtOAc/n-hexanes 1:10).  Spectral data in agreement with 
reported.220   
General Procedure D: Synthesis of Flavonoids (105–108).221 3N HCl (2 mL) was 
added to a solution of the appropriate flavonone (101–104) in MeOH (10 mL).  The mixture was 
refluxed for 45 min then poured into 10 mL of ice-cold water and extracted with EtOAc (3 × 20 
mL).  The combined organic layers were dried over Na2SO4, filtered, and the solvent removed in 
vacuo.  The resulting residue was purified by flash column chromatography using EtOAc/n-
hexanes (1:4) to yield the flavonoids as off-white to yellow powders. 
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5,7-dihydroxy-6-(3-methylbut-2-enyl)-2-phenylchroman-4-one (105).  Synthesized 
using general procedure D to afford 0.0171 g (24% yield) as off-white powder, mp 196–198 °C.  
Rf = 0.68 (EtOAc/n-hexanes 1:3).  
1H NMR (500 MHz, CDCl3)  12.40 (s, 1H), 7.42 (m, J = 7.5, 
15.9, 5H), 6.20 (s, 1H), 6.01 (s, 1H), 5.40 (dd, J = 3.0, 13.0, 1H), 5.26 (m, 1H), 3.36 (d, J = 7.1, 
2H), 3.08 (dd, J = 13.0, 17.1, 1H), 2.83 (dd, J = 3.1, 17.2, 1H), 1.82 (s, 3H), 1.77 (s, 3H).  13C 
NMR (126 MHz, CDCl3)  196.05, 163.93, 161.39, 161.16, 138.64, 135.95, 129.00, 128.97, 
126.27, 121.51, 107.06, 103.10, 95.72, 79.23, 43.61, 26.00, 21.28, 18.04. HRMS (m/z): [M-H] 
calcd for C20H19O4, 323.1283; found 323.1167.  HPLC in 65% MeCN/35% H2O, tR = 12.207 
min; purity = 95.5%. 
 
5,7-dihydroxy-2-(2-hydroxyphenyl)-6-(3-methylbut-2-enyl)chroman-4-one (106).  
Synthesized using general procedure D to afford 0.0277 g (37% yield) as light yellow powder, 
mp. 178–180 °C.  Rf = 0.30 (EtOAc/n-hexanes 1:3).  
1H NMR (500 MHz, Acetone)  12.48 (s, 
1H), 7.55 – 7.51 (m, 1H), 7.24 – 7.19 (m, 1H), 6.97 – 6.91 (m, 2H), 6.09 (s, 1H), 5.78 (dd, 1H), 
5.27 – 5.22 (m, 1H), 3.26 (d, 2H), 3.09 (dd, 1H), 2.83 (dd, 1H), 1.75 (s, 3H), 1.64 (s, 3H).   13C 
NMR (126 MHz, Acetone)  197.95, 165.30, 162.84, 162.73, 155.30, 131.77, 130.68, 128.21, 
127.01, 124.10, 121.21, 116.80, 109.60, 103.61, 95.85, 75.83, 43.13, 26.39, 22.16, 18.36.  
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HRMS (m/z): [M-H] calcd for C20H19O5, 339.1233; found 339.1140.  HPLC in 50% MeCN/50% 
H2O, tR = 20.062 min; purity = 96.7%.   
 
5,7-dihydroxy-2-(3-hydroxyphenyl)-6-(3-methylbut-2-enyl)chroman-4-one (107).  
Synthesized using general procedure D to afford 0.0471 g (47% yield) as light yellow powder, 
mp. 185–187 °C.  Rf = 0.28 (EtOAc/n-hexanes 1:3).  
1H NMR (500 MHz, Acetone)  12.45 (s, 
1H), 7.25 (t, 1H), 7.05 – 6.97 (m, 2H), 6.88 – 6.82 (m, 1H), 6.06 (s, 1H), 5.47 (dd, 1H), 5.26 – 
5.20 (m, 1H), 3.25 (d, 2H), 3.11 (dd, 1H), 2.78 (dd, 1H), 1.75 (s, 3H), 1.64 (s, 3H).  13C NMR 
(126 MHz, Acetone)  197.47, 165.30, 162.77, 162.27, 158.97, 142.23, 131.79, 131.08, 124.03, 
118.76, 116.72, 114.62, 109.62, 103.64, 95.82, 80.26, 44.24, 26.36, 22.12, 18.34.  HRMS (m/z): 
[M-H] calcd for C20H19O5, 339.1233; found 339.1027.  HPLC in 50% MeCN/50% H2O, tR = 
16.271 min; purity = 96.3%. 
 
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-enyl)chroman-4-one (108).220  
Synthesized using general procedure D to afford 0.0396 g (36% yield) as yellow powder, mp. 
188–190 °C.  Rf = 0.23 (EtOAc/n-hexanes 1:3).  
1H NMR (500 MHz, Acetone)  12.34 (s, 1H), 
7.29 – 7.20 (m, 2H), 6.79 – 6.73 (m, 2H), 5.90 (s, 1H), 5.29 (dd, 1H), 5.14 – 5.06 (m, 1H), 3.12 
(d, 2H), 3.03 (dd, 1H), 2.58 (dd, 1H), 1.62 (s, 3H), 1.50 (s, 3H).  13C NMR (126 MHz, Acetone) 
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 197.86, 165.31, 162.77, 162.51, 159.16, 131.74, 131.44, 129.52, 124.08, 116.64, 109.51, 
103.60, 95.79, 80.38, 44.11, 26.36, 22.12, 18.33.  HRMS (m/z): [M-H] calcd for C20H19O5, 
339.1233; found 339.1169.  HPLC in 50% MeCN/50% H2O, tR = 16.136 min; purity = 96.6%. 
 
Dioclein (86).207  Synthesized following the procedures of Spearing et al.207 to afford 
0.0245 g (23% yield over 3 steps) as a yellow powder.  Rf = 0.33 (EtOAc/n-hexanes 1:1).  
1H 
NMR (500 MHz, Acetone)  11.99 (s, 1H), 8.20 (s, 1H), 7.91 (s, 1H), 7.03 (d, 1H), 6.78 (d, 1H), 
6.70 (dd, 1H), 6.24 (s, 1H), 5.75 (dd, 1H), 3.92 (s, 3H), 3.72 (s, 3H), 3.08 (dd, 1H), 2.85 (dd, 
1H).  13C NMR (126 MHz, Acetone)  198.83, 162.53, 160.55, 156.45, 152.00, 147.97, 131.75, 
127.45, 117.59, 117.10, 114.59, 104.24, 93.09, 76.20, 61.03, 57.14, 43.12.  HRMS (m/z): [M-H] 
calcd for C17H15O7, 331.0818; found 331.0627.  HPLC in 40% MeCN/60% H2O, tR = 5.480 min; 
purity = 97.6%. 
Binding and Efficacy Studies 
Radioligand Binding Studies.213  MOP receptor binding sites were labeled using [3H]D-
Ala2-MePhe4,Gly-ol5]-enkephalin ([3H]DAMGO, SA = 44 – 48 Ci/mmol) while DOP receptor 
binding sides were labeled using [3H][D-Ala2, D-Leu5]-enkephalin ([3H]DADLE, SA = 40 – 50 
Ci/mmol)  in rat brain homogenates.  KOP receptor binding sites were labeled using [3H]N-
methyl-2-phenyl-N-[(5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]dec-8-yl]acetamide 
([3H]U69,593, SA = 50 Ci/mmol).  On the day of the assay, Cell pellets were thawed on ice for 
15 minutes followed by homogenization with a polytron in 10 mL/pellet of ice-cold 10mM Tris-
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HCl, pH 7.4.  The membranes were centrifuged at 30,000 × g for 10 minutes, then resuspended 
in 10 mL/pellet ice-cold 10mM Tris-HCl, pH 7.4 followed again by centrifugation at 30,000 × g 
for 10 minutes.  Membranes were then resuspended in 25°C 50 mM Tris-HCl, pH 7.4 (~100 
mL/pellet hMOP-CHO, 50 mL/pellet hDOP-CHO, and 120 mL/pellet hKOP-CHO).  All assays 
were performed in 50 mM Tris-HCl, pH 7.4 in a final assay volume of 1.0 mL, with a protease 
inhibitor cocktail: bacitracin (100 µg/mL), bestatin (10 µg/mL), leupeptin (4 µg/mL) and 
chymostatin (2 µg/mL).  Drug dilution curves were determined with buffer containing 1 mg/mL 
BSA. 20 μM levallorphan ([3H]DAMGO and [3H]DADLE) or 10 μM (-)-U69,593 (for 
[3H]U69,593 binding) was used to account for nonspecific binding.  [3H]Radioligands were used 
at concentrations of approximately 2 nM.  After 2 hours of incubation at 25°C, triplicate samples 
were filtered with Brandell Cell Harvesters (Biomedical Research & Development Inc., 
Gaithersburg, MD), over Whatman GF/B filters.  The filters were the punched into 24-well 
plates in which 0.6 mL of LSC-cocktail (Cytoscint) was added.  After an overnight extraction, 
the samples were counted in a Trilux liquid scintillation counter at 44% efficiency.  
Approximately 30 μg protein was in each assay tube for the opioid binding assays.  The 
inhibition curves were determined by displacing a single concentration of radioligand by 10 
concentrations of drug. 
Calcium Mobilization Assay.214  All cells were maintained in F-12 nutrient medium 
(Ham), supplemented with 10% fetal bovine serum (FBS), 1% penicillin and streptomycin (p/s), 
and 0.2% normocin. Cell culture supplies were from Invitrogen (Carlsbad, CA) unless otherwise 
specified.  Chinese hamster ovary (CHO) cells stably expressing MOR-, KOR-, DOR-, or CB1-
Gαq16 were removed from their flasks using Versene and quenched with the Ham media, 
centrifuged and re-suspended in media. Cells were counted with a Cellometer Auto T4 
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(Nexcelom Bioscience, Lawrence, MA) and 30,000 cells were transferred to each well of a black 
Costar 96-well optical bottom plate (Corning Corporation, Corning, NY). Each plate was 
incubated at 37°C/5% CO2 overnight to confluence. The culture media was removed from the 
plates and cells were subsequently loaded with a fluorescent calcium probe (Calcium 5 dye, 
Molecular Devices, Sunnyvale, CA) in an HBSS-based buffer containing 20 mM HEPES, 0.25% 
BSA, 1% DMSO (or 0.5% DMSO + 0.5% EtOH for CB1-expressing cells), and 10 μM 
probenecid (Sigma) in a total volume of 225 µL. Cells were incubated at 37°C/5% CO2 for 1 h 
and then stimulated with DMSO solutions of DAMGO, U69,593, DPDPE, ethanol solutions of 
CP55,940 or DMSO solutions of test compounds at various concentrations using a Flexstation 3 
plate-reader, which automatically added 25 µL of the compounds at 10X concentration to each 
well after reading baseline values for ∼17 sec. Agonist-mediated change in fluorescence (485 nm 
excitation, 525 nm emission) was monitored in each well at 1.52 sec intervals for 60 sec and 
reported for each well. Data were collected using Softmax version 4.8 (MDS Analytical 
Technologies) and analyzed using Prism software (GraphPad, La Jolla, CA). Nonlinear 
regression analysis was performed to fit data and obtain maximum response (Emax), EC50, 
correlation coefficient (r2) and other parameters. All experiments were performed at least 2 
times to ensure reproducibility and data reported as mean ± standard error, unless noted 
otherwise. 
PathHunter™ -Arrestin Assay.218 All cells were maintained in F-12 nutrient medium 
(Ham), supplemented with 10% fetal bovine serum (FBS), 1% penicillin and streptomycin (p/s), 
and 0.2% normocin. Cell culture supplies were from Invitrogen (Carlsbad, CA) unless otherwise 
specified.  Chinese hamster ovary (CHO) cells stably expressing KOP or GPR-55 were removed 
from their flasks using Cell Dissociation Buffer and quenched with the Ham media, centrifuged 
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and re-suspended in media. Cells were counted with a Cellometer Auto T4 (Nexcelom 
Bioscience, Lawrence, MA) and a volume of cell suspension to equal 30,000 cells/well was 
centrifuged and re-suspended in PathHunter™ Cell Plating 2 Reagent. 90 L of the cell 
suspension was transferred to each well of white Costar 96-well optical bottom plates (Corning 
Corporation, Corning, NY).  Each plate was incubated at 37°C/5% CO2 overnight to confluence.  
U69,593, LPI, or test compounds at various concentrations were dissolved in a PBS-based buffer 
containing 10% DMSO.  10 L of the compound solutions were transferred to the assay plates, 
making a total well volume of 100 L and 1% DMSO concentration.  Cells were incubated at 
37°C/5% CO2 for 90 min, and then 50 L of detection reagents (prepared from the assay kit as a 
working solution the day of the assay: 1 part Galacton Star® + 5 parts Emerald II™ + 19 parts 
PathHunter™ Cell Assay Buffer) were transferred to each well.  The cells were incubated at 
room temperature in the dark for 1 h, and then the luminescence read using a Flexstation 3 plate 
reader.  Data were collected using Softmax version 4.8 (MDS Analytical Technologies) and 
analyzed using Prism software (GraphPad, La Jolla, CA). Nonlinear regression analysis was 
performed to fit data and obtain maximum response (Emax), EC50, correlation coefficient (r2) and 
other parameters. All experiments were performed at least 2 times to ensure reproducibility and 
data reported as mean ± standard error, unless noted otherwise. 
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CHAPTER 4: FUTHER INVESTIGATION OF THE BINDING MODE OF 
SALVINORIN A AT KOP RECEPTORS 
Introduction 
 Salvinorin A (108), structurally classified as a neoclerodane diterpene, is the principle 
constituent responsible for the psychoactivity of the widely available plant Salvia divinorum 
Epling & Jativa (Lamiaceae).222  The structure and absolute configuration of salvinorin A were 
determined through NMR and X-ray crystallography studies.223-224  S. divinorum is indigenous to 
Oaxaca, Mexico and an infusion of the leaves is used traditionally by native shamans for 
divination ceremonies, to treat the magical curse panzón de borrego, as well as to treat mundane 
ailments such as anemia, diarrhea, headache, and rheumatism.222, 225  Salvinorin A is a potent 
hallucinogen and rivals classical hallucinogens such as lysergic acid diethylamide (109, LSD) 
and 4-bromo-2,5-dimethoxyamphetamine (110, DOB).226-227 Because of the intense experience it 
produces, S. divinorum has become popular as a recreational drug.228-229  This has caused S. 
divinorum to be labeled as a “drug of concern” by the Drug Enforcement Administration (DEA), 
and several states in the U. S. have enacted legislation to criminalize its use and sale.230-231  
Interestingly, unlike the classical hallucinogens, salvinorin A does not exert its effects 
through the 5-HT2A (serotonin) receptor.
180  Rather, it was found to be a selective agonist at KOP 
receptors.180  Salvinorin A is the first non-nitrogenous compound to have high affinity and 
selectivity for the KOP receptor, and its structure is unique among known KOP ligands, such as 
bremazocine, U69,593, JDTic, norBNI, and GNTI, as well as known hallucinogens, such as 
LSD, DOB, and phencyclidine (111, PCP) (Figure 18).  Previous hypotheses proposed that a 
basic nitrogen atom was required for opioid receptor affinity; at physiological pH, the positively  
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charged nitrogen atom in the ligand would interact with an aspartic acid residue in the third 
transmembrane region of the GPCR.232-234  However, salvinorin A lacks a nitrogen atom, 
indicating that hypotheses for opioid receptor-ligand binding interactions merit re-evaluation.235  
Given the molecule’s unique features, salvinorin A is a target for pharmacological exploration 
and SAR development. 
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Terpenes 
As previously stated, salvinorin A is structurally classified as a neoclerodane diterpene.  
Neoclerodane diterpenes are a subclass of the terpene class of natural products.  Terpenes 
provide interesting investigational targets for organic chemists and pharmacologists because of 
their structural complexity, diversity, and unique pharmacological profiles.236  Many clinically 
used medications, such as taxol (anti-cancer) and artemisinin (anti-malarial), are members of the 
terpene class.  Because they are secondary metabolites, terpenes are found in very low 
concentrations in living organisms.237  
Biosynthetically, terpenes are constructed from chemically activated isoprene units, 3-
isopentenyl pyrophosphate (115, IPP) and dimethylallyl pyrophosphate (116, DMAPP), which 
are produced from the mevalonic acid pathway (Figure 19).238-242  In the mevalonic acid 
pathway, two units of acetyl CoA condense, facilitated by acetyl CoA transferase (ACT), to yield 
acetoacetyl CoA.  This then condenses with another unit of acetyl CoA to produce 3-hydroxy-3-
methylglutaryl CoA (112, HMG CoA) via the help of HMG CoA synthase (HMGCS).  HMG 
CoA is then reduced to mevalonate (113) by HMG CoA reductase (HMGCR), which is NADPH 
dependent.  Mevalonate is subsequently phosphorylated first by mevalonate kinase (MVK), then 
by phosphomevalonate kinase (PMVK), yielding mevalonate-5-pyrophosphate (114).  The 
actions of a decarboxylase enzyme then afford IPP, which itself can be enzymatically isomerized 
to DMAPP.243  In order to build terpenes, chain elongation of DMAPP and/or IPP units occurs 
through a series of electrophilic alkylations that consist of three steps: 1) removal of the carbon-
oxygen bond of DMAPP/IPP to form a carbocation;244 2) alkylation of the double bond of 
another IPP unit, generating a second carbocation;245 and 3) stereoselective elimination to  
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quench the carbocation and produce a new allylic diphosphate which has been elongated by one 
isoprene unit (Figure 20).245 Successive elongations in a head-to-tail manner yield a 10 carbon 
chain called geranyl diphosphate (117, GPP). 244  Further chain elongation iterations yield 
farnesyl diphosphate (118, FPP), containing 15 carbons, and geranylgeranyl diphosphate (119, 
GGPP), containing 20 carbons, and even longer chain products.246  Chain elongation, 
rearrangement, and cyclization of GPP, FPP, and GGPP, all performed enzymatically, leads to 
the construction of all terpenes. 
Terpenes are classified by the number of isoprene units present in the carbon skeleton.237 
The chemical formula of isoprene is C5H8, meaning that each isoprene unit equates to five 
carbons present in the terpene skeleton.237 Using this definition, types of terpenes include: 
hemiterpenes, monoterpenes, sesquiterpenes, diterpenes, sesterterpenes, and triterpenes, and  
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these consist of one through six isoprene units, respectively.246 Additional terpenes include 
tetraterpenes, with eight isoprene units, and polyterpenes, which include isoprene chains. Each 
type of terpene in the classification system is further divided into subclasses.237 
There are over 50 different subclasses of diterpene skeletons and many of these 
subclasses include compounds with biological activity.246 Some of the best-studied are labdanes, 
kauranes, gibberlins, beyeranes, aphidicolins, cembranes and abietanes.  The clerodanes—
ubiquitous in nature and found in a variety of plants, fungi, and microorganisms—are another 
subclass of diterpenes that are known to have biological activity.247  A diterpene is classified as a 
clerodane (120) if it contains four isoprene units and four contiguous stereocenters on a cis or 
trans decalin ring system (Figure 21).247 Approximately 25% of clerodanes contain the cis ring 
fusion, columbin (121) being one example. Columbin is a diterpenoid furanolactone, isolated 
from several plants including Sphenocentrum jollyanum Pierre (Menispermaceae) and Jateorhiza 
Columba Miers (Menispermacea).248-249  Columbin has been shown to have both anti-
inflammatory activity and chemopreventative activity against colorectal cancer,248-250 and is sold 
as a crude drug preparation called Calumbae Radix or Tinosporae Radix.248  The rest of the 
clerodanes contain the trans ring fusion exemplified by clerodin (122). Clerodin, isolated from  
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Clerodendrum infortunatum L. (Lamiaceae), is an insect anti-feedant and potential natural 
pesticide.251-253 In addition to the relative configuration of the trans or cis junctions of the fused 
rings, clerodanes are further classified by their relative configuration at C-8 and C-9.247  This 
additional clarification gives four types of clerodane skeletons defined with respect to 
configuration of ring fusion and substitution pattern at C-8 and C-9: trans-cis (TC), trans-trans 
(TT), cis-cis (CC) and cis-trans (CT).247 Clerodanes are even further classified by their absolute 
stereochemistry.  Structures that have the same absolute stereochemistry as clerodin are termed 
neoclerodanes and enantiomers of clerodin are referred to as ent-neoclerodanes.254-255  
Because of their structural complexity, neoclerodane diterpenes have been investigated 
for structure-activity relationships (SAR) through synthetic organic means as well as 
pharmacological studies.  However, such studies have been rather difficult to conduct because 
the neoclerodane diterpene class in general has sensitivity to the conditions of many typical 
organic reactions. This sensitivity complicates and lengthens the analog design and development 
process as new synthetic methodologies often need to be explored and established.  Despite this 
difficulty, one particular neoclerodane diterpene that has attracted relatively recent interest is 
salvinorin A.   
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Salvinorin A KOP Receptor In Vitro Pharmacology 
In 2002, Roth et al. identified that salvinorin A was a potent and selective agonist at KOP 
receptors.180  For this study, salvinorin A (10 M) and LSD (10 M) were screened against a 
panel of 50 GPCRs, transporters, and ligand-gated ion channels.  Salvinorin A inhibited only 
[3H]bremazocine-labeled KOP receptors, and neither MOP receptors, nor DOP receptors, nor 
any of the other targets in the screen.  Further evaluation found that for salvinorin A at KOP 
receptors Ki ≤ 16 nM, whereas at both MOP and DOP receptors Ki ≥ 5,000 nM.  Studies of 
agonist/antagonist properties revealed that, for the inhibition of adenylate cyclase, salvinorin A 
was a potent agonist (EC50 = 1.05 nM), comparable to the known KOP agonist U69,593 (EC50 = 
1.2 nM).  Salvinorin A was also found to be a potent agonist in the [35S]GTP--S assay (EC50 = 
235 nM), again comparable to U69,593 (EC50 = 377 nM). 
 In 2004, Chavkin et al. independently reproduced and confirmed findings that salvinorin 
A was a KOP receptor agonist via displacement of [3H]bremazocine and inhibition of andenylate 
cyclase.256  They further showed that salvinorin A also behaved as a full KOP agonist in the 
fluorescent calcium mobilization assay, where salvinorin A (EC50 = 7 nM) was comparable to or 
better than the known KOP agonists U69,593 (EC50 = 13 nM), U50,488 (EC50 = 24 nM), and 
dynorphin A (EC50 = 83 nM).  Wang et al. found that while salvinorin A (EC50 = 4.6 nM) and 
U50,488 (EC50 = 2.2 nM) had very similar potencies as measured by the [
35S]GTP--S functional 
assay, salvinorin A was 40-fold less potent than U50,488 at promoting KOP receptor 
internalization.257 
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Salvinorin A KOP Receptor In Vivo Pharmacology 
Hallucinogenic and other CNS Effects 
 For traditional spiritual uses, S. divinorum is ingested by one of three routes: 1) chewing 
and swallowing the leaves, 2) crushing the leaves to extract the juices and swallowing the 
extract, and 3) smoking the leaves.258  In 1994, Siebert reported that salvinorin A is inactivated in 
the gastrointestinal tract before entering the bloodstream; when encapsulated doses of salvinorin 
A were swallowed by human volunteers, no effect was detected.226  Thus absorption through the 
oral mucosa and inhalation are the most efficient routes to achieve efficacy.  Initial studies of the 
psychoactive effects of salvinorin A reported that a smoked dose of 200–500 g produced 
intense hallucinations with peak effects lasting 5–10 min and lingering, diminishing effects 
lasting approximately 1 h.226-227  
 In 2011, Johnson et al. reported a double-blind, placebo controlled study in which 16 
doses of salvinorin A were evaluated in four human volunteers.259  Drug doses of 0.375–21 
g/kg or placebo were administered via vaporization and inhalation, and participants’ blood 
pressure and heart rate were monitored at 2 min intervals for 1 h post administration.  
Participants were also verbally cued to rate perceived drug strength at 2 min intervals for 1 h post 
administration, as well as retrospectively after the session was completed.  In order further 
characterize the subjective aspects of the salvinorin A experience in comparison to classical 
hallucinogens, approximately 1 h after the session, participants filled out two questionnaires: the 
Hallucinogen Rating Scale (HRS) and the Mysticism Scale (M Scale).  The study found that the 
participant-rated drug strength peaked at 2 min post administration, the first time point measured, 
and decreased such that, at 20 min post administration mean ratings only indicated a “possible 
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mild” drug effect.  Study participants rated salvinorin A doses in the 4.5–21 g/kg range as 
significantly stronger than placebo, and this dose range was also reflected in their answers on the 
HRS and M Scale questionnaires.  The study found no dose-related physiological changes in 
heart rate or blood pressure, nor any observable resting or kinetic tremors.  Furthermore, no 
study participants refused to receive the same or higher dose of drug at the end of any session.  
These results indicate that inhaled salvinorin A has hallucinogenic effects comparable to 
classical hallucinogens and is physiologically safe and psychologically tolerated at the doses 
tested. 
 In 2012, Addy reported a larger (30 participants) double-blind, placebo controlled study 
of the psychological effects of salvinorin A in humans.260  Participants in the study smoked a 
dose of 1,017 g of salvinorin A deposited on 25 mg of dried S. divinorum leaf material or 
placebo; the unaltered leaf material was presumed to be non-psychoactive and was used as the 
placebo for the study.  Prior to and 1 h after administration, participants’ blood pressure and 
heart rate were measured, as well as body temperature and respiration rate.  In order to measure 
salvinorin A inebriation, during experimental sessions, researchers recorded participants’ 
behavior using a standardized scale.  Behaviors recorded during the first 20 min post drug 
administration were used for analysis, and 1 h after administration study participants filled out 
the HRS.  The researchers also conducted follow-up interviews with all study participants 
approximately 8 weeks after their final experimental session.  In agreement with the previously 
described study, this study also found no dose-related physiological changes during experimental 
sessions, and both doses of salvinorin A were tolerated by the study participants.  After inhaling 
a dose of salvinorin A, participants displayed increased talking, laughing, and movement in 
comparison to placebo, as well as physical contact with the experimental monitor and paranoid 
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ideation.  In HRS scores, the active dose of salvinorin A produced an experience significantly 
different from placebo with 43% of study participants reporting their experience as similar to 
dreaming and 50% reporting it as unlike any previous experience.  In the follow-up interviews, 
87% of study participants reported salvinorin A use after-effects lasting fewer than 24 h, and 
70% reported after-effects lasting more than 24 h, persisting for up to 3 days post use.  However, 
no participant reported that they would refuse to use salvinorin A or S. divinorum again.  Finally, 
in agreement with the previous study, this study’s findings indicate that inhaled salvinorin A has 
hallucinogenic effects comparable to classical hallucinogens and is physiologically safe and 
psychologically tolerated at the doses tested. 
 In 2007, Butelman et al. reported that salvinorin A produced dose- and time-dependent 
neuroendocrine effects in non-human primates.261 Serum prolactin concentration has been used 
in non-human primates to evaluate the potency, receptor selectivity, and efficacy of opioid 
agonists in vivo.262-263 Rhesus monkeys were given vehicle, salvinorin A, or U69,593 (all drug 
concentrations 0.0032–0.056 mg/kg i.v.) and serum samples were taken at certain time points 
through 2 h.  For antagonist experiments, monkeys were given a single dose of antagonist 30 min 
before agonist challenge and subsequent serum sample collection.  The study found that i.v. 
salvinorin A caused a robust dose- and time- dependent increase in prolactin concentrations that 
were observable 5 min after injection, peaked at 15 min, and gradually declined over 2 h.  The 
effects of U69,593 were similar to those of salvinorin A, except that elevated prolactin levels 
persisted through the 2 h end point of the study indicating a longer duration of action.  The study 
also evaluated the differences between i.v. and s.c. injection of salvinorin A and found that s.c. 
injection produced a slower on-set and overall smaller release of prolactin.  In both the i.v. and 
s.c. studies, the effects of salvinorin A were more robust in female monkeys than in male 
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monkeys.  For antagonist experiments, 0.1 mg/kg nalmefene, a universal opioid antagonist, was 
found to strongly attenuate the effects of 0.032 mg/kg salvinorin A.  The non-selective 5-HT2 
antagonist ketanserin (0.1 mg/kg) demonstrated no attenuation of the effects of salvinorin A 
(0.032 mg/kg).  These findings support previous conclusions that salvinorin A produces its 
effects through KOP receptors and not 5-HT2.  Finally, the study reported that the rhesus monkey 
OPRK1 gene had 98.4% sequence homology to the human OPRK1 gene. 
 In a following study in 2009, Butelman et al. investigated the fast on-set and entry into 
the CNS and the unconditioned behavioral effects of salvinorin A in non-human primates.264  
Salvinorin A (0.032 or 0.1 mg/kg i.v.) or U69,593 (0.01, 0.032, or 0.056 mg/kg i.v.) was 
administered to rhesus monkeys as a bolus dose and behavior was observed at certain time points 
through an end point of 90 min.    For antagonist experiments, a single dose of antagonist was 
administered 30 min prior to agonist challenge.  Behavioral effects were characterized with two 
rating scales measuring sedation and posture, which are known to be sensitive to centrally-acting 
KOP agonists as well as non-opioids that have sedative effects, and less sensitive to peripherally 
restricted KOP agonists.265-266  Facial relaxation and ptosis were also monitored.  In order to 
study on-set and CNS entry, salvinorin A (0.032 mg/kg i.v.) was given and cerebrospinal fluid 
(CSF) samples were collected at certain time points through 30 minutes, with a final sample 
collected at approximately 3 h post injection.  These studies found salvinorin A produced dose-
dependent increases in sedation and postural scores with peak effects observed 5 min post 
administration and declining by 30 min.  This was comparable to the effects of U69,593 which 
also produced dose-dependent increases in behavior scores with a fast on-set, but had a longer 
duration of action through 60 min.  Salvinorin A also caused facial relaxation and ptosis with a 
very rapid onset (1–2 min post administration) and short duration of action (15 min), similar to 
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U69,593, although the timing of the effects of U69,593 were less well defined due to apparent 
intersubject variability.  Pretreatment with the universal opioid antagonist nalmefene (0.1 mg/kg) 
nearly completely attenuated all behavioral effects of salvinorin A (0.032 mg/kg).  Further, 
nalmefene (administered 11 min post salvinorin A) was able to completely reverse on-going 
salvinorin A facial relaxation and ptosis.  This finding suggests that the effects of salvinorin A 
are both initiated and maintained by KOP receptors.  In contrast, pretreatment with either the 
CB1 antagonist rimonabant (1 mg/kg) or the 5-HT2 antagonist ketanserin (0.1 mg/kg) was no 
different than pretreatment with vehicle.  In the CSF studies, salvinorin A was found to enter the 
CNS almost immediately; it was detectable at time 0 after injection and concentration peaked at 
2 min, decreasing through the end-point of the experiment.  This result is in agreement with a 
study by Hooker et al. which traced [11C]salvinorin A in live baboon brains using non-invasive 
positron emission tomography (PET); the drug was found to rapidly enter the brain, reaching 
peak concentration in 40 s, as well as rapidly clear the brain, having a half-life of 8 min and 
diminishing to below 25% of maximum in less than 30 min.267  Collectively, these findings are 
consistent with descriptive information from humans and support that salvinorin A is a centrally 
acting KOP agonist with fast on-set and short duration of action.   
Metabolism 
 Schmidt et al. reported that the principal metabolite of salvinorin A ex vivo in both human 
and rhesus monkey plasma is the C-2 deacetylated derivative, salvinorin B (123), which they 
observed to accumulate as the quantity of salvinorin A decreased (Figure 22).268  Kutrzeba et al. 
confirmed that salvinorin B is the major metabolite of salvinorin A; using a variety of live fungal 
species as well as rat brain and liver homogenate, they were unable to observe any metabolic  
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products other than salvinorin B.269  In a follow up study, Schmidt et al. reported that for in vivo 
experiments with rhesus monkeys, the plasma concentration of salvinorin B did not increase, and 
was below the lower limits of detection over the course of study.270  These results likely indicate 
that salvinorin B is rapidly cleared from the body, or that it accumulates in other tissues and 
organs that were not examined.  A study in human volunteers by Pichini et al. found that 0.4–
1.2% of a total theoretically administered smoked dose of salvinorin A (0.58 mg) is excreted in 
urine.   
 Tsujikawa et al. attempted to characterize the esterase enzymes responsible for salvinorin 
A metabolism in rat plasma via incubation with selective inhibitors.271  They confirmed through 
a control study that the degradation of salvinorin A was not due to inherent chemical instability, 
but to metabolizing enzymes; incubating salvinorin A in buffer at 37 °C for 24 h produced no 
observable degradation products.  Further, the degradation of salvinorin A to salvinorin B in rat 
plasma could be inhibited by the addition of NaF, a general esterase inhibitor.  The study found 
that the metabolism of salvinorin A in rat plasma could be inhibited by sodium bis-p-nitrophenyl 
phosphate (BNPP), which is selective for carboxylesterase (CES), in a concentration-dependent 
manner.  Salvinorin A metabolism could also be inhibited by phenylmethylsulfonyl fluoride 
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(PMSF), which is selective for the class of serine esterases.  This particular finding supports the 
involvement of CES in the plasma metabolism of salvinorin A to salvinorin B because CES is a 
serine esterase.  Selective inhibitors for other enzymes—butyrylcholinesterase, 
acetylcholinesterase, and arylesterase—did not inhibit the metabolism of salvinorin A, further 
implicating CES.  In rat plasma in the presence of the esterase inhibitor NaF, the study also 
observed another major metabolite of the salvinorin A scaffold, the lactone-ring open form of 
salvinorin B (124).  The appearance of this metabolite could be reduced by the addition of 
EDTA, a calcium chelating agent.  Considering that rats have calcium-dependent lactonase 
enzymes in their serum,272 this suggests that a such a lactonase is involved in the metabolism of 
salvinorin B. 
 Teksin et al. investigated the in vitro metabolism of salvinorin A with ten CYP450 
isoforms and UGT2B7, the major enzyme involved in drug metabolism via glucuronidation.273  
When concentrations of 5 and 50 M salvinorin A were incubated with CYP2D6, CYP1A1, 
CYP2C18, and CYP2E1 for 1 h, statistically significant reductions in remaining concentration 
were observed.  In order to further characterize in vitro metabolism, salvinorin A (5, 10, and 50 
M) was incubated with UGT2B7.  Similar to the CYP450 experiments, statistically significant 
reductions in remaining concentration were observed for all concentrations of salvinorin A.  
Additionally, the study observed that for CYP1A1, CYP2C18, CYP2E1, and UGT2B7 
metabolism of salvinorin A appeared saturable at high concentrations; that is, lower 
concentrations of salvinorin A were metabolized more efficiently than higher concentrations.  
These findings suggest that CYP2D6, CYP1A1, CYP2C18, CYP2E1, and UGT2B7 are involved 
in the metabolism of salvinorin A. 
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Toxicity 
 Mowry et al. published the first study of the toxicity of pure salvinorin A using rats and 
mice.274  Acute exposure to salvinorin A (1,600 g/kg) showed no statistically significant effect 
on rat heart rate and there were no apparent effects on cardiac conduction.  Acute exposure also 
did not produce changes in body temperature or galvanic skin response (an indication of 
sympathetic nervous system activity).  Pulse pressure did appear to increase between 20–40 min 
post exposure, however this increase was only numerical and not statistically significant.  No 
histological differences were observed between experimental and control populations in mouse 
liver, spleen, kidney, bone marrow, or brain tissue after 14 days of chronic exposure to salvinorin 
A (400, 800, 1,600, 3,200, or 6,400 g/kg).  Based on their findings, the researchers concluded 
that salvinorin A had very little physiological effect, consistent with literature and anecdotal 
reports. 
Drug Discrimination 
 Butelman et al. published the first investigation of the KOP discriminative effects of 
salvinorin A in rhesus monkeys.275  Monkeys were trained to discriminate the KOP agonist 
U69,593 from vehicle.  U69,593 (0.001–0.01 mg/kg) produced dose- and time-dependent 
generalization, and when tested under identical conditions, salvinorin A (0.001–0.032 mg/kg) 
also dose-dependently generalized.  In a control experiment, the psychoactive NMDA antagonist 
ketamine (0.1–3.2 mg/kg) was not generalized, indicating that not all hallucinogenic or 
psychotomimetic compounds are generalized by monkeys trained to discriminate U69,593.  
Pretreatment with the opioid antagonist quadazocine (0.32 mg/kg) fully blocked the 
discriminative effects of both U69,593 and salvinorin A.  Interestingly, the long-acting, KOP 
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selective antagonist GNTI only blocked the discriminative effects of salvinorin A in two of the 
three subjects.   
Willmore–Fordham et al. expanded experimentation into rats and also found that 
salvinorin A fully substituted for U69,593.276  These effects could be completely blocked by pre-
administration of the KOP antagonist norBNI.  Baker et al. went further and compared salvinorin 
A, and two derivatives of salvinorin B (2-methoxymethyl- and 2-ethoxymethylsalvinorin B) to 
U69,593 and U50,488.277  The study found that in rats trained to distinguish U69,593 from 
vehicle, salvinorin A and both salvinorin B derivatives fully substituted for U69,593.  Further, 
they also found that in rats trained to distinguish salvinorin A from vehicle, both U69,593 and 
U50,488 produced full generalization.  This cross-generalization further supports that salvinorin 
A acts as a KOP agonist.  In a follow up study, Killinger et al. found that in rats trained to 
discriminate the 5-HT2 agonist LSD from vehicle, salvinorin A did not generalize.
278  Neither did 
salvinorin A generalize in rats trained to distinguish ketamine from vehicle, further supporting 
that salvinorin A does not act in the same manner as other known hallucinogens.  Finally, 
Walentiny et al. reported that salvinorin A did not substitute for 9- tetrahydrocannabinol (9-
THC) in mice trained to discriminate 9-THC from vehicle, indicating that salvinorin A does not 
direct its effects through the cannabinoid receptor system. 
 In a follow up study to their earlier work, Butelman et al. further expanded their 
investigation and characterized the discriminative effects of salvinorin A in rhesus monkeys in 
comparison to an array of structurally diverse KOP agonists, as well as MOP and DOP agonists, 
a 5-HT2 agonist, and a NMDA antagonist.
279  In this study, monkeys were trained to discriminate 
salvinorin A from vehicle.  The centrally acting KOP agonists bremazocine, U69,593, and 
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U50,488 were found to generalize, but the peripherally restricted KOP agonist ICI204,488 was 
only generalized in one of the three subjects.  This result seems to indicate that the effects of 
salvinorin A are predominantly centrally mediated.  Further, the MOP agonist fentanyl, the DOP 
agonist SNC80, the 5-HT2 agonist psilocybin, and the NMDA antagonist ketamine were not 
generalized by any subjects.  As before, the opioid antagonist quadazocine fully blocked 
discriminative stimulus effects of salvinorin A.  In contrast, the 5-HT2 angatonist ketanserin did 
not cause any blockade.  These findings are supported by a study by Li et al. in which U50,488 
and salvinorin A did not generalize in rhesus monkeys trained to distinguish the hallucinogenic 
5-HT2 agonist DOM from vehicle (LSD did generalize).
280  Collectively, the results of these 
studies support that salvinorin A exerts its effects centrally as a KOP receptor agonist and 
underscore its uniqueness as a hallucinogen.   
Antinociceptive Effects 
 Since documented ethnomedicinal uses for S. divinorum include relief from headaches 
and rheumatism, several studies have been conducted in animal models regarding the 
antinociceptive effects of salvinorin A.  Wang et al. reported that salvinorin A (30 mg/kg s.c) 
showed very low and inconsistent activity in the compound 48/80-induced scratching test in 
mice, which pretreatment with norBNI (20 mg/kg) was able to reverse.257  They also found 
salvinorin A (15–50 mg/kg, administered 20 min prior to acetic acid challenge) was similarly 
inactive in the acetic acid abdominal constriction test in the same species.  However, Harding et 
al. reported the ED50 of salvinorin A in the p-phenylquinone writhing and tail-flick assays in 
mice to be 0.59 mg/kg and 1.98 mg/kg s.c., respectively, comparable to morphine.281  They also 
tested salvinorin A in the hotplate assay, but did not observe any antinociceptive activity.  No 
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time course for these experiments was reported.  In a subsequent study, McCurdy et al. 
confirmed the activity of salvinorin A in the tail-flick assay in mice, observing dose- and time-
dependent antinociceptive effects at doses of 1.0, 2.0, and 4.0 mg/kg that could be reversed by 
pre-treatment with norBNI (10 mg/kg).282  They also found that salvinorin A (1.0 mg/kg) showed 
antinociceptive effects in the hotplate test in the same species.  Further, they observed robust 
dose- and time-dependent antinociceptive effects from salvinorin A in the mouse acetic acid 
abdominal constriction assay.  In all of their experiments, McCurdy et al. note the short duration 
of action of salvinorin A with peak effects being observed at the 10-min time point and 
diminishing after that.  They posit that experimental time course could explain the lack of 
antinociception in the acetic acid abdominal constriction assay reported by Wang et al.; 20 min 
after administration the effects of salvinorin A are no longer present.  John et al. also confirmed 
the dose- and time-dependent antinociceptive effects of salvinorin A in the mouse tail-flick 
assay, and further demonstrated that while the effects of salvinorin A could be reversed by pre-
treatment with KOP antagonist norBNI, pre-treatment with the MOP antagonist FNA or the 
DOP antagonist naltrindole did not diminish antinociception.283  Fichna et al. characterized the 
antinociceptive effects of salvinorin A in a mouse model of inflammatory bowel disease and 
found that it could attenuate the pain-related behaviors associated with injection of mustard oil; 
further, the antinociception could be inhibited by both norBNI and the CB1 antagonist AM251, 
but not the CB2 antagonist AM630.284  Finally, Ansonoff et al. evaluated the antinociceptive 
effects of salvinorin A in KOP receptor knockout mice.285  They found that a dose of 7.5 g 
injected i.c.v. showed antinociceptive effects in the tail flick assay using wild type mice; in the 
KOP receptor knockout mice the same dose produced no antinociception.  This indicates that the 
antinociceptive actions of salvinorin A are KOP receptor dependent.  
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Mood Regulation 
 Given the previously discussed body of evidence that activation of the KOP receptor 
system can produce pro-depressive-like behaviors in laboratory animals, several studies 
investigating the effects of salvinorin A in this area have been published.  Carlezon et al. 
examined the effects of salvinorin A in two rat models of depressive-like behavior, the forced 
swim test (FST) and the intracranial self-stimulation (ICSS) test.286  They found that in the FST, 
salvinorin A produced behaviors that were opposite to those typically elicited by selective 
serotonin reuptake inhibitors (SSRIs); salvinorin A (0.25–2.0 mg/kg) dose-dependently increased 
occurrences of immobility, and simultaneously dose-dependently decreased occurrences of 
swimming behavior.  Importantly, the doses of salvinorin A tested were not found to effect 
locomotor activity in an open field, confirming that the effects of the drug are not due to general, 
non-specific behavioral depression.  The ICSS assay electrically stimulates areas of the brain (in 
this study, the medial forebrain bundle) associated with reward via an implanted electrode.  Rats 
are then trained to self-stimulate by pushing a lever, and the effects of different drugs can be 
measured by observing the change in lever-pressing behavior.  Addictive drugs lower the 
electrical threshold required to maintain ICSS, presumably because they enhance the effects of 
stimulation.  Aversive drugs increase the threshold required to maintain ICSS.  Salvinorin A 
(0.5–2.0 mg/kg) was found to dose-dependently increase ICSS thresholds, suggesting that it was 
able to reduce the rewarding of effects medial forebrain bundle stimulation.  This type of 
observation in rodents reflects anhedonia (a hallmark of clinical depression), therefore providing 
additional evidence that salvinorin A has pro-depressive like effects.  Finally, microdialysis 
experiments found that 1.0 mg/kg salvinorin A produced a rapid decrease in extracellular 
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concentrations of DA in the NAc with no effect on 5-HT concentrations.  This provides evidence 
that the effects of salvinorin A in the FST are not due to reduction in 5-HT activity. 
 Braida et al. expanded the evaluation of the effects of salvinorin A in rodent models of 
emotional behavior to the elevated plus maze paradigm and the tail suspension test, as well as the 
FST.287  The elevated plus maze is used as a rodent model of anxiety.  The apparatus includes an 
open-arm and a closed-arm; a greater number of entries into or a greater percentage of 
experimental time spent in the open-arm indicates an anxiolytic effect.  The study found that in 
this model, pretreatment with salvinorin A (0.1–160 g/kg) 20 min prior to maze testing 
produced an increase in the number of entries into the open-arm similar to the clinically used 
anxiolytic diazepam.  Salvinorin A also increased the percentage of experimental time spent in 
the open-arm, although to only half the amount of time observed upon treatment with diazepam. 
Additionally, no dose-related increase in effect was observed.  Still, these findings indicate that 
salvinorin A has some anxiolytic effect.  The KOP antagonist norBNI given in combination with 
the CB1 antagonist AM251 was able to completely block the effects of salvinorin A.  In the tail 
suspension test, salvinorin A (0.001–1.0 g/kg) produced a significant decrease in the amount of 
time spent immobile, and this was reversed by both norBNI and AM251, alone or in 
combination.  The reduction in immobility was comparable to treatment with the antidepressant 
imipramine, suggesting an antidepressant-like effect from salvinorin A.  This observation was 
echoed in the FST, where it was found that salvinorin A (0.001–10 g/kg) dose-dependently 
decreased the occurrence of immobility and simultaneously increased swimming.  The 
antagonists norBNI and AM251, alone or in combination, were able to block this effect.  These 
findings appear to be in direct conflict with the findings of Carlezon et al.  The authors suggest 
that the differences between the studies can be explained by dosing.  Carlezon et al. administered 
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relatively large doses of salvinorin A in triple-administration; Braida et al. administered 
relatively small doses acutely.  Although the data were not reported, they state that the highest 
dose of salvinorin A they used (1 mg/kg) given in triple-administration produced pro-depressant-
like effects, indicating that salvinorin A has anxiolytic effects at very low or acute doses, and is a 
pro-depressant at higher, repeated doses. 
 Ebner et al. extended the observations of Carlezon et al. regarding the effects of 
salvinorin A on extracellular DA levels in rats.288  They found that salvinorin A (2.0 mg/kg) 
significantly decreased DA release in both the NAc core and NAc shell, in agreement with 
Carlezon et al.  Further, salvinorin A had no impact on the rate of DA reuptake in either brain 
region.  In parallel, through ICSS testing, it was found that salvinorin A dose- and time-
dependently increased thresholds, again in agreement with Carlezon et al.  A third assay used in 
the study was operant responding for sucrose reward.  In this model, animals are trained to press 
a lever to obtain a sucrose pellet; the training schedule assesses motivation to respond by 
progressively increasing the number of lever-presses required to receive the sucrose pellet 
reward.  Alterations in lever-pressing behavior after drug administration can be attributed to 
changes in motivation or motor deficits.  The study found that salvinorin A (2.0 mg/kg) 
significantly lowered the breakpoint in responding, the point in the schedule where the animals 
stop lever-pressing behavior, indicative of a decrease in motivation.  Salvinorin A also 
suppressed the rate of lever-pressing.  Collectively, these findings confirm the idea that 
salvinorin A can alter mood states by simultaneously decreasing DA release as well as reward 
function and motivation. 
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Drug Abuse 
 Because the KOP receptor agonists U50,488 and U69,593 were reported to decrease 
cocaine self-administration in rodents,155, 158 and because previous literature has shown that 
cocaine-induced reinstatement of extinguished cocaine self-administration behavior in rodents 
can be attenuated by pre-treatment with KOP receptor agonists, several groups have undertaken 
investigations into whether or not salvinorin A has similar effects.  Morani et al. reported that 
KOP agonists salvinorin A, U69,593, U50,488, and spiradoline produced a dose-dependent 
reduction in cocaine-induced reinstatement in rats.289  Additionally, Zhang et al. found that 
salvinorin A (1.0 and 3.2 mg/kg) dose-dependently decreased DA levels in the caudate putamen 
of mice, and that the decrease was reversible by pretreatment with norBNI, suggesting KOP 
receptor system involvement.290  Further, the study found that salvinorin A (1.0 and 3.2 mg/kg) 
produced conditioned place aversion, which was blocked by pretreatment with norBNI, similar 
to findings published about other KOP agonists.  Gehrke et al. expanded upon these findings and 
reported that the same doses of salvinorin A also decreased DA in the NAc of rats (in agreement 
with previously described findings from Carlezon et al.), and that the effect was norBNI-
reversible.291   
Interestingly, Gehrke et al. also found that while acute administration of salvinorin A led 
to a decrease in DA levels, DA dynamics after repeated administration were unaltered.  
Additionally, repeated administration of salvinorin A (3.2 mg/kg) appeared to enhance cocaine-
induced increases in extracellular DA, but not locomotor activity.  This is in contrast to reports in 
the literature on KOP agonists such as U69,593 that show that repeated administration reduces 
cocaine-induced locomotor activity.  A study by Chartoff et al. investigated whether acute KOP 
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receptor activation would attenuate the effects of cocaine, whereas prior, repeated KOP receptor 
activation would potentiate the effects of cocaine.149  In rats, they found that acute administration 
of salvinorin A 5 min prior to cocaine challenge blocked cocaine-induced locomotor activity.  
These conditions also led to increased c-Fos expression (indicative of cAMP or Ca2+ second 
messenger system activation) in the NAc, dorsal striatum, and other brain regions.  In rats that 
had been previously repeatedly administered salvinorin A, cocaine-induced locomotor activity 
was enhanced.  This was paired with no change in c-Fos expression in the dorsal striatum.  In a 
follow-up study, Potter et al. found that in rapid response to repeated treatment with salvinorin 
A, ICSS thresholds in rats increased (decreased reward), whereas in a delayed response (24 h 
post administration), ICSS thresholds decreased (increased reward).292  Further, they found that 
prior, repeated exposure to salvinorin A blunted the ability of cocaine to decrease ICSS 
thresholds, indicating a reduction in reward-related effects.  Treatment with norBNI was able to 
normalize these effects.  Collectively, these findings further underscore that salvinorin A is able 
to modulate reward-related effects and is unique among KOP receptor agonists. 
Given the relatively high doses of salvinorin A used by other studies, Braida et al. 
characterized the effects of relatively low doses of salvinorin A on DA concentration, 
conditioned place preference, and self-administration in rats.293  They found that salvinorin A (40 
g/kg) increased extracellular DA levels in the shell of the NAc.  Further, they report that 
salvinorin A (0.1–40 g/kg) produced a conditioned place preference.  In contrast, a dose of 80 
g/kg had no apparent effect, and a dose of 160 g/kg provoked aversion.  The effects of 
salvinorin A could be blocked by co-administration of the KOP antagonist norBNI and CB1 
antagonist rimonabant, but not by either antagonist alone.  Additionally, the study found that at 
the low doses used (0.1–0.5 g/2 L saline), the animals would self-administer salvinorin A; if 
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the dose was increased to 1 g/2 L, self-administration would significantly decrease.  The 
authors suggest that these observations explain salvinorin A use by humans as well as suggest 
abuse potential.  Very low doses are obtained from smoking the leaves, which would account for 
the reinforcing effect that is modeled by place preference and self-administration in rodents.  At 
the relatively high doses used in other studies, salvinorin A then becomes aversive.  Beerepoot et 
al. reported similar observations; co-administration of U69,593 or 2mg/kg salvinorin A and the 
D2/D3 agonist quinpirole potentiated locomotor sensitization to quinpirole, whereas 0.04 mg/kg 
salvinorin A attenuated quinpirole locomotor sensitization.294 These findings suggest that the 
actions of salvinorin A in vivo are more complex than previously appreciated. 
Proposed Salvinorin A and KOP Receptor Binding Interactions 
 Since salvinorin A was identified as the first non-nitrogenous opioid ligand, it has 
challenged previous hypotheses as to the binding epitope of ligands at opioid receptors.  Previous 
hypotheses proposed that a basic nitrogen atom was required for opioid receptor affinity; at 
physiological pH, the positively charged nitrogen atom in the ligand would interact with an 
aspartic acid residue (Asp138) in the third transmembrane region of the GPCR.232-234  However, 
salvinorin A lacks a nitrogen atom, so it is unlikely that the molecule ionically binds to the 
receptor in this manner.  In support of this, in a study reported by Singh et al., a ligand-based 
pharmacophore model generated from KOP selective arylacetamide agonists failed to identify 
salvinorin A as a KOP ligand, suggesting that it binds to the receptor through a unique 
recognition site.295  Several studies have been devoted to elucidating the binding interactions 
between salvinorin A and the KOP receptor, including the development of chimeric opioid 
receptors, site-directed mutagenesis, as well as computational models.  In 2012, both the MOP  
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and KOP receptor crystal structures were reported, co-crystallized with the selective antagonists 
FNA and JDTic, respectively.296-297 
 In 2002, after they identified salvinorin A as a selective KOP receptor agonist, Roth et al. 
also attempted to predict ligand–receptor binding interactions via molecular modeling using a 
previously reported computational model of the KOP receptor and U69,593 as a starting 
point.180, 298  In their best ligand–receptor complex, the furan ring of salvinorin A is oriented 
towards TM1 and TM2, with a proposed hydrogen bonding interaction between Gln115 and the 
oxygen of the furan (Figure 23).  The 4-methoxycarbonyl is oriented towards TM5 and TM6, 
with a proposed hydrogen bonding interaction between Tyr312 and the carbonyl oxygen.  
Finally, the carbonyl oxygen of the lactone is proposed to hydrogen bond with Tyr139 and the 
carbonyl oxygen of the C-2 acetate is proposed to hydrogen bond with Tyr313.  They also 
identified several variable residues in their proposed salvinorin A–KOP receptor binding region  
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that are not conserved in the MOP and DOP receptors; these residues produce significant 
electronic and steric alterations that could explain the KOP selectivity of salvinorin A. 
 In 2005, Yan et al. used site-directed mutagenesis in combination with molecular 
modeling to attempt to elucidate binding interactions between salvinorin A and the KOP 
receptor.299  They observed a dramatic decrease (22-fold) in the binding affinity of salvinorin A 
to the Y313A mutant; when the mutation was changed to Y313F, no loss in affinity was 
observed indicating a hydrophobic interaction between Tyr313 and salvinorin A.  They also 
found that mutations to Tyr119, Tyr320, and Tyr139 resulted in loss of affinity; in the cases of 
Tyr119 and Tyr320, mutation to Phe accounted for the loss of affinity, indicating hydrogen 
bonding interactions with salvinorin A.  The study then translated the mutagenesis observations 
into a proposed binding model in which the oxygen of the furan ring hydrogen bonds with 
Tyr119 and Tyr320, the C-2 acetate has hydrophobic interactions with Tyr313, and the C-4 ester 
interacts with Ile294 and Glu297 (Figure 24). 
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In 2006, Kane et al. investigated the binding and selectivity of salvinorin A using a 
combination of chimeric and single-point mutant opioid receptors.300  Chimeric receptors can 
probe various receptor regions in order to determine which are required for binding.  For this 
study, chimeric receptors were designed around the BglII and AflIII restriction sites, which are 
located in TMV and TMIII, respectively.  From BglII chimera, the study found that a 
combination of KOP(1–227)/DOP(215–372) bound salvinorin A with approximately 10-fold 
higher affinity (2.5 nM ± 0.4) than the wild type receptor (17.5 nM ± 1.5).  The converse 
chimera, DOP(1–214)/KOP(228–380) did not bind salvinorin A at all.  Additionally, from AflIII 
chimera, it was found that KOP(1–141)/DOP(132–372) showed a considerable loss of affinity 
(910 nM ± 245) compared to the analogous KOP/DOP BglII chimera (2.5 nM ± 0.4).  
Collectively, these results imply that the KOP region between the BglII and AflIII restriction sites 
(the latter half of TMIII, IL2, TMIV, EL2, and the beginning of TMV) may play a role in 
salvinorin A binding.  Of these regions, TMIII and IL2 are unlikely due to their depth in the 
membrane-bound receptor, however EL2 has been implicated in past studies if KOP ligand–
receptor interactions.  From site-directed mutagenesis the study confirmed the previously  
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reported importance of Gln115, Tyr313, and Tyr320 to salvinorin A binding, although other 
residues were found to have less significant effects on binding than previously observed (Figure 
25).  Vortherms et al. expanded this research, creating more detailed chimeric receptors in which 
single TM or loop regions were exchanged between receptor subtypes.301  They found that 
substituting the TMII and EL2 regions of the KOP receptor into the MOP or DOP receptors 
resulted in binding affinity for salvinorin A; conversely, substituting TMII and EL2 from DOP 
into the KOP receptor markedly reduced salvinorin A binding.  Further, through site-directed 
mutagenesis, the study found that V108A and V118K (both in TMII of KOP receptor) 
significantly decreased affinity for salvinorin A.  Since Val118 does not face into the putative 
binding pocket of rhodopsin-based KOP receptor models, this finding seems to indicate that the 
subtype selectivity of salvinorin A for KOP receptors is due to helical rotations of TMII.  In a 
2008 follow-up study to their 2006 work, Kane et al. further identified Ile316 as an important 
residue through site-directed mutagenesis; the I316A mutant abolished salvinorin A affinity for 
the receptor.302  In the putative binding pocket, Ile316 is located in space between Tyr313 and 
Tyr320, residues previously identified as having important interactions with salvinorin A (Figure  
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26). This is consistent with the general hypothesis that salvinorin A–KOP receptor binding 
interactions are primarily hydrophobic. 
 In 2006, Singh et al. used an integrated approach to develop a model for salvinorin A–
KOP receptor binding; they developed quantitative, ligand-based pharmacophores 
simultaneously refined with target-based methods.303  First, a training set of 15 previously 
reported salvinorin A derivatives was used to develop a ligand-based pharmacophore that was 
validated against a different test set of 12 previously reported derivatives, as well as a set of 
negative controls (known inactive molecules).  The pharmacophore model was successfully able 
to distinguish between ligands with moderate to low affinity for KOP receptors and did not 
predict any affinity for the negative control molecules.  Some important features of the 
pharmacophore are hydrophobic regions, corresponding to the furan ring and the C-4 ester, 
which are 8.38 Å apart, and hydrogen bonding regions around the C-2 acetate and C-4 ester.  
Next, a target-based model was then created from induced-fit docking of salvinorin A into a 
binding site guided by previous site-directed mutagenesis studies.  In accordance with previously 
reported data, the salvinorin A binding pocket was formed primarily between TMII and TMVII 
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and was largely hydrophobic.  In accordance with previous reports, the model predicted 
hydrophobic interactions between the furan ring of salvinorin A and Tyr320 and between the C-
19 methyl group and Tyr119.  Interestingly, the model also predicted a hydrogen bonding 
interaction between the ester oxygen of the C-2 acetate and Gln115, and a hydrogen bonding 
interaction between the C-4 ester carbonyl oxygen and Tyr313, as well as a hydrophobic 
interaction between the methyl of the ester and the aromatic ring of the residue (Figure 27).  
Overall, it was found that the hydrophobic and hydrogen bonding regions from the 
pharmacophore model coincided well with the residues identified from the receptor docked 
model. 
 More recently in 2010, McGovern et al. used comparative molecular field analysis 
(CoMFA) to describe three dimensional quantitative SARs of salvinorin A derivatives.304  A 
training set of derivatives modified at the C-2 acetate moiety was correlated with published 
binding affinity data.  This model suggested a region of steric bulk tolerance around the C-2 
position that could accommodate alkyl ester chains up to four carbons in length.  This region also 
fell within a hydrophobic pocket formed by Tyr312, Tyr313, and Ile316, residues previously 
reported to be important to salvinorin A binding. 
 Finally, in 2012 the co-crystal structure of the human KOP receptor with the antagonist 
JDTic was published.297  In the co-crystal structure, the protonated amines in both the piperidine 
and isoquinoline moieties of JDTic form salt bridges with Asp138, and Tyr312 has a hydrogen 
bonding interaction with the oxygen of the amide (Figure 28).  JDTic also appears to have 
interactions with Val108, Val118, and Ile294, residues which, along with Tyr312, are different in 
the KOP receptor vs. the MOP and DOP receptors.  Also of note, the isopropyl group of JDTic  
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was observed to form a hydrophobic interaction with a conserved Trp287, a residue thought to be 
a key part of the GPCR receptor activation mechanism.  This finding indicates that this particular 
residue may have a critical role in the pharmacological properties of JDTic.  Using the JDTic–
KOP receptor co-crystal structure as a model, the authors attempted to dock 22-
thiocyanatosalvinorin A (RB-64, an irreversible KOP agonist that reportedly binds to Cys315 in 
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the KOP receptor)305 into the same binding pocket used by JDTic.  This study predicted that the 
2-position of the salvinorin A scaffold would be able to access Cys315 while maintaining many 
of the binding interactions implicated by site-directed mutagenesis (Figure 29).  Even so, 
additional studies, such as the co-crystallization of the KOP receptor with a selective agonist or, 
ideally, with salvinorin A, are still required for the binding interactions of salvinorin A and the 
KOP receptor to be fully elucidated and understood. 
SAR Studies of Salvinorin A 
Introduction 
 A wide variety of semi-synthetic modifications have been made to salvinorin A in order 
to develop SAR at the KOP receptor, and there are published reviews that cover these 
derivatives.236, 306-308  The general SAR of the salvinorin A scaffold known presently is 
summarized in Figure 30.  Reduction or removal of the C-1 carbonyl is tolerated, and when 
removed, the introduction of a 1,10-alkene is likely to be an antagonist.  Reduction or hydrolysis 
of the C-4 ester reduces affinity; replacement with small alkyl groups is tolerated, but larger  
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groups reduce affinity.  Reduction of the C-17 lactone is tolerated, as is introduction of a 8,17-
alkene.  Removal of the furan ring reduces affinity; however, reduction or replacement with 
other heterocycles is tolerated.  Inversion of the stereochemistry at C-12 produces partial KOP 
agonists.  Bioisosteric replacements of the C-2 acetate are tolerated and can modulate receptor 
selectivity, and these modifications will be discussed in depth. 
Modifications at the C-2 Position 
The most extensively investigated position on the salvinorin A core is the C-2 acetate 
moiety.  This is likely due to relatively easy methodology to selectively hydrolyze the acetate to 
produce the C-2 free hydroxyl, salvinorin B.  In this methodology, salvinorin A is treated with 
Na2CO3 in MeOH at room temperature, yielding salvinorin B (123) in 77% yield after trituration 
(Scheme 4).309  No chromatography is involved.  Salvinorin A can also be converted to 2-epi-
salvinorin B (2-epi-123) through Mitsunobu conditions (DIAD, PPh3) using 4-nitrobenzoic acid 
as the nucleophile; the intermediate is subsequently hydrolyzed with K2CO3 in MeOH to afford 
2-epi-123 in 64% yield over the two steps (Scheme 4).310 From salvinorin B and 2-epi-salvinorin 
B, modifications have been made to the C-2 position in order to study 1) esters other than 
acetate, 2) bioisosteric replacements for esters (amides, carbamates, carbonates, sulfonates, and 
thioesters), and 3) ethers and amines. 
Herkinorin and Other Ester Modifications 
Because of the relatively straightforward chemistry involved, initial attempts to probe the 
role of the C-2 carbonyl substituent involved the synthesis of various aliphatic esters.  These 
esters are typically generated using standard acylating conditions; salvinorin B and catalytic 4-
(dimethylamino)pyridine (DMAP) are dissolved in CH2Cl2 and treated with the appropriate acid  
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chloride or anhydride in the presence of a weak base (pyridine, Et3N, or DIPEA), or salvinorin B, 
EDCI or DCC, and HOBt are dissolved in CH2Cl2 and treated with the appropriate carboxylic 
acid in the presence of a weak base (Et3N or DIPEA) (Figure 31).
256, 311  Modification at the C-2 
position has generated analogs with differing activities, from full agonists to partial agonists in 
the inhibition of cAMP production.  Of particular interest, while salvinorin A was found to be a 
full agonist, propionate 126 (Ki = 32.63 nM, EC50 = 4.7 nM) and heptanoate 130 (Ki = 3199 nM, 
EC50 = 40 nM) were found to be partial agonists with lower affinity compared to salvinorin A.
256  
Salvinorin B, had no affinity at opioid receptors.  Subjecting salvinorin B to a mixture of formic 
acid and acetic acid produced the C-2 formate (125), which had decreased affinity and potency at 
KOP receptors by approximately 5-fold (Ki = 18 nM, EC50 = 315 nM) relative to salvinorin A.
312  
Increasing the ester chain to a butyl group (127) decreased KOP affinity and potency at KOP 
receptors approximately 2-fold (Ki = 4.9 nM, EC50 = 9.9 nM) relative to salvinorin A,
311 while 
adding some MOP receptor affinity (Ki = 520 nM).
313  KOP receptor binding affinity was 
reported to decrease with increasing ester chain length (C3-C5; 127, 128: Ki = 15 nM, 129: Ki = 
70 nM), but no such effect was observed for MOP receptor affinity.   
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Branching is generally poorly tolerated at the KOP receptor; isopropyl 131 had 10-fold 
decreased affinity (Ki = 19 nM) compared to salvinorin A,
281 and tert-butyl 132 and cyclopropyl 
133 abolished affinity (Ki > 10,000 nM).
256  Introduction of an alkene to the isopropyl (134) 
resulted in a 20-fold decrease in KOP receptor affinity (Ki = 42 nM) relative to salvinorin A (2-
fold decrease relative to 131) and a 4-fold increase in MOP receptor affinity (Ki = 260 nM) (11-
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fold increase relative to 131).281  Substitution of the 2-methylacroyl group in 134 with a methyl 
glyoxyl group (135) led to a 10-fold loss in KOP receptor affinity (Ki = 430 nM).
281 
Introduction of nitrogen containing substituents generally has detrimental effects on KOP 
receptor affinity.  KOP affinity was abolished (Ki > 10,000 nM) for acetamido 136, as well as for 
derivatives 137 and 138, both of which contain basic amino substituents.311  Introduction of a 
tert-butoxycarbonylamino (Boc) group (139) reduced affinity for KOP receptors by 47-fold (Ki = 
90 nM) relative to salvinorin A.313 
Incorporation of aromaticity at the C-2 position has produced one of the most interesting 
salvinorin A analogs to date.  A benzoyl substitution at C-2 (141, herkinorin) reduced affinity for 
KOP receptors 47-fold (Ki = 90 nM), but increased MOP receptor affinity 83-fold (Ki = 12 nM) 
compared to salvinorin A (KiKOP = 1.9 nM, KiMOP > 1,000 nM).
281  The [35S]GTP--S functional 
assay revealed herkinorin to be a selective, full agonist at MOP receptors (EC50MOP = 500 nM, 
EC50KOP = 1320 nM), signifying the first example of a non-nitrogenous MOP agonist.  
Pharmacological evaluation has found that, unlike morphine and DAMGO, herkinorin does not 
promote the recruitment of -arrestin-2 to the MOP receptor, nor does it promote receptor 
internalization, even in cells engineered to overexpress GRK.314  This makes herkinorin a 
striking example of functional selectivity/biased agonism at opioid receptors and a useful tool for 
the study of opioid tolerance and dependence.  It has been hypothesized that -arrestin mediated 
receptor desensitization and internalization are responsible for the development of tolerance to 
and dependence upon opioid agonists.  However, in vitro studies comparing herkinorin (non-
internalizing) and DAMGO (internalizing) revealed that chronic treatment with either drug 
resulted in cellular signs of tolerance and dependence, indicating that internalization is perhaps 
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not a critical factor in these phenomena.315  Studies of prolactin levels in non-human primates 
have provided neuroendocrine evidence that herkinorin has both MOP and partial KOP agonist 
effects in vivo.316  In a recent study, it was found that not only did herkinorin produce dose-
dependent, naloxone-reversible antinociceptive effects in rats in the formalin test, but chronic 
herkinorin treatment (5-day) did not diminish efficacy, and herkinorin produced antinociceptive 
effects in rats made opioid tolerant through chronic morphine treatment.317  Collectively, all 
these studies highlight the uniqueness of herkinorin and its potential as a biological probe as well 
as a pharmacotherapy, and underscore the value of the salvinorin A scaffold for opioid ligand 
research. 
 After the identification of herkinorin, the structural features responsible for MOP/KOP 
receptor selectivity were investigated.  Aromaticity plays an important role, as the cyclohexyl 
analog 140 showed greatly reduced affinity at all opioid receptors (Ki > 1,000 nM).318  
Incorporation of a 2-Br (142) or 3-Br (143) substituent to the aromatic ring had no effect on KOP 
affinity, but decreased MOP affinity 9-fold (for both, Ki = 110 nM) compared to herkinorin.
313  
The 4-Br substituent (144) caused an 8-fold decrease in KOP affinity (Ki = 740 nM) relative to 
herkinorin, while maintaining MOP affinity,313 in contrast to a previous study indicating that 144 
had no MOP affinity.256  Incorporation of electron-donating and electron-withdrawing 
substituents on the aromatic ring was also examined.  Addition of a 2-substituent (145, 149), 
regardless of the electronic nature, decreased both MOP and KOP affinity, implying that steric 
interactions may hinder the binding of these ligands.318  In comparison to herkinorin, 
introduction of a 3-OMe (146: Ki = 30 nM) or 4-OMe (147: Ki = 70 nM) substituent decreased 
MOP affinity approximately 3-fold and 6-fold, respectively, however KOP affinity was 
decreased 6-fold (for both Ki = 550 nM), resulting in a net increase in receptor selectivity for 
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MOP.318  Piperonylate 148 showed no affinity for opioid receptors.256  Addition of a 3-NO2 
substituent (149) completely abolished MOP receptor affinity and reduced KOP receptor affinity 
10-fold compared to herkinorin, and the addition of a 4-NO2 substituent (151) reduced MOP 
affinity 22-fold (Ki = 260 nM) and KOP affinity 6-fold (Ki = 570 nM).
318  Additionally, 4-
position derivatives 144, 147, and 151, similarly to herkinorin, did not promote -arrestin-2 
recruitment or MOP receptor internalization.318 
Heteroaromatic and extended chain aromatic esters at the C-2 position have also been 
investigated.  Nicotinoyl ester (152) showed a 6-fold loss in MOP affinity (Ki = 73 nM) relative 
to herkinorin, and a 21-fold loss in KOP affinity (Ki = 1930 nM).281  Replacement of the benzoyl 
group in herkinorin with a 2-thiophene (153) reduced KOP affinity 3-fold (Ki = 260 nM) with 
little effect on MOP affinity, and the 3-thiophene analog (154) was essentially indistinguishable 
from herkinorin.318  The 1-napthoyl derivative (155) abolished MOP affinity,256, 318 however, the 
2-napthoyl derivative (156) showed a 15-fold (Ki = 180 nM) decrease in MOP receptor affinity 
relative to herkinorin and a 61-fold decrease (Ki = 5490 nM) in KOP receptor affinity.
318  Similar 
to 3-thiophene 154, benzofuran 157 was essentially indistinguishable from herkinorin.318  
However, extension of the aromatic ring by one (158) or two (159) carbons reduced binding 
affinity over all, and in the case of 159 also abolished MOP/KOP receptor selectivity (158: KiMOP 
= 1090 nM, KiKOP = 290 nM; 159: KiMOP = 280 nM, KiKOP = 180 nM).
313 
Bioisosteric Replacements for Esters at C-2 
 Amide substituents as bioisosteric replacements for the C-2 acetate have been 
investigated (Figure 32).  These analogs are generated by first converting salvinorin B to the -
halogen (160) with either SOCl2 or CBr4/PPh3, followed by SN2 displacement with NaN3 to yield  
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the C-2 azide (161, Scheme 5).310, 318  Azide 161 can then be reduced to the primary amine (162) 
with either TMSCl/NaI in CH3CN or zinc metal and NH4Cl, and amides produced using standard 
coupling conditions of the appropriate acyl chloride or anhydride and catalytic DMAP in the 
presence of weak base.  Substitution of an acetamido group (163) decreases affinity and potency 
at KOP receptors, and extension to a propionamido (164) continues the trend.310, 318  The N-
methyl analogs of 163 (165) and 164 (166) showed similar affinity and potency to salvinorin A 
(Ki = 1.3 nM, EC50 = 4.5 nM), although 166 did exhibit increased potency (EC50 = 0.75 nM).
310  
A similar trend is observed with N-ethyl substituents of 163 (167) and 164 (168), however, 167 
and 168 have lower affinity and potency than 165 and 166.310  Similar to herkinorin, the N-
benzamide analog 169 had increased affinity and selectivity for MOP over KOP receptors (Ki = 
3.1 nM), making it the most potent (EC50 = 360 nM) MOP agonist ever derived from salvinorin 
A.318  Unlike herkinorin, benzamide 169 was found to promote MOP receptor desensitization 
and internalization.318 
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Figure 32. Selected C-2 bioisosteric analogs of salvinorin A.
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177: R = CH3
178: R = C6H5
179: R = 4-CH3C6H4
180: R = COCH3
181: R = COC6H5
182: R = H
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Carbamoyl derivatives at the C-2 position were synthesized by exposing salvinorin B to 
the appropriate isocyanate in the presence of catalytic DMAP or TMSCl.281, 311  Replacement of 
the acetyl group with a carbamate (170) was well tolerated and had very similar in affinity and 
potency to salvinorin A.311  Extension to a N-methyl- (171) or N-ethyl carbamate (172) produced 
a trend of decreasing KOP affinity and potency.311  Incorporation of an allyl carbamoyl group 
(173) decreased affinity at KOP receptors 63-fold (Ki = 120 nM) relative to salvinorin A, but 
showed moderate MOP affinity (Ki = 640 nM).
281  Phenylcarbamoyl 174 maintained similar 
KOP affinity to 173, but increased MOP affinity (Ki = 16 nM) similar to herkinorin.
281  Initially, 
carbonates (produced using the appropriate chloroformate and catalytic DMAP) appeared to be 
poorly tolerated at KOP receptors; carbonates 175 and 176 completely abolished affinity.319 
However, in a more recent study, carbonate 176 was found to have modest KOP affinity (Ki = 
171 nM).320   This difference may be attributed to choice of radioligand for the binding assay; 
[3H]bremazocine and [3H]diprenorphine in the earlier study, and [3H]U69,593 in the more recent 
study. 
109 
 
 Sulfonate esters (synthesized by treating salvinorin B with the appropriate sulfonyl 
chloride in the presence of catalytic DMAP) have also been targeted as replacements for the C-2 
acetate.281, 313  Substitution of a mesylate group (177) produced KOP receptor affinity and 
potency very similar to that of salvinorin A.281  Benzenesulfonate 178 had 32-fold reduced 
affinity at KOP receptors (Ki = 60 nM) compared to salvinorin A, and surprisingly, unlike the 
aromatic ester (herkinorin), amide, and carbamoyl derivatives, had no affinity for MOP 
receptors.313  Incorporation of a 4-methyl group to 178 (179) showed little change in KOP 
affinity, but increased MOP affinity (Ki = 220 nM).
313  Collectively, the SAR for sulfonate esters 
does not parallel the SAR for standard esters, implying that these “bioisosteres” are not actually 
binding to the receptor identically. 
 Thioester bioisosteric analogs at the C-2 position are synthesized in very similar fashion 
to the amide analogs: salvinorin B is converted to the -halogen (160) at C-2 (Scheme 5).318, 321  
Replacement of the C-2 acetate with a thioacetate (180) decreased both affinity and potency at 
KOP receptors.318, 321  As with the ester and the amide derivatives, incorporation of a benzene 
ring in the C-2 position (181) increased MOP affinity (Ki = 290 nM).318  Removal of the acetyl 
group to the free thiol (182) decreased KOP affinity and potency.321 
C-2 Ether, Amine, and Halogen Analogs 
 The conversion of salvinorin A to various ethers has generated a large number of analogs 
(Figure 33).  Generally, simple alkyl ethers at the C-2 position are synthesized by treating 
salvinorin B with the appropriate alkyl halide in the presence of Ag2O or DMAP and weak 
base.310-311, 319, 322  Methyl ether derivative (183) was very similar to salvinorin B and had 169-
fold reduced KOP affinity (Ki = 220 nM) and 82-fold reduced KOP potency (EC50 = 389 nM)  
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compared to salvinorin A.311  Extension of the chain to ethyl (184) increases KOP affinity and 
potency (Ki = 7.9 nM, EC50 = 18.6 nM), but further chain extension beyond that (185, 186), 
including allyl (187) and benzyl (188), returns to a trend of increasingly diminished affinity and 
potency.311  Trimethylsilyl ether (189) had essentially no affinity for opioid receptors.281 
 Introduction of a methoxymethyl ether (190) at the C-2 position was found to increase 
affinity and potency at KOP receptors (Ki = 0.4 nM, EC50 = 0.6 nM) greater than that of 
salvinorin A.319  One possible explanation for this is that the additional oxygen substituent could 
be involved in synergistic binding interactions with the KOP receptor.322  This finding prompted 
investigation into a large series of oxygenated, halogenated, and silylated C-2 methyl ether 
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derivatives.  Aliphatic straight-chain (192, 193) and branched (194, 195) derivatives showed 
similar affinity and potency compared to salvinorin A.322  Ethoxymethyl ether derivative 191 
demonstrated the highest KOP affinity and potency (Ki = 0.32 nM, EC50 = 0.14 nM) of all 
salvinorin A derivatives known to date.322  The incorporation of halogen atoms (196, 197, 202) 
and additional oxygen atoms (198) had the effect of reducing KOP affinity and potency 
compared to 191.322  Silyl 199 and benzyl 200 also showed a loss of affinity and potency 
compared to both 191 and salvinorin A.322  Conversion of 190 to the methyl thiomethyl analog 
(201) caused a 22-fold drop in KOP affinity (Ki = 13 nM) and a 78-fold drop in potency (EC50 = 
31 nM).322  Alkylation of the acetal carbon had a negative effect on KOP affinity and potency 
relative to 191.  These ether derivatives are produced by treating salvinorin B with the 
appropriate alkene in the presence of catalytic p-TsOH or PPTS.322  Epimers 203a and 203b 
were partially separated from each other (absolute configuration undetermined) had found to 
have reduced affinities and potencies (203a: Ki = 11 nM, EC50 = 10 nM; 203b: Ki = 6.6 nM, 
EC50 = 5.7 nM) in comparison to 191, but were comparable to salvinorin A.
322  Dimethyl analog 
204 showed even further reduced affinity and potency (Ki = 72 nM, EC50 = 72 nM).
322  The 
epimeric mixture of tetrahydropyran 205 had similar affinity and potency (Ki = 4 nM, EC50 = 2.8 
nM) to salvinorin A, however as they were not separated, the effects of the individual epimers 
remains to be determined.322 
 Amines can be installed at the C-2 position by converting 2-epi-salvinorin B to the triflate 
and then displacing with the appropriate alkyl amine.310-311  The conversion of the methoxy 
group in 183 to a methylamino (206) decreased both affinity and efficacy at KOP receptors.310  
Increasing the chain length to ethyl (207) or isopropylamino (208), or adding an N-methyl (209), 
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increased KOP affinity and potency relative to 206, but was still less compared to salvinorin 
A.310 
 Although halogenation of the C-2 position has been reported for intermediates in the 
synthesis of other analogs,318, 323 a full series of C-2 halogenated analogs was not described until 
very recently.324  Pharmacological evaluation revealed that C-2- analogs (214, 215, 216) 
generally displayed higher affinity and efficacy than their C-2- counterparts (210, 211, 212), 
with the exception of iodo analogs 213 and 217 which had approximately equal affinity and 
potency.324  Overall, installation of a halogen atom in place of the C-2 acetate diminished affinity 
and potency at KOP receptors. 
C-2 Epimer Analogs 
 Finally, the stereochemical requirements of the C-2 position have been examined (Figure 
34).  C-2 inverted analogs of salvinorin A can be synthesized using previously described 
synthetic methods, but simply starting from 2-epi-salvinorin B (or by starting from salvinorin B 
in the case of C-2 amine derivatives).  Inversion of the C-2 acetate of salvinorin A (218) resulted 
in decreased affinity at KOP receptors, but was also the first neoclerodane diterpene reported to 
have DOP antagonist activity.325  Additionally, amine 219 was the most potent amine analog 
reported, approximately equal to salvinorin A at KOP receptors.310  In spite of these two 
interesting analogs, epimerization at the C-2 position was generally found to be detrimental for 
opioid binding affinity and potency of esters, ethers, thiols, amides, and amines.310, 321 
 Even though a large number of C-2 analogs of salvinorin A have already been made, 
there is still opportunity for further investigation.  This is especially true regarding the 
stereochemical preferences of C-2 ligands with additional stereocenters.  Continued investigation  
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of such ligands will inevitably lead to deeper understanding of the SAR of the salvinorin A 
scaffold, and will potentially provide new biological probes for the study of opioid receptors or 
new pharmacotherapies to treat disease.  
Rationale and Specific Aims 
 Salvinorin A is a selective KOP receptor agonist that is structurally unique from other 
known opioid ligands.  This is important because a novel structural motif grants the possibility 
that compounds may be developed with altered pharmacological and side effect profiles at opioid 
receptors.  The development of herkinorin, a potent MOP agonist, shows that the opioid receptor 
selectivity of the salvinorin A scaffold can be modulated through synthetic changes.  Relatively 
recent research has also revealed that modifications to the salvinorin A scaffold are tolerated at 
the KOP receptor, and even improve affinity and potency (e. g. ethers 190 and 191).  However, 
as alkoxy ethers 190 and 191 have a relatively high degree of conformational flexibility, the 
structural basis underlying their improved profiles is not currently known.  Because opioid 
receptors themselves have been linked to a variety of conditions from pain to mood disorders and 
drug abuse, further development of salvinorin A SAR promises to yield novel opioid ligands that 
may be used as biological probes and/or eventually as clinical therapies.  Since the endogenous 
opioid system has also been linked to other endogenous systems, such as the cannabinoid system  
114 
 
 
 
 
 
 
 
 
as well as the physiological stress response, investigation into salvinorin A SAR also has the 
potential to uncover new pharmacological targets for CNS disease treatment. 
Specific Aim 1: Prepare selected analogs of salvinorin A at the C-2 position through semi-
synthesis in order to elucidate the binding mode of alkoxy ethers at C-2. 
 Research has shown that modifications made to replace the acetate off the C-2 position in 
the salvinorin A scaffold are tolerated at opioid receptors.  Specifically, converting the acetate to 
a benzoyl to make herkinorin (141) alters the receptor selectivity of the scaffold from KOP to 
MOP.281  Converting the acetate to a methoxy- (190) or ethoxymethyl (191) ether improves both 
KOP affinity and potency.322  However, the structural basis that underlies this improvement is 
unknown.  One hypothesis is that the alkoxy ether moieties at C-2 are rather flexible and can 
adopt different conformations when interacting with the KOP receptor; for example an eclipsed 
or an extended conformation (Figure 35).  Another possibility is that the oxygen atom in the 
alkoxy ether moieties could participate in hydrogen bonding interactions with the receptor that 
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are not exploited by salvinorin A.  Thus C-2 modified derivatives of salvinorin A will 
synthesized in order to further describe the SAR of salvinorin A while identifying analogs with 
more desirable pharmacological profiles than the parent molecule. The concept of 
conformational constraint will be applied in order to design ligands in which the flexible portions 
have been pre-organized.  Cyclic ligands such as tetrahydropyrans and tetrahydrofurans will 
directly mimic both the eclipsed and extended conformations and probe steric tolerances.  
Acyclic ligands such as a formate, a carbonate, and a carbamate will also probe steric tolerances 
as well as the effects of electronic changes on affinity and potency. Analogs at the C-2 position 
will have improved or comparable receptor affinity, selectivity, and efficacy compared to the 
parent ligands.  They will also aid in the investigation and elucidation of the structural basis for 
the observed improvements in affinity and potency of alkoxy ether ligands over salvinorin A.   
Specific Aim 2: Evaluate C-2 analogs of salvinorin A for opioid receptor affinity and 
efficacy through radioligand binding, [35S]GTP--S, and fluorescent calcium mobilization 
assays.   
 Using known methodology, compounds generated from Specific Aim 1 will be evaluated 
for in vitro affinity at opioid receptors through the displacement of the ligands [3H]DAMGO 
(MOP), [3H]DADLE (DOP), and [3H]U69,593 (KOP).213  Selected compounds having receptor 
affinity of Ki ≤ 100 nM will be further evaluated for efficacy in the [
35S]GTP--S functional 
assay using a known protocol.68  Other selected compounds will be evaluated in the fluorescent 
calcium mobilization assay using a known protocol.214  A second functional assay was selected 
in order to confirm rank-order potencies among the compounds tested.  Since the fluorescent 
calcium mobilization assay is a different format from the [35S]GTP--S assay, preservation of 
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rank-order potencies of compounds between the two assays supports that the data being 
generated is not an artifact of the particular assay system.  These proposed assays are intended to 
characterize the opioid receptor behavior of C-2 analogs of salvinorin A. 
Specific Aim 3: Use molecular modeling in order to further examine the possible binding 
mode of C-2 alkoxy ethers in the KOP receptor crystal structure. 
 With the very recent publication of the co-crystal structure of the KOP receptor and 
JDTic, it may be possible to explain binding and functional data through docking studies with the 
ligands of interest.297  Additionally, a model of salvinorin A in the KOP crystal structure would 
aid in elucidating which of the several proposed residues are actually important for receptor 
binding interactions.  Further, the development of a reliable salvinorin A–KOP receptor model 
would allow for in silico design and testing of ligands and enhance the SAR development 
process.  To this end, compounds generated from Specific Aim 1 will be evaluated in receptor 
docking studies based on the KOP–JDTic co-crystal structure, and their docking scores will be 
compared with binding and potency data generated from Specific Aim 2.  If the model is viable, 
the calculated docking scores will correlate with the in vitro binding affinity and/or potency data 
from Specific Aim 2, and the model may be used in the future for in silico ligand design and 
evaluation.   
The purpose of these specific aims is to provide greater insight into the role the C-2 
position plays in opioid affinity and potency.  Generating and evaluating such compounds also 
provides further support that the salvinorin A scaffold can be amended to produce ligands with 
altered opioid receptor interactions.  These ligands will serve as novel opioid receptor probes and 
may lead to the development of new therapies for clinical use.  The ability to develop novel 
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opioid ligands based on the structure of salvinorin A demonstrates its value as a lead molecule, 
and suggests that the neoclerodane diterpene structural class may be useful as a generic scaffold 
for the construction of molecules with opioid receptor activity.  The results of these studies will 
be presented and discussed. 
Results and Discussion 
Introduction 
 In an effort to elucidate the binding conformation of C-2 ether analogs of salvinorin A in 
hopes of explaining the improved affinity and potency, a series of derivatives was generated.  
These compounds were meant to mimic either the eclipsed or extended conformation that may be 
adopted by alkoxy ether 191 (Figure 35).  In order to mimic the eclipsed conformation, 
unsubstituted tetrahydrofuran and tetrahydropyran derivatives were designed and produced; 
tetrahydropyrans would directly mirror the eclipsed conformation and tetrahydrofurans would 
probe the size requirements of the binding pocket.  In order to mimic the extended conformation, 
acyclic, branched ethers were synthesized in which the carbon between the oxygen atoms was 
alkylated.  Analogs in which the alkylation was a methyl group tested flexibility requirements; 
they are less conformationally flexible than the unbranched alkyoxy ethers, but more flexible 
than the ring-constrained derivatives.  Analogs in which the alkylation was a methyl-bromo 
moiety probed flexibility requirements as well as steric tolerances.  In order to directly mirror the 
extended conformation, methylated tetrahydropyran derivatives were produced.  A formate at C-
2 investigated size requirements for binding, having only one additional carbon atom and one 
additional oxygen atom compared to salvinorin B.  Extending the C-2 moiety to an ethyl 
carbonate once again was a model for the extended conformation, but with the additional 
118 
 
carbonyl oxygen also tested for the possibility of an additional interaction with residues in the 
binding pocket.  An ethyl carbamate C-2 derivative probed whether or not electronic changes at 
this position would follow previously reported SAR trends for receptor subtype selectivity; the 
incorporation of allyl- and benzylcarbamates diminished KOP affinity and increased MOP 
affinity.281 
Synthesis 
 For comparison purposes, compounds 190 and 191 were synthesized according to 
Scheme 6.  Salvinorin A (108) was extracted from commercially available dried S. divinorum 
leaves and converted to salvinorin B (123) as previously described.309  Treatment of 123 with the 
appropriate chloromethyl ether in the presence of DIPEA yielded the desired ether products 190 
and 191 in 41% and 54% yield, respectively.319  
 Compounds 220, 221, and 222a,b were synthesized according to Scheme 6.  To a 
solution of 123 in CH2Cl2 was added 3,4-dihydro-2H-pyran or 2,3-dihydrofuran, followed by a 
catalytic amount of PPTS.  This afforded the previously reported tetrahydropyran (220 and 
221)322 in 41% combined yield, and novel tetrahydrofuran (222a,b) C-2 derivatives in 68% 
combined yield.  Under these synthetic conditions, epimers were formed and, in the case of 
tetrahydropyrans 220 and 221, were separated from each other through flash column 
chromatography, and characterized by NMR studies and X-ray crystallography.  The epimers 
222a,b were separated from each other by flash column chromatography and characterized by 
NMR only. 
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NMR spectroscopy studies and X-ray crystallography were used to assign the 
stereochemistry of the new stereocenter in compounds 220 and 221.  For carbohydrates, 
anomeric 1JC,H values are useful for the assignment of configuration at that position because 
pyranoses with an axial proton have a 1JC,H value that is approximately 10 Hz lower than the 
corresponding value in pyranoses with an equatorial anomeric proton.326-328  For compounds 220 
and 221 it was determined that the anomeric 1JC,H
 values were 168.55 Hz and 159.36 Hz 
respectively, which are consistent with published reported of substituted pyranoses.  These data 
indicate that 220 contains an equatorial, -H (R) and 221 contains an axial, -H (S) (Figure 36).   
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Tetrahydropyran 220, the less polar epimer, crystallized and the structure was determined using 
X-ray crystallography (Figure 37).  This confirmed the orientation of the hydrogen that was 
predicted by NMR analysis.  In the crystal structure, the tetrahydropyran moiety forms an -
Figure 36. 1D 13C NMR spectrum with composite pulse 1H-decoupling (blue) and 
gated decoupling to show JC,H (black) for the anomeric carbon of 220 (A) and 221 (B). 
Figure 37.  X-ray crystallographic structure of 220. 
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glycosidic bond with the salvinorin A core in an axial position and the anomeric hydrogen in an 
equatorial,  position.  Subsequently, tetrahydropyran 221 must be the other epimer. 
 Compounds 223a,b and 224a,b were synthesized according to Scheme 6.  A suspension 
of 123 in ethyl vinyl ether with a catalytic amount of PPTS was refluxed for 2 h, yielding an 
epimeric mixture of the previously reported ethers 223a,b in 21% combined yield.322  The 
epimers were separated from each other by flash column chromatography and the less polar 
epimer (223a) was isolated.  The more polar epimer (223b) appeared to degrade during 
purification and could not be completely purified (purity = 81.9%) through trituration, additional 
flash column chromatography, or HPLC.  The impurity was not determined, although there were 
no traces of either 123 or the other epimer 223a as detectable by HPLC.  Both 223a and 223b 
were characterized by NMR.  In order to produce novel ethers 224a,b (11% combined yield), 
ethyl vinyl ether was added in a dropwise fashion to a solution of Br2 in CH2Cl2, and the reaction 
mixture was stirred until the solution turned colorless (~15 min).  DIPEA was then added, 
followed by the dropwise addition of a suspension of 123 in CH2Cl2.  These synthetic conditions 
yielded a mixture of epimers which were separated from each other by HPLC and characterized 
by NMR. 
 Compounds 225, 226, and 227 were synthesized according to Scheme 6.  Following a 
literature procedure, a mixture of acetic anhydride and acetic acid was added to a mixture of 123 
in pyridine at 0 °C.312  The mixture was allowed to warm to room temperature and stirred for 30 
min, affording formate 225.  Carbonate 226 was produced by treating a solution of 123 in 
CH2Cl2 with ethyl chloroformate in the presence of DMAP and Et3N at room temperature for 24  
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h.256, 319  Following a literature procedure, carbamate 227 was produced by treating a mixture of 
123 in pyridine with ethyl isocyanate at 35 °C overnight.311 
 The synthesis of compounds 231 and 232a,b followed Scheme 7.  For in situ generation 
of the Grignard reagent, a solution of commercially available 4-bromo-1-butene in THF was 
added via dropping funnel to a suspension of Mg turnings and catalytic I2 in THF at reflux.
329  
When the reaction was complete (~20 min), the mixture was cooled to -78 °C and CuI was 
added, and the reaction mixture was allowed to stir for 30 min at that temperature.  
Commercially available R-(+)-propylene oxide or S-(-)-propylene oxide was then added in a drop 
wise manner.  The reaction mixture warmed to -10 °C and was allowed to stir overnight, yielding 
alcohol intermediate 228, which could be purified by flash column chromatography, in 71% 
yield.  The olefin of alcohol 228 was subsequently oxidatively cleaved using RuCl3·3H2O and  
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NaIO4 in CH3CN/H2O (6:1), and the resultant aldehyde cyclized in situ to afford intermediate 
229 with no additional purification.330  Acetylation of crude 229 was immediately performed by 
treatment with acetic anhydride and catalytic DMAP in the presence of Et3N to give intermediate 
230 with no additional purification.331  Finally, catalytic PPTS and crude pyran 230 were added 
to a solution of 123 in 1,2-dichloroethane (1,2-DCE) and the mixture was heated to 80 °C for 24 
h.332  These synthetic conditions afforded methyltetrahydropyran 231 (9% yield) as a single 
isomer that could be purified from starting materials by flash column chromatography, and 
methyltetrahydropyrans 232a,b (15% combined yield) as a mixture of epimers that could be 
separated from each other by HPLC.  Methyltetrahydropyrans 231 and 232a,b were 
characterized by NMR.  Methyltetrahydropyran 231 also crystallized and the structure was 
determined using X-ray crystallography (Figure 38).  
Figure 38. X-ray crystallographic structure of 231. 
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Similar to the structure of 220, in the structure of 231 the methyltetrahydropyran moiety 
forms an -glycosidic bond with the salvinorin A core in the axial position and the anomeric 
hydrogen in a equatorial,  position.  The S-methyl group and the anomeric hydrogen are also on 
the same side of the tetrahydropyran ring making the absolute configuration of the anomeric 
center -H (S) (compared to -H (R) as in 220).  The oxygen of the tetrahydropyran ring in 231 
is also oriented in the opposite direction of the tetrahydropyran oxygen of 220.  The anomeric 
1JC,H values of methyltetrahydropyrans 232a,b were examined during NMR characterization; 
using the same reasoning as previously described, the less polar epimer (232a) had a 1JC,H value 
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Figure 39. Proposed stereochemical assignments for tetrahydropyran derivatives.
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of 158.73 Hz and the more polar epimer (232b) had a 1JC,H value of 170.73 Hz.  These data 
indicate that the anomeric proton in 232a is in the axial, -H position making the absolute 
configuration of the stereocenter R, and that the anomeric proton in 232b is in the equatorial, -H 
position making the absolute configuration of the stereocenter S (Figure 39).  However, these 
proposed assignments need to be confirmed through X-ray crystallography. 
Radioligand Binding Results 
 Compounds 190, 191, 220, 221, 222a,b, 223a,b, 224a,b, 225, 226, and 227 were 
evaluated for affinity at human opioid receptors using methodology previously described (Table 
7).213  For previously reported ethers 190 and 191, the results of the radioligand binding assay 
were in agreement with published data.322  From previous literature, tetrahydropyran epimers 220 
and 221 were not completely separated from each other before pharmacological evaluation.  For 
a mixture of predominantly one of the epimers, absolute configuration undetermined, the 
reported KOP binding affinity and potency were Ki = 4.0 nM and EC50 = 2.8 nM.
322  
Tetrahydropyrans 220 and 221 have now been separated and isolated from each other, and the 
observed binding affinities reveal an eutomer (220) and distomer (221), indicating a preference 
for the hydrogen of the new stereocenter to be in the  (R) configuration.320  Interestingly, the 
related tetrahydrofuran derivatives 222a,b have only modest binding affinities at KOP receptors 
that are very similar to each other and show no preference for stereochemistry.  One possible 
explanation for this is that by reducing the ring size by one carbon, a binding interaction within 
the receptor is eliminated or weakened, negating the influence of the configuration of the new 
stereocenter.  Additionally, the 1JC,H values at the new stereocenter in these derivatives were 
obtained during NMR characterization, and although they followed the accepted trend for  
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Table 7.  Opioid receptor binding affinity for compounds 108, 
190, 191, 220, 221, 222a,b, 223a,b, 224a,b, 225, 226, and 227. 
 Ki nM
a ± SD 
Compound 
[3H]DAMGO 
(MOP) 
[3H]DADLE 
(DOP) 
[3H]U69,593 
(KOP) 
108b   7.4 ± 0.7 
190 390 ± 20 2,840 ± 180 1.9 ± 0.2 
191 41 ± 3 1,017 ± 99 3.13 ± 0.40 
220 > 10,000 > 10,000 6.21 ± 0.40 
221 > 10,000 > 10,000 300 ± 23 
222a > 10,000 > 10,000 75 ± 3 
222b > 10,000 > 10,000 81 ± 6 
223a 777 ± 40 > 5,000 6.7 ± 0.32 
223b > 5,800 > 5,000 1,233 ± 33 
224a > 3,000 > 5,000 5,621 ± 680 
224b 3,523 ± 389 > 5,000 7,438 ± 764 
225 ND  ND 41 ± 1 
226 ND ND 171 ± 7 
227 1,540 ± 140 ND ND 
aReceptor binding was performed in CHO cells expressing the 
human MOP, DOP, or KOP receptors.  All results are N = 3. 
bData from Lozama, A. et al. J. Nat. Prod. 2011, 74, 718–726. 
ND indicates that Ki was found to be >10,000 nM in a range 
finding study. 
 
pyranoses as previously described, the difference was less pronounced (174.18 Hz and 171.85 
Hz), so configuration was not assigned.  
Like the tetrahydropyran derivatives ethers 223a,b were also previously reported but 
were not completely separated from each other before pharmacological evaluation.  The 
literature reports both epimers to have very similar binding affinities (Ki = 11 nM and Ki = 6.6 
nM) and potencies (EC50 = 10 nM and EC50 = 5.7 nM).
322  The less polar epimer (223a) has now 
been isolated and separated.320  Observed by HPLC, the more polar epimer (223b) appeared to 
degrade during purification and was not completely purified (purity = 81.9 %), although there 
was no detectable starting material or 223a contamination.  Like tetrahydropyrans 220 and 221, 
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ethers 223a,b also reveal an eutomer (223a) and distomer (223b), indicating a preference for 
configuration of the new stereocenter.  The 1JC,H values at the new stereocenter in these 
derivatives were obtained during NMR characterization, and although they followed the accepted 
trend for pyranoses as previously described, the difference was less pronounced (165.60 Hz and 
163.82 Hz).  However, given this observation and the trend in the radioligand binding data in 
which the less polar epimers (220 and 223a) had the highest affinity, it is likely that the absolute 
configuration of the new stereocenter in 223a is the same as that of 220.  This hypothesis needs 
to the confirmed through X-ray crystallography.  The related brominated ethers 224a,b had very 
poor binding affinities at the KOP receptor and show no preference for stereochemistry.  One 
explanation for this is that the brominated moiety was too bulky and precluded binding to the 
receptor altogether. 
 Formate 225 produced KOP radioligand binding data that was well in agreement with 
published reports312, 324 and was 6-fold lower than that of salvinorin A.  This would seem to 
indicate that the slightly smaller C-2 substituent was missing a binding interaction in the receptor 
that salvinorin A and C-2 ligands with larger substituents are able to exploit.  Carbonate 226 and 
carbamate 227 behaved differently than previously reported.  In two previously published 
radioligand binding studies, carbonate 226 showed no appreciable affinity at the KOP receptor 
vs. [3H]bremazocine256 or [3H]diprenorphine.319  The data generated in this report showed that 
carbonate 226 displaces [3H]U69,593 at the KOP receptor at Ki = 171 ± 7 nM,
320 23-fold lower 
than salvinorin A and 55-fold lower than ether 191.  Moderate KOP receptor affinity for 
carbonate 226 is actually unsurprising considering how similar it appears to ether 191; the lower 
KOP binding affinity implies that the additional carbonyl moiety is not particularly favorable.  
Additionally, carbamate 227 was reported to have a KOP receptor binding affinity (vs. 
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[3H]diprenorphine) and potency of Ki = 462 ± 20 nM and EC50 = >1,000 nM.
311  This report 
found that while carbamate 227 has no appreciable affinity at the other opioid receptors, it does 
displace [3H]DAMGO at the MOP receptor at Ki = 1540 ± 140 nM.
320  While this particular Ki is 
unimpressive, it does agree with previously published reports in which alkyl carbamates at the C-
2 position of salvinorin A were found to lose KOP affinity and gain MOP affinity relative to the 
parent compound.281  
[35S]GTP--S Functional Assay Results 
 Compounds 190, 191, 220, 222a,b, 223a, 231, and 232a, were also evaluated for 
functional activity at KOP receptors using the [35S]GTP--S functional assay (Table 8).68  
Compounds 190, 191, and 220 were found to have potencies comparable to or better than 
salvinorin A (108), in agreement with literature reports.322  Compounds 222a,b were observed to 
be 30- and 17-fold less potent than salvinorin A as agonists, respectively.320  Similar to the 
radioligand binding results, this may be due to the smaller ring size eliminating the possibility of 
or weakening certain binding interactions with the receptor.  Ether 223a, which had binding 
affinity identical to tetrahydropyran 220, was found to be 2.5-fold less potent than 220 and 4-fold 
less potent than salvinorin A.  One explanation for this could be that in order to avoid steric 
interactions, 223a would adopt an extended conformation (review Figure 35), implying that such 
a conformation is not favored by the KOP receptor.  Methyltetrahydropyran 231 was 
approximately 3-fold less potent than tetrahydropyran 220 and 7-fold less potent than salvinorin 
A.  This result further supports the hypothesis that the KOP receptor does not favor an extended 
conformation; the addition of a methyl group to a structure otherwise comparable in activity to 
salvinorin A resulted in reduced potency at KOP receptors.  Methyltetrahydropyran 232a had  
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Table 8.  Selected [35S]GTP--S KOP receptor 
potency and efficacy data for compounds 108, 190, 
191, 220, 222a,b, 223a, 231, and 232a. 
Compound  EC50 nM
a ± SD Emax ± SD 
108d 40 ± 10 120 ± 2 
190b 6 ± 1 118 ± 2 
191b 0.65 ± 1 127 ± 5 
220b 60 ± 6 109 ± 3 
222ab 1220 ± 230 112 ± 8 
222bb 690 ± 80 103 ± 4 
223ab 150 ± 14 101 ± 3 
231c 202 ± 60 90 ± 6 
232ac 5100 ± 980 80 ± 9 
aReceptor binding was performed in CHO cells 
expressing the human KOP receptor.  All results are 
at least N = 3. 
bEmax is % at which compound stimulates binding 
compared to U50,488 (500 nM). 
cEmax is % at which compound stimulates binding 
compared to U69,593. 
dData from Lozama, A. et al. J. Nat. Prod. 2011, 74, 
718–726. 
 
very poor potency (176-fold lower) compared to salvinorin A, and its epimer 232b was 
completely inactive at concentrations up to 10 M. 
Interestingly, when compounds 191, 220, 231, and 232a,b were screened at 10 M at 
DOP and MOP receptors in this assay format, 191 appeared to be a full DOP agonist (Emax = 
100% vs. DPDPE) as well as a partial MOP agonist (Emax = 67% vs. DAMGO).  
Methyltetrahydropyran 232b, which was found to be completely inactive at KOP receptors, 
appeared to be a potential DOP partial agonist, showing Emax = 49% vs. DPDPE.  
Tetrahydropyran 220 was less active than 191 and 232b, having Emax = 33% vs. DPDPE and 
Emax = 16% vs. DAMGO. Compounds 231 and 232a showed negligible (≤ 30%) activity at DOP 
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and MOP receptors.  These preliminary results will need to be further explored with additional in 
vitro screening. 
Calcium Mobilization Results 
 In order to examine whether or not the rank-order potencies from the [35S]GTP--S assay 
were preserved across different assay formats, compounds 191, 220, 231, and 232a were 
evaluated in a second functional assay format, the fluorescent calcium mobilization assay (Table 
9).214  The rank-order potencies were preserved between the different functional assays, and as 
expected and in agreement with published literature,322 191 and 220 were full agonists and had 
potency comparable to or better than salvinorin A.  Methyltetrahydropyran 231 was 
approximately 19-fold less potent than tetrahydropyran 220 and 8-fold less potent than salvinorin 
A and a full agonist, continuing the trend observed in the [35S]GTP--S functional assay results.  
Methyltetrahydropyran 232a also appeared to have much worse potency (762-fold lower) 
compared to 220 and salvinorin A (332-fold lower) in this assay format, and the epimer 232b 
was inactive at concentrations up to 10 M. 
Table 9.  Selected opioid receptor potency for 
compounds 108, 191, 220, 231, and 232a in the 
calcium mobilization assay format. 
Compound EC50 ± SEM nM
a Emax ± SEM
b 
108 1.7 ± 0.6 103 ± 2 
191 0.36 ± 0.03 110 ± 6 
220 0.74 ± 0.06 108 ± 5 
231 14.4 ± 5 101 ± 2 
232a 564 ± 80 91 ± 2 
aReceptor binding was performed in CHO cells 
expressing the human KOP receptors.  All results 
are at least N = 3. 
bEmax is % at which compound stimulates binding 
compared to U69,593. 
 
131 
 
 
 
Crystal Structure Considerations 
 Using the published KOP–JDTic co-crystal structure as a starting point (Figure 40), 
attempts were made to model the C-2 ligands in this report in the KOP receptor binding site, in 
hopes of correlating docking scores with affinity and potency data.  Docking runs into the KOP–
JDTic co-crystal structure (PDB ascension code 4DJH) were performed using SYBYL 8.0 
(Tripos) and Suflex–Dock (Tripos).  Default parameters were used except where noted.  The 
KOP–JDTic co-crystal structure was used as a monomer instead of a dimer.  The structures of 
salvinorin A (CSD code BUJJIZ) and C-2 analogs were energy minimized using the Tripos 
Force Field (Gasteiger–Hückel charges), and the coordinates of JDTic were used to generate the 
protomol (the putative binding pocket for docking ligands).   Unfortunately, the docking scores  
Figure 40. X-ray crystal structure of JDTic (magenta) in the KOP 
receptor (green) with relevant residues (yellow). 
132 
 
 
did not correlate with the binding affinity data (data not shown).  On closer inspection of the 
docking run, it seemed that while salvinorin A was able to fit into a binding pocket near JDTic, it 
did not overlap very well with the antagonist and could take several very different poses itself 
(Figure 41A).  Extracting the proposed important binding residues from the crystal structure, it is 
apparent that all of the residues do form a sort of binding pocket within the receptor, but 
salvinorin A is not interacting with them in a way that resembles the models previously proposed 
through mutagenesis studies,180, 299-304 and in fact seems to be shunted off to one side of the 
pocket, too far away from most of the residues (Figure 41B).  One possible explanation for the 
failure of the docking run is that the crystal structure is of an unfavorable conformation of the 
KOP receptor. JDTic is a KOP antagonist, whereas salvinorin A and the ligands herein are KOP 
agonists; it is possible that JDTic binds to an inactive receptor conformation that would 
otherwise preclude the binding of the salvinorin A scaffold.  This hypothesis is supported by the 
fact that in the original co-crystal structure report, in order to model the covalently binding 
Figure 41. A) Overlay of JDTic (magenta) from KOP crystal structure with poses of 
salvinorin A (cyan, green, orange).  Poses of salvinorin A (cyan, green, orange) with residues 
(yellow) putatively involved in receptor binding. 
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ligand RB-64 (22-thiocyanatosalvinorin A) in the receptor, the torsion angle of the Cys315 
residue it supposedly binds to had to be modified by +60.0° in order for the sulfhydryl sidechain 
to point into the binding pocket and be accessible to the C-2 position of the salvinorin A 
scaffold.297  Further, in order to allow room for RB-64 to fit, Gln115, Asp138, Ile290, Ile294, 
Tyr313, and Ile316 were allowed to flex via a “rotamer library,” which is not further defined.  In 
attempting to repeat this work and manually draw the structure of RB-64 bound to Cys315 in the 
KOP receptor to use as a starting point for further C-2 docking studies, it became clear that the 
rotamer library allowed for a very large amount of flexibility in the receptor structure.  It was 
impossible to draw the ligand in the receptor as depicted in the report without making large 
changes to the orientations of Tyr312 and Tyr313.  Since the rotamer library (which includes 
Tyr313) was not clearly defined, it was not possible to reliably reproduce a model of RB-64 in 
the KOP receptor, calling into question the usefulness of this particular model.  This clearly 
indicates that conformational changes in the receptor need to take place in order for salvinorin A 
to bind.  What these changes are exactly will likely not be unambiguously elucidated until 
salvinorin A (or a derivative) is co-crystallized with the KOP receptor. 
 Another way to explain the binding and functional data is to examine the crystal 
structures of the molecules themselves.  When the crystal structures of salvinorin A (CSD code 
BUJJIZ), tetrahydropyran 220, and methyltetrahydropyran 231 are overlaid, the differences in 
the C-2 appendages seem to indicate that the three molecules are binding the KOP receptor 
differently from each other (Figure 42A).  When salvinorin A and 220 are compared, the oxygen 
of the tetrahydropyran ring occupies the same space as the methyl of the acetate, while the 
anomeric hydrogen occupies the same space as the acetate carbonyl oxygen (Figure 42B).  This 
implies that 220 takes advantage of a different hydrogen bonding interaction than salvinorin A  
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does.  When salvinorin A and 231 are compared, the oxygen is flipped, occupying space left 
empty by salvinorin A, but in the general vicinity of the acetate carbonyl oxygen (Figure 42C).  
This may indicate that 231 and salvinorin A are able to take advantage of the same hydrogen 
bonding interaction, but 231 may be able to participate in some lipophilic interactions with its 
greater bulk compared to the acetate moiety.  When the structures of 220 and 231 are compared, 
the most apparent feature is that the anomeric hydrogen of both derivatives occupies the same 
space (Figure 42D).  This explains the stereochemical preference in the receptor binding affinity 
data; the anomeric hydrogen of 221, the epimer of 220, would not be in the same space, 
Figure 42. A) Overlay of the crystal structures of salvinorin A (magenta), 220 (cyan), and 
231 (green). B) Overlay of the crystal structures of salvinorin A (magenta) and 220 (cyan). C) 
Overlay of the crystal structures of salvinorin A (magenta) and 231 (green). D) Overlay of the 
crystal strucutres of 220 (cyan) and 231 (green). 
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potentially physically interfering with binding and leading to the comparatively poor affinity. 
This also seems to explain the lower potency of 231 relative to 220; in order for the anomeric 
hydrogen of 231 to be in the same space as 220 for binding, the pyran ring itself is flipped, 
orienting the oxygen in a different position than in 220 and extending the additional methyl 
group into a region in space occupied by neither salvinorin A nor 220.  In short, in examining the 
overlaid crystal structures of salvinorin A, 220, and 231, it appears as if the KOP receptor prefers 
an eclipsed conformation (like 220) over an extended conformation (like 231), especially in 
regards to potency. 
Additional Experimental Results in a Rat Model of Relapse 
 Finally, among the compounds in the series, tetrahydropyran 220 had binding affinity and 
potency comparable to salvinorin A and also lacked a hydrolyzable ester at C-2.  It has been 
reported that ether 190, another derivative with this same structural feature, has a longer duration 
of action in vivo than salvinorin A.333  Therefore, in combination with its comparatively simpler 
synthesis and purification, 220 seemed the best candidate for further evaluation in vivo.  Using 
established methodology,289 tetrahydropyran 220 was evaluated for its effect on cocaine-induced 
drug-seeking in rats at doses of 0.3 mg/kg and 1 mg/kg (Figure 43).320 Drug self-administration 
studies in animals can be used as a model of addiction relapse phenomena in humans;334-335 if a 
compound is able to reduce or prevent reinstatement of extinguished cocaine self-administration 
in rats, it may be a useful pharmacotherapy for the treatment of drug abuse.  
 Briefly, the rats were trained on a fixed ratio 5 schedule of reinforcement for cocaine self-
administration where a single cocaine infusion was given (0.5 mg/kg/infusion, paired with light 
cue) for every 5 correct lever presses.  The first phase involved 2 h sessions until responding  
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showed less than 20% variation across three consecutive days (cocaine baseline).  In phase 2, 
cocaine was replaced with heparinized saline and daily 2 h sessions continued in the same 
operant chambers until active lever presses were < 20 for a session (typically 2–3 days).  When 
the extinction criteria were met, reinstatement of cocaine-induced cocaine-seeking was tested the 
following day.  Rats received i.p. injections of vehicle (75% DMSO), tetrahydropyran 220 (0.3 
mg/kg or 1 mg/kg), or salvinorin A (108, 0.3 mg/kg) 5–10 min prior to a priming injection of 
cocaine (20 mg/kg i.p.).  Immediately following the cocaine injection, rats were placed into the 
Figure 43. The effect of 220 on cocaine-induced drug-seeking.  In the first phase (cocaine 
baseline), the active lever delivered an infusion of cocaine.  Recorded active lever responses 
consisted of access to cocaine (0.5 mg/kg/infusion) for a period of 2 h in operant chambers.  
At the beginning of the second phase (extinction), cocaine was replaced with sterile 
heparinized saline and responses were recorded for 2 h, until active lever responses were < 
20 for a 2 h daily session.  At the beginning of the third phase, animals received an i.p. 
injection of vehicle (75% DMSO, N = 7), 220 (0.3 mg/kg, N = 3), 220 (1 mg/kg, N = 6), or 
salvinorin A (108) (0.3 mg/kg, N = 7) 5–10 min prior to a priming injection of cocaine (20 
mg/kg).  Responding in phase 3 was measured for 2 h (±SEM). 
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operant chamber and responding was recorded for a further 2 h.  The results show a statistically 
significant reduction in responding between vehicle and the 1 mg/kg dose of 220.  In fact, the 1 
mg/kg dose of 220 attenuated responding comparably to 0.3 mg/kg salvinorin A, the positive 
control, which has previously been shown to attenuate cocaine-induced reinstatement of drug-
seeking at a dose of 0.3 mg/kg or greater.289  This finding represents the first example of a 
salvinorin A analog that has demonstrated anti-addictive capabilities. 
Conclusions 
 C-2 modified derivatives of salvinorin A were synthesized in order to further describe the 
SAR of salvinorin A while identifying analogs with more desirable pharmacological profiles 
than the parent molecule.  Alkyl chain ethers at the C-2 position have been reported to have 
improved KOP receptor affinity and potency compared to salvinorin A.  However, such 
derivatives are rotationally flexible and may adopt different conformations when bound with the 
KOP receptor, and the oxygen atom may be able to participate in new hydrogen bonding 
interactions.  Thus, the focus of the series of compounds synthesized was to examine the 
molecular basis for the reported improved KOP receptor affinity and potency of C-2 alkoxy 
ethers. 
 Pharmacological evaluation of the C-2 analog series revealed some preferences inherent 
in the KOP receptor binding pocket.  First, there was a stereochemical preference observed.  
Compounds 220, 223a, and 232a had consistently much better affinity and/or potency than their 
epimers 221, 223b, and 232b (which was actually completely inactive).  Further, compounds 
222a,b, the tetrahydrofurans and smallest cyclic analogs, showed no preference for 
configuration, implying that their smaller size might have eliminated a binding interaction in the 
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receptor, negating the influence of stereochemistry.  Additionally, through examination of the 
crystal structures of tetrahydropyran 220 and methyltetrahydropyran 231, related cyclic 
derivatives with differing potencies, it was revealed their anomeric hydrogens occupied the same 
space, indicating that a different orientation might be unfavorable for KOP affinity.  Further, the 
oxygen atoms of the pyran rings were oriented differently from each other, resulting in the 
additional methyl of 231 extending into space beyond 220; since 231 had the lesser potency this 
implies that an extended conformation is not favorable for KOP receptor potency.  Second, there 
were steric limitations observed in the binding pocket.  Compounds 224a,b, the brominated 
analogs, had no affinity for the KOP receptor while their related, non-brominated analogs 
(223a,b) did have affinity.  This implies that the brominated derivatives 224a,b were too large to 
bind to the receptor or other factors were involved.  Finally, the possibility of hydrogen bonding 
interactions not used by salvinorin A was uncovered.  In examining overlaid crystal structures of 
salvinorin A and tetrahydropyran 220, it was revealed that the pyran oxygen atom of 220 reaches 
a region of space not occupied by heteroatoms from salvinorin A.  Since 220 has similar affinity 
and potency to salvinorin A, this implies that it is able to interact with features in the receptor 
binding pocket that are different than those used by salvinorin A.  In an interesting twist, when 
compounds 191 and 232b were screened at 10 M at DOP and MOP receptors in the [35S]GTP-
-S functional assay format, 191 appeared to be a full DOP and partial MOP agonist, and 232b 
appeared to be a partial DOP agonist.  These results need to be further investigated and 
confirmed with additional in vitro pharmacological evaluation, but they do indicate a need for 
further SAR development of the salvinorin A scaffold, especially in regard to C-2 position 
modifications. 
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 Further evaluation of tetrahydropyran 220 for its effects on cocaine-induced drug-seeking 
in rats revealed that 220 was able to significantly attenuate cocaine-induced drug-seeking 
behavior at a dose of 1 mg/kg.  The effects were very comparable to the effects of 0.3 mg/kg 
salvinorin A, a dose previously reported to attenuate the same drug-seeking behavior in the same 
assay.  Thus, tetrahydropyran 220 represents the first example of a salvinorin A analog that has 
experimentally demonstrated anti-addictive capabilities. 
Future Directions 
It is vital that the SAR exploration of salvinorin A at opioid receptors continue, especially 
since pharmacological evaluation of C-2 constrained derivatives of salvinorin A has revealed that 
there may be features within the KOP receptor binding pocket that are available for binding 
interactions not used by salvinorin A.  Given the recent publication of the KOP receptor co-
crystal structure, further structure-based development of neoclerodane diterpenes promises to 
yield additional useful analogs with opioid activity and potential anti-addictive properties. 
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CHAPTER 5: EXPERIMENTAL PROCEDURES FOR SALVINORIN A ANALOGS 
Chemistry 
General Procedures.  Unless otherwise indicated, all reagents were purchased from 
commercial suppliers and are used without further purification.  All melting points were 
determined on a Thomas–Hoover capillary melting apparatus and are uncorrected.  NMR spectra 
were recorded on a Bruker Avance-300 spectrometer, Bruker DRX-400 with qnp probe or a 
Bruker AV-500 with cryoprobe using  values in ppm (TMS as internal standard) and J (Hz) 
assignments of 1H resonance coupling. High resolution mass spectrometry data was collected on 
either a LCT Premier (Waters Corp., Milford, MA) time of flight mass spectrometer or an 
Agilent 6890 N gas chromatograph in conjunction with a Quatro Micro GC mass spectrometer 
(Micromass Ltd, Manchester UK).  Thin-layer chromatography (TLC) was performed on 0.25 
mm plates Analtech GHLF silica gel plates using mixtures of EtOAc/n-hexanes as the solvent 
system.  Spots on TLC were visualized when appropriate with 254 nm UV light, 
phosphomolybdic acid in ethanol, or vanillin in ethanol.  Column chromatography was 
performed with Silica Gel (32–63  particle size) from MP Biomedicals (Solon, OH).  Analytical 
HPLC was carried out on an Agilent 1100 Series Capillary HPLC system with diode array 
detection at 209 nm, 214 nm, and 235 nm on a Phenomenex Luna C18 column (250 × 10.0 mm, 
5 m) with isocratic elution in mixtures of CH3CN/H2O as noted at a flow rate of 5.0 mL/min. 
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Salvinorin B (123).  Salvinorin A (108) was extracted from commercially available dried 
S. divinorum leaves and converted to salvinorin B (123) as previously described by Tidgewell et 
al.309  Na2CO3 (1.96 g, 18.5 mmol, 4 equiv.) was added to a suspension of salvinorin A (2.00 g, 
4.62 mmol) in methanol (100 mL).  The reaction mixture was stirred at room temperature for 4 h, 
after which time the solvent was removed in vacuo.  The residue was dissolved in methylene 
chloride (100 mL) and washed with 2 N HCl (2 × 60 mL), H2O (50 mL), and brine (50 mL).  The 
organic layer was dried over Na2SO4, filtered, and the solvent removed in vacuo.  The residue 
was triturated from EtOAc/n-hexanes to afford 1.4607 g of salvinorin B (81% yield) as a light 
green to off-white powder.  Spectral data in agreement with reported.309  
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 2-(furan-3-yl)-9-(methoxymethoxy)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (190). 
Chloromethyl methyl ether (0.195 mL, 2.56 mmol, 5 equiv.) was added in a drop wise manner to 
a solution of 123 (0.200g, 0.512 mmol, 1 equiv.) and N,N-diisopropylethylamine (0.446 mL, 
2.56 mmol, 5 equiv.) in anhydrous methylene chloride (20 mL) under an argon atmosphere.  The 
mixture was stirred at room temperature overnight.  The reaction mixture was washed with 
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saturated aqueous NaHCO3 (3 × 10 mL), brine (10 mL), dried over Na2SO4, filtered, and the 
solvent removed in vacuo.  The remaining residue was purified by flash column chromatography 
using EtOAC/n-hexanes (1:3) to afford 0.0894 g (41% yield) as a white powder.  HPLC in 60% 
MeCN/40% H2O, tR = 4.778 min; purity = 99.1%.  Spectroscopic information was in agreement 
with published data.311, 319 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-(ethoxymethoxy)-2-(furan-3-yl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (191).  
Chloromethyl ethyl ether (0.475 mL, 5.12 mmol, 5 equiv.) was added in a drop wise manner to a 
solution of 123 (0.400 g, 1.02 mmol, 1 equiv.) and N,N-diisopropylethylamine (0.890 mL, 5.12 
mmol, 5 equiv.) in anhydrous methylene chloride (40 mL) under an argon atmosphere.  The 
mixture was stirred at room temperature overnight.  TLC indicated that starting material was still 
present after 16 h, thus an additional 5 equiv. (0.475 mL, 5.12 mmol) of chloromethyl ethyl ether 
was added and the mixture stirred for an additional 24 h.  The reaction mixture was washed with 
saturated aqueous NaHCO3 (3 × 40 mL), brine (40 mL), dried over Na2SO4, filtered, and the 
solvent removed in vacuo.  The remaining residue was purified by flash column chromatography 
using EtOAC/n-hexanes (2:3) to afford a brown oil, which was subsequently triturated from 
DCM/n-hexanes to give 0.2487 g (54% yield) as a white powder.  HPLC in 60% MeCN/40% 
H2O, tR = 7.151 min; purity = 98.1%.  Spectroscopic information was in agreement with 
published data.319  
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-
((R)-tetrahydro-2H-pyran-2-yloxy)dodecahydro-1H-benzo[f]isochromene-7-carboxylate 
(220) and (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 2-(furan-3-yl)-6a,10b-dimethyl-4,10-
dioxo-9-((S)-tetrahydro-2H-pyran-2-yloxy)dodecahydro-1H-benzo[f]isochromene-7-
carboxylate (220).  3,4-dihydro-2H-pyran (0.579 mL, 6.16 mmol, 8 equiv.) was added to a 
solution of 123 (0.300 g, 0.768 mmol, 1 equiv.) and pyridinium p-toluene sulfonate (60 mg, cat.) 
in anhydrous methylene chloride (30 mL) at 0 °C under an argon atmosphere.  The mixture was 
allowed to warm to room temperature and stirred for 5 h.  The reaction was quenched with 
triethylamine (100 L) and the solvent was removed in vacuo.  The remaining residue was 
purified by flash column chromatography using EtOAC/n-hexanes (3:7) to give 0.0939 g (220) 
Rf = 0.56 (EtOAc/n-hexanes 1:1) and 0.0560 g (220) Rf = 0.48 (EtOAc/n-hexanes 1:1) as white 
powders (41% combined yield).  HPLC in 60% MeCN/40% H2O, tR = 7.902 min; purity = 
99.2% (220) and HPLC in 60% MeCN/40% H2O, tR = 7.200 min; purity = 98.5% (220).  
Spectroscopic information was in agreement with reported data.319  
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-
((R)-tetrahydrofuran-2-yloxy)dodecahydro-1H-benzo[f]isochromene-7-carboxylate and 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-((S)-
tetrahydrofuran-2-yloxy)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (222a and 
222b).  2,3-dihydrofuran (0.465 mL, 6.15 mmol 8 equiv.) was added to a solution of 123 (0.300 
g, 0.768 mmol, 1 equiv.) and pyridinium p-toluene sulfonate (60 mg, cat.) in anhydrous 
methylene chloride (30 mL) at 0 °C under an argon atmosphere.  The mixture was allowed to 
warm to room temperature and stirred overnight.  The reaction was quenched with triethylamine 
(100 L) and the solvent was removed in vacuo.  The remaining residue was purified by flash 
column chromatography using EtOAC/n-hexanes (3:7) to give 0.1497 g (222a) Rf = 0.44 
(EtOAc/n-hexanes 2:5) and 0.0888 g (222b) Rf = 0.31 (EtOAc/n-hexanes 2:5) as white powders 
(68% combined yield).  222a:  1H NMR (500 MHz, CDCl3) δ 7.42 (dt, J = 0.8, 1.6, 1H), 7.40 (t, 
J = 1.7, 1H), 6.38 (dd, J = 0.8, 1.8, 1H), 5.54 (dd, J = 5.0, 11.7, 1H), 5.26 (d, J = 4.1, 1H), 4.21 
(dd, J = 7.8, 12.1, 1H), 3.86 (dd, J = 6.3, 7.5, 2H), 3.71 (s, 3H), 2.70 (dd, J = 3.4, 13.4, 1H), 2.55 
(dd, J = 5.1, 13.3, 1H), 2.29 (ddd, J = 3.4, 7.4, 13.4, 1H), 2.20 – 2.08 (m, 3H), 2.06 – 1.92 (m, 
3H), 1.88 – 1.80 (m, 1H), 1.77 (dt, J = 3.0, 13.3, 1H), 1.69 – 1.59 (m, 2H), 1.54 (dd, J = 8.3, 
21.1, 2H), 1.46 (s, 3H), 1.10 (s, 3H). 13C NMR (126 MHz, CDCl3)  206.90, 171.97, 171.29, 
143.74, 139.36, 125.34, 108.35, 103.43, 77.19, 71.99, 67.28, 64.25, 53.99, 51.83, 51.52, 43.58, 
41.99, 38.19, 35.51, 33.10, 32.29, 23.19, 18.15, 16.44, 15.20.  HRMS (m/z): [M+Na] calcd for 
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C25H32O8Na, 483.1995; found 483.1997 0.4 ppm.  HPLC in 60% MeCN/40% H2O, tR = 5.013 
min; purity = 95.2%.  222b:  1H NMR (500 MHz, CDCl3) δ 7.43 (d, J = 0.7, 1H), 7.40 (t, J = 1.7, 
1H), 6.39 (dd, J = 0.7, 1.7, 1H), 5.55 (dd, J = 5.1, 11.7, 1H), 5.19 (d, J = 4.6, 1H), 4.14 (dd, J = 
7.3, 12.4, 1H), 3.97 (td, J = 6.0, 8.0, 1H), 3.82 (td, J = 6.1, 7.8, 1H), 3.71 (s, 3H), 2.66 (dd, J = 
3.3, 13.5, 1H), 2.55 (dd, J = 5.1, 13.4, 1H), 2.40 (ddd, J = 3.3, 7.1, 13.3, 1H), 2.17 – 2.02 (m, 
6H), 1.98 – 1.90 (m, 1H), 1.90 – 1.83 (m, 1H), 1.78 (dt, J = 3.1, 13.3, 1H), 1.67 – 1.57 (m, 2H), 
1.53 (d, J = 4.3, 1H), 1.47 (s, 3H), 1.10 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 205.35, 171.98, 
171.35, 143.71, 139.44, 125.37, 108.43, 102.04, 77.43, 72.03, 67.63, 64.35, 53.86, 51.85, 51.54, 
43.47, 42.03, 38.23, 35.48, 32.33, 31.82, 23.30, 18.18, 16.39, 15.18.  HRMS (m/z): [M+K] calcd 
for C25H32O8K, 499.1734; found 499.1731, 0.6 ppm.  HPLC in 60% MeCN/40% H2O, tR = 4.393 
min; purity = 95.2%. 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-((R)-1-ethoxyethoxy)-2-(furan-3-yl)-
6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate and 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-((S)-1-ethoxyethoxy)-2-(furan-3-yl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (223a and 223b).  
A suspension of 123 (0.200 g, 0.512 mmol) and pyridinium p-toluene sulfonate (20 mg, cat.) in 
ethyl vinyl ether (20 mL) was heated to reflux for 2 h.  The solvent was removed in vacuo and 
the remaining residue was purified by flash column chromatography using EtOAC/n-hexanes 
(3:7) to give 0.0350 g (223a) Rf = 0.28 (EtOAc/n-hexanes 3:7) and 0.0156 g (223b) Rf = 0.21 
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(EtOAc/n-hexanes 3:7) as white powders (21% combined yield).  HPLC in 50%  MeCN/50% 
H2O, tR =  10.596 min; purity = 95.0% (223a) and HPLC in 50% MeCN/50% H2O, tR =  8.769 
min; purity = 81.9% (223b). Spectroscopic information was in agreement with reported data.319  
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-((R)-1-bromo-2-ethoxypropan-2-yloxy)-2-
(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate and (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-((S)-1-bromo-2-ethoxypropan-2-
yloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate (224a and 224b).  Ethyl vinyl ether (0.184 mL, 1.92 mmol, 2.5 equiv) was added in 
a dropwise fashion to a solution of bromine (0.080 mL, 1.54 mmol, 2 equiv) in anhydrous 
methylene chloride (15 mL) at 0° C under an argon atmosphere, turning the solution colorless.  
The reaction was allowed to stir for 15 minutes.  N,N-diisopropylethylamine (0.535 mL, 3.07 
mmol, 4 equiv) was then added to the reaction mixture, followed by the dropwise addition of a 
suspension of 123 (0.300 g, 0.768 mmol, 1 equiv) in anhydrous methylene chloride (15 mL).  
The reaction stirred for 24 h without recharging the ice bath.  The reaction mixture was then 
diluted with methylene chloride (20 mL) and extracted with saturated aqueous NaHCO3 (3 × 50 
mL).  The combined aqueous layers were washed with methylene chloride (50 mL).  The 
combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, and the 
solvent removed in vacuo.  The remaining residue was purified by HPLC with an isocratic 
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solvent gradient of 50% MeCN/50% H2O and a flow rate of 3 mL/min to give 0.0230 g (224a) Rf 
= 0.63 (EtOAc/n-hexanes 2:5) and 0.0239 g (224b) Rf = 0.56 (EtOAc/n-hexanes 2:5) as white 
powders (11% combined yield).  224a:  1H NMR (500 MHz, C6D6) δ 7.11 – 7.09 (m, 1H), 7.04 
(t, J = 1.7, 1H), 6.13 (dd, J = 0.7, 1.7, 1H), 5.16 (dd, J = 5.0, 11.8, 1H), 4.65 (dd, J = 4.2, 6.3, 
1H), 3.76 – 3.70 (m, 1H), 3.65 – 3.54 (m, 2H), 3.30 (s, 3H), 3.27 (dd, J = 4.2, 10.7, 1H), 3.16 
(dd, J = 6.3, 10.7, 1H), 2.29 (dd, J = 5.2, 13.1, 1H), 2.24 – 2.19 (m, 2H), 2.17 – 2.09 (m, 1H), 
2.06 (dd, J = 7.3, 9.9, 1H), 1.46 (ddd, J = 3.3, 5.9, 10.2, 2H), 1.38 (d, J = 14.6, 3H), 1.25 (d, J = 
2.5, 4H), 1.04 (t, J = 7.0, 3H), 0.86 (s, 3H).  13C NMR (126 MHz, C6D6) δ 205.44, 171.96, 
170.34, 144.15, 139.69, 126.91, 108.98, 100.90, 77.37, 71.82, 64.19, 62.26, 53.97, 51.66, 51.58, 
43.93, 42.04, 38.52, 35.88, 33.40, 32.51, 19.01, 16.54, 15.63, 15.46.  HRMS (m/z): [M+Na] calcd 
for C25H33BrO8Na, 563.1257; found 563.1265, 1.4 ppm.  HPLC in 60% MeCN/40% H2O, tR = 
9.104 min; purity = >99.9%.   224b: 1H NMR (500 MHz, C6D6) δ 7.10 – 7.07 (m, 1H), 7.05 (t, J 
= 1.7, 1H), 6.12 (dd, J = 0.8, 1.8, 1H), 5.17 (dd, J = 5.0, 11.7, 1H), 4.92 (dd, J = 3.8, 7.4, 1H), 
3.85 – 3.79 (m, 1H), 3.55 (dd, J = 3.8, 10.9, 1H), 3.41 (dq, J = 7.0, 9.0, 1H), 3.33 – 3.23 (m, 5H), 
2.29 – 2.18 (m, 3H), 2.10 (ddd, J = 6.5, 9.1, 9.5, 2H), 1.46 (dd, J = 7.8, 10.4, 3H), 1.24 (s, 3H), 
1.23 (s, 1H), 1.12 (dd, J = 13.4, 26.2, 2H), 1.04 (t, J = 7.0, 3H), 0.85 (s, 3H).  13C NMR (126 
MHz, C6D6) δ 206.22, 171.92, 170.31, 144.13, 139.76, 126.86, 109.03, 101.22, 77.96, 71.79, 
63.99, 60.75, 53.89, 51.61, 51.58, 43.96, 42.05, 38.45, 35.88, 33.32, 31.61, 18.99, 16.56, 15.73, 
15.41.  HRMS (m/z): [M+Na] calcd for C25H33BrO8Na, 563.1257; found 563.1265, 1.4 ppm.  
HPLC in 60% MeCN/40% H2O, tR = 9.799 min; purity = 98.5%. 
148 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-(formyloxy)-2-(furan-3-yl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (225).  
Synthesized according to the procedures of Munro et al.322  HPLC in 60% MeCN/40% H2O, tR = 
5.905 min; purity = 95%.  Spectroscopic information was in agreement with reported data.322  
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-(ethoxycarbonyloxy)-2-(furan-3-yl)-
6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (226).311, 
319  Ethyl chloroformate (0.055 mL, 0.576 mmol, 3 equiv) was added in a dropwise fashion to a 
solution of 123 (0.075 g, 0.192 mmol, 1 equiv), DMAP (0.070 g, 0.576 mmol, 3 equiv), and 
triethylamine (0.080 mL, 0.576 mmol, 3 equiv) in anhydrous methylene chloride (15 mL) under 
an atmosphere of argon.  The reaction stirred at room temperature for 24 h.  After TLC indicated 
completion of the reaction, the mixture was diluted with EtOAc (20 mL) and then extracted with 
saturated aqueous NaHCO3 (3 × 50 mL).  The combined organic layers were washed with H2O 
149 
 
(50 mL) and brine (50 mL), and then dried over Na2SO4, filtered, and the solvent was removed in 
vacuo.  The remaining residue was purified by flash column chromatography using EtOAC/n-
hexanes (2:5) to give 0.0681 g (77% yield) Rf = 0.40 (EtOAc/n-hexanes 2:5) and as white 
powder.  1H NMR (500 MHz, CDCl3) δ 7.42 (s, 1H), 7.40 (t, J = 1.7, 1H), 6.38 (d, J = 1.0, 1H), 
5.54 (dd, J = 5.1, 11.7, 1H), 4.98 (dd, J = 7.7, 12.4, 1H), 4.30 – 4.18 (m, 2H), 3.73 (s, 3H), 2.75 
(dd, J = 3.7, 13.1, 1H), 2.54 (dd, J = 5.2, 13.4, 1H), 2.43 – 2.28 (m, 2H), 2.20 – 2.17 (m, 1H), 
2.08 (dd, J = 2.9, 11.7, 1H), 1.83 – 1.76 (m, 1H), 1.68 – 1.62 (m, 1H), 1.58 (s, 3H), 1.46 (s, 3H), 
1.34 (t, J = 7.1, 3H), 1.12 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 201.77, 171.40, 171.09, 
154.19, 143.74, 139.48, 125.18, 108.41, 77.61, 72.01, 64.74, 64.02, 53.43, 52.04, 51.39, 43.34, 
42.04, 38.11, 35.46, 30.65, 18.12, 16.40, 15.17, 14.17.  HRMS (m/z): [M+Na] calcd for 
C24H30O9Na, 485.1788; found 485.1804, 3.3 ppm.  HPLC in 60% MeCN/40% H2O, tR = 7.645 
min; purity = 95.8%. 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-(ethylcarbamoyloxy)-2-(furan-3-yl)-
6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (227).  
Synthesized according to the procedures of Beguin et al.311  HPLC in 60% MeCN/40% H2O, tR = 
5.074 min; purity = >99.9%.  Spectroscopic information was in agreement with reported data.311 
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(R)-hept-6-en-2-ol (R-228).  Synthesized according to the procedures of Elzner et al.329  
To Mg turnings (834 mg, 34.3 mmol, 2 equiv.) and I2 (cat.) in an oven-dried 3-neck flask under 
an atmosphere of argon was added approximately 5 mL of a solution of 4-bromo-1-butene (2.6 
mL, 25.7 mmol, 1.5 equiv.) in 25 mL anhydrous THF via dropping funnel.  The suspension 
turned orange-brown and was heated with a heat gun until the color spontaneously lightened to a 
very light grey-brown (approximately 2 minutes of heating).  The rest of the 4-bromo-1-butene 
solution was then added slowly via dropping funnel, as the reaction mixture was heated to reflux.  
When the addition was finished, the reaction mixture was allowed to continue refluxing for an 
additional 20 minutes.  The mixture was allowed to cool to room temperature, then cooled to -78 
°C, and CuI (490 mg, 2.57 mmol, 0.15 equiv.) was added followed by an additional 10 mL of 
anhydrous THF.  The reaction stirred at -78 °C for 30 minutes.  After this time (R)-(+)-propylene 
oxide (1.2 mL, 17.1 mmol) was added at -78 °C in a dropwise manner.  The reaction mixture 
was then warmed to -10 °C and allowed to stir overnight without recharging the ice-brine bath.  
The now dark brown-black reaction mixture was quenched by carefully pouring it into 200 mL 
of 1:1 sat. aq. NH4Cl:H2O at 0 °C and stirring for 1 h.  After this time, the mixture had turned 
bright blue and was then extracted with diethyl ether (3 × 50 mL).  The organic layers were 
collected, dried over Na2SO4, filtered, and the solvent removed in vacuo.  The residue was 
purified by flash column chromatography using EtOAC/n-hexanes (1:5) to give 1.3826 g (71% 
yield) Rf = 0.34 as a light yellow oil. 
1H NMR (500 MHz, CDCl3)  5.81 (ddt, J = 6.7, 10.2, 16.9, 
1H), 5.07 – 4.92 (m, 2H), 3.80 (s, 1H), 2.13 – 2.02 (m, 2H), 1.61 – 1.40 (m, 4H), 1.19 (d, J = 6.2, 
3H).  13C NMR (126 MHz, CDCl3)  138.71, 114.61, 68.02, 38.73, 33.69, 25.03, 23.53. 
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(S)-hept-6-en-2-ol (S-228).  Synthesized from (S)-(-)-propylene oxide following the 
procedure described for R-228 to give 1.3727 g (70% yield) Rf = 0.34 (EtOAc/n-hexanes 1:4) as 
a light yellow oil.  1H NMR (500 MHz, CDCl3)  5.81 (ddt, J = 6.7, 10.2, 16.9, 1H), 5.07 – 4.91 
(m, 2H), 3.81 (dd, J = 5.7, 11.5, 1H), 2.14 – 2.01 (m, 2H), 1.57 – 1.40 (m, 4H), 1.19 (d, J = 6.2, 
3H).  13C NMR (126 MHz, CDCl3)  138.71, 114.61, 68.03, 38.73, 33.69, 25.03, 23.53. 
 
(6R)-6-methyltetrahydro-2H-pyran-2-ol (R-229).  Synthesized according to the 
procedures of Yang et al.330 To a solution of alcohol R-228 (500 mg, 4.38 mmol) and 
RuCl3·3H2O (40 mg, 0.153 mmol, 3.5 mol%) in CH3CN:H2O (6:1, 28 mL) was added NaIO4 
(1.87 g, 8.76 mmol, 2 equiv.) in portions over 5 min.  The reaction mixture stirred for 1 h and 
was complete by TLC observation, Rf = 0.29 (EtOAc/n-hexanes 1:4).  The mixture was 
quenched with sat. aq. Na2S2O3 (30 mL), stirring for 20 min.  The layers were allowed to 
separate, and the aqueous layer was extracted with diethyl ether (3 × 30 mL).  The combined 
organic layers were washed with H2O (50 mL), brine (50 mL), dried over Na2SO4, filtered, and 
the solvent very carefully removed in vacuo to afford the crude pyranol R-229 as a light yellow 
to orange oil which was immediately and entirely carried on to acetylation without further 
purification.  
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(6S)-6-methyltetrahydro-2H-pyran-2-ol (S-229).  Synthesized from S-228 following 
the procedure described for R-229. 
 
(6R)-6-methyltetrahydro-2H-pyran-2-yl acetate (R-230).  Synthesized from the crude 
product R-229 according to the procedures of Coombs et al.331  To a solution of crude alcohol R-
229 (4.38 mmol) in anhydrous methylene chloride (15 mL) at 0 °C under an atmosphere of argon 
was added DMAP (54 mg, 0.438 mmol, 0.1 equiv.) and acetic anhydride (621 L, 6.57 mmol, 
1.5 equiv.), followed by triethylamine (1.22 mL, 8.76 mmol, 2 equiv.) in a dropwise manner.  
The reaction stirred at 0 °C for 20 min and was complete by TLC observation, Rf = 0.71 
(EtOAc/n-hexanes 1:2).  The reaction was quenched by the addition of sat. aq. NaHCO3 (20 
mL).  The organic layer was washed with 1:1 H2O:NaHCO3 (2 × 20 mL).  The combined 
aqueous layers were extracted with methylene chloride (2 × 20 mL).  Finally, the combined 
organic layers were washed with H2O (50 mL), brine (50 mL), dried over Na2SO4, filtered, and 
the solvent very carefully removed in vacuo to afford the crude acetylated pyran R-230 as a light 
yellow to orange-brown oil which was entirely carried on to coupling reactions without further 
purification. 
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(6S)-6-methyltetrahydro-2H-pyran-2-yl acetate (S-230).  Synthesized from S-229 
following the procedure described for R-230. 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 2-(furan-3-yl)-6a,10b-dimethyl-9-(((2S,6S)-6-
methyltetrahydro-2H-pyran-2-yl)oxy)-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate (231). Synthesized following the procedures of Magauer et al.332  To a solution of 
123 (250 mg, 0.640 mmol) in anhydrous 1,2-dichloroethane (20 mL) under an atmosphere of 
argon was added pyridinium p-toluene sulfonate (8 mg, 0.032 mmol, 0.05 equiv.) followed by 
crude pyran S-230 (4.38 mmol, 6.8 equiv.) in anhydrous 1,2-dichloroethane (5 mL).  The 
reaction was heated to 80 °C for 6 – 8 h, after which time additional pyridinium p-toluene 
sulfonate (8 mg, 0.032 mmol, 0.05 equiv.) was added, and the reaction was continued through 24 
h.  The reaction mixture was then allowed to cool to room temperature and diluted with EtOAc 
(70 mL).  The organic layers were washed with sat. aq. NaHCO3 (3 × 50 mL), H2O (50 mL), 
brine (50 mL), dried over Na2SO4, filtered, and the solvent removed in vacuo.  The single 
product was purified by flash column chromatography using EtOAc/n-hexanes (1:2) and 
triturated from EtOAc/Et2O/n-hexanes to give 0.0277 g (9% yield) Rf = 0.49 (EtOAc/n-hexanes 
2:3) as a white powder. 1H NMR (500 MHz, CDCl3)  7.43 – 7.38 (m, 2H), 6.37 (s, 1H), 5.53 
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(dd, J = 5.0, 11.7, 1H), 4.92 (d, J = 3.0, 1H), 4.26 (dd, J = 7.9, 11.9, 1H), 3.83 (dd, J = 5.4, 10.1, 
1H), 3.73 (s, 3H), 2.73 (dd, J = 4.0, 12.9, 1H), 2.52 (dd, J = 5.1, 13.3, 1H), 2.34 – 2.09 (m, 4H), 
2.06 – 2.02 (m, 1H), 1.94 – 1.74 (m, 4H), 1.63 (dd, J = 8.2, 12.9, 2H), 1.56 – 1.48 (m, 2H), 1.46 
(s, 3H), 1.34 – 1.21 (m, 2H), 1.12 (d, J = 4.7, 6H). 13C NMR (126 MHz, CDCl3)  207.05, 
171.99, 171.28, 143.74, 139.35, 125.29, 108.32, 97.12, 76.52, 72.01, 65.61, 64.23, 54.09, 51.88, 
51.53, 43.55, 42.02, 38.26, 35.49, 32.89, 32.77, 29.03, 21.88, 18.16, 17.66, 16.49, 15.22.  HRMS 
(m/z): [M+Na] calcd for C27H36O8Na, 511.2308; found 511.2297, 2.2 ppm.  HPLC in 60% 
MeCN/40% H2O, tR = 13.376 min; purity = 98.2%. 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 2-(furan-3-yl)-6a,10b-dimethyl-9-(((2R,6R)-
6-methyltetrahydro-2H-pyran-2-yl)oxy)-4,10-dioxododecahydro-1H-benzo[f]isochromene-
7-carboxylate (232a) and (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 2-(furan-3-yl)-6a,10b-
dimethyl-9-(((2S,6R)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (232b).  Synthesized following the procedures of Magauer 
et al.332  To a solution of 123 (250 mg, 0.640 mmol) in anhydrous 1,2-dichloroethane (20 mL) 
under an atmosphere of argon was added pyridinium p-toluene sulfonate (8 mg, 0.032 mmol, 
0.05 equiv.) followed by crude pyran R-230 (4.38 mmol, 6.8 equiv.) in anhydrous 1,2-
dichloroethane (5 mL).  The reaction was heated to 80 °C for 6 – 8 h, after which time additional 
pyridinium p-toluene sulfonate (8 mg, 0.032 mmol, 0.05 equiv.) was added, and the reaction was 
continued through 24 h.  The reaction mixture was then allowed to cool to room temperature and 
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diluted with EtOAc (70 mL).  The organic layers were washed with sat. aq. NaHCO3 (3 × 50 
mL), H2O (50 mL), brine (50 mL), dried over Na2SO4, filtered, and the solvent removed in 
vacuo.  The diastereomer products were purified from unreacted and excess starting material by 
flash column chromatography using EtOAC/n-hexanes (3:7) to give 0.5911 g as a light yellow 
powder.  The diastereomer products were then separated from each other by HPLC with an 
isocratic solvent gradient of 50% MeCN/50% H2O and a flow rate of 5 mL/min to give 0.0226 g 
(232a) Rf  = 0.31 (EtOAc/n-hexanes 2:3) and 0.0246 g (232b) Rf = 0.27 (EtOAc/n-hexanes 2:3) 
as off-white powders (15% combined yield).  232a: 1H NMR (500 MHz, CDCl3)  7.46 – 7.38 
(m, 2H), 6.41 (s, 1H), 5.55 (dd, J = 5.0, 11.8, 1H), 4.44 (dd, J = 2.0, 9.3, 1H), 4.32 (dd, J = 7.5, 
12.2, 1H), 3.70 (s, 3H), 3.48 – 3.40 (m, 1H), 2.71 (dd, J = 3.2, 13.5, 1H), 2.56 (dd, J = 5.1, 13.3, 
1H), 2.46 – 2.38 (m, J = 7.4, 1H), 2.31 – 2.09 (m, 3H), 2.06 – 1.93 (m, 2H), 1.90 – 1.73 (m, J = 
13.3, 3H), 1.70 – 1.60 (m, 2H), 1.52 (d, J = 16.8, 2H), 1.47 (s, 3H), 1.25 (s, 2H), 1.19 (d, J = 6.2, 
3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3)  206.90, 171.82, 171.25, 143.73, 139.43, 
125.42, 108.35, 101.68, 78.26, 72.31, 71.97, 64.24, 53.98, 51.83, 51.65, 43.78, 41.97, 38.19, 
35.54, 32.94, 32.25, 30.61, 21.98, 21.62, 18.16, 16.49, 15.18.  HRMS (m/z): [M+Na] calcd for 
C27H36O8Na, 511.2308; found 511.2323, 2.9 ppm.  HPLC in 60% MeCN/40% H2O, tR = 10.260 
min; purity = 95.3%.  232b: 1H NMR (500 MHz, CDCl3)  7.42 – 7.38 (m, J = 1.7, 2H), 6.37 (s, 
1H), 5.56 (dd, J = 5.1, 11.7, 1H), 4.89 (d, J = 2.6, 1H), 4.18 (dd, J = 7.3, 12.3, 1H), 4.05 – 3.96 
(m, J = 4.4, 11.2, 1H), 3.71 (s, 3H), 2.67 (dd, J = 3.3, 13.4, 1H), 2.57 (dd, J = 5.1, 13.3, 1H), 2.39 
(ddd, J = 3.3, 7.2, 13.3, 1H), 2.20 – 2.12 (m, 2H), 2.06 (dd, J = 3.0, 12.0, 1H), 1.99 – 1.90 (m, J 
= 13.0, 1H), 1.82 – 1.73 (m, 2H), 1.68 – 1.59 (m, 4H), 1.56 – 1.50 (m, 2H), 1.49 (s, 3H), 1.25 (t, 
J = 19.0, 2H), 1.13 (s, 3H), 1.03 (d, J = 6.3, 3H).  13C NMR (126 MHz, CDCl3)  205.52, 171.98, 
171.30, 143.74, 139.24, 125.44, 108.28, 95.63, 77.32, 72.04, 65.64, 64.49, 53.82, 51.87, 51.55, 
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43.40, 42.08, 38.24, 35.50, 32.66, 31.80, 29.27, 21.73, 18.18, 18.05, 16.45, 15.21.  HRMS (m/z): 
[M+Na] calcd for C27H36O8Na, 511.2308; found 511.2310, 0.4 ppm.  HPLC in 60% MeCN/40% 
H2O, tR = 11.917 min; purity = 99.5%   
Binding and Efficacy Studies 
 
Radioligand Binding Studies.213 MOP receptor binding sites were labeled using [3H]D-
Ala2-MePhe4,Gly-ol5]-enkephalin ([3H]DAMGO, SA = 44 – 48 Ci/mmol) while DOP receptor 
binding sides were labeled using [3H][D-Ala2, D-Leu5]-enkephalin ([3H]DADLE, SA = 40 – 50 
Ci/mmol)  in rat brain homogenates.  KOP receptor binding sites were labeled using [3H]N-
methyl-2-phenyl-N-[(5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]dec-8-yl]acetamide 
([3H]U69,593, SA = 50 Ci/mmol).  On the day of the assay, Cell pellets were thawed on ice for 
15 minutes followed by homogenization with a polytron in 10 mL/pellet of ice-cold 10mM Tris-
HCl, pH 7.4.  The membranes were centrifuged at 30,000 × g for 10 minutes, then resuspended 
in 10 mL/pellet ice-cold 10mM Tris-HCl, pH 7.4 followed again by centrifugation at 30,000 × g 
for 10 minutes.  Membranes were then resuspended in 25°C 50 mM Tris-HCl, pH 7.4 (~100 
mL/pellet hMOP-CHO, 50 mL/pellet hDOP-CHO, and 120 mL/pellet hKOP-CHO).  All assays 
were performed in 50 mM Tris-HCl, pH 7.4 in a final assay volume of 1.0 mL, with a protease 
inhibitor cocktail: bacitracin (100 µg/mL), bestatin (10 µg/mL), leupeptin (4 µg/mL) and 
chymostatin (2 µg/mL).  Drug dilution curves were determined with buffer containing 1 mg/mL 
BSA. 20 μM levallorphan ([3H]DAMGO and [3H]DADLE) or 10 μM (-)-U69,593 (for 
[3H]U69,593 binding) was used to account for nonspecific binding.  [3H]Radioligands were used 
at concentrations of approximately 2 nM.  After 2 hours of incubation at 25°C, triplicate samples 
were filtered with Brandell Cell Harvesters (Biomedical Research & Development Inc., 
Gaithersburg, MD), over Whatman GF/B filters.  The filters were the punched into 24-well 
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plates in which 0.6 mL of LSC-cocktail (Cytoscint) was added.  After an overnight extraction, 
the samples were counted in a Trilux liquid scintillation counter at 44% efficiency.  
Approximately 30 μg protein was in each assay tube for the opioid binding assays.  The 
inhibition curves were determined by displacing a single concentration of radioligand by 10 
concentrations of drug. 
[35S]GTP--S Functional Assay.68  The [35S]GTP--S assays were conducted as 
previously described.  Buffer A is 50 mM Tris-HCl, pH 7.4, containing 100 mM NaCl, 10 mM 
MgCl2, 1 mM EDTA and buffer B is buffer A with the addition of  1.67 mM dithiothreitol (DTT) 
and 0.15% bovine serum albumin (BSA).  On the day of the assay, cells were thawed on ice for 
15 min and homogenized using a polytron in 50 mM Tris-HCl, pH 7.4, containing a protease 
inhibitor cocktail: bacitracin (100 µg/mL), bestatin (10 µg/mL), leupeptin (4 µg/mL) and 
chymostatin (2 µg/mL). The homogenate was centrifuged at 30,000 × g for 10 minutes at 4°C, 
and the supernatant discarded. The membrane pellets were then resuspended in buffer B and 
used for [35S]GTP--S binding assays.  50 µL of buffer A plus 0.1% BSA, 50 µL of GDP in 
buffer A/0.1% BSA (final concentration = 40 µM), 50 µL of drug in buffer A/0.1% bovine 
serum albumin, 50 µL of [35S]GTP--S in buffer A/0.1% BSA (final concentration = 50 pM), and 
300 µL of cell membranes (50 µg of protein) in buffer B were added in test tubes.  Final 
concentration of reagents in assay were: 50 mM Tris-HCl, pH 7.4, containing 100 mM NaCl, 10 
mM MgCl2, 1 mM EDTA, 1 mM DTT, 40 μM GDP, and 0.1% BSA. Media was incubated at 
55°C for 3 hours.  Non-specific binding was accounted for and determined using GTP--S (40 
µM).  Vacuum filtration through Whatman GF/B filters separated bound and free [35S]GTP--S.  
The filters were punched into 24-well plates followed by the addition of 0.6 mL of liquid 
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scintillation media (Cytoscint).  An overnight extraction was performed and samples were 
counted in a Trilux liquid scintillation counter at an efficiency of 27%. 
Calcium Mobilization Assay.214  All cells were maintained in F-12 nutrient medium 
(Ham), supplemented with 10% fetal bovine serum (FBS), 1% penicillin and streptomycin (p/s), 
and 0.2% normocin. Cell culture supplies were from Invitrogen (Carlsbad, CA) unless otherwise 
specified.  Chinese hamster ovary (CHO) cells stably expressing MOR-, KOR-, DOR-, or CB1-
Gαq16 were removed from their flasks using Versene and quenched with the Ham media, 
centrifuged and re-suspended in media. Cells were counted with a Cellometer Auto T4 
(Nexcelom Bioscience, Lawrence, MA) and 30,000 cells were transferred to each well of a black 
Costar 96-well optical bottom plate (Corning Corporation, Corning, NY). Each plate was 
incubated at 37°C/5% CO2 overnight to confluence. The culture media was removed from the 
plates and cells were subsequently loaded with a fluorescent calcium probe (Calcium 5 dye, 
Molecular Devices, Sunnyvale, CA) in an HBSS-based buffer containing 20 mM HEPES, 0.25% 
BSA, 1% DMSO (or 0.5% DMSO + 0.5% EtOH for CB1-expressing cells), and 10 μM 
probenecid (Sigma) in a total volume of 225 µL. Cells were incubated at 37°C/5% CO2 for 1 h 
and then stimulated with DMSO solutions of DAMGO, U69,593, DPDPE, ethanol solutions of 
CP55,940 or DMSO solutions of test compounds at various concentrations using a Flexstation 3 
plate-reader, which automatically added 25 µL of the compounds at 10X concentration to each 
well after reading baseline values for ∼17 sec. Agonist-mediated change in fluorescence (485 nm 
excitation, 525 nm emission) was monitored in each well at 1.52 sec intervals for 60 sec and 
reported for each well. Data were collected using Softmax version 4.8 (MDS Analytical 
Technologies) and analyzed using Prism software (GraphPad, La Jolla, CA). Nonlinear 
regression analysis was performed to fit data and obtain maximum response (Emax), EC50, 
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correlation coefficient (r2) and other parameters. All experiments were performed at least 2 
times to ensure reproducibility and data reported as mean ± standard error, unless noted 
otherwise. 
 X-ray Crystallography for 220.  The asymmetric unit contains one C26H34O8 molecule 
that has two slightly different conformations.  All displacement ellipsoids are drawn at the 50% 
probability level. 
 Needle-shaped single crystals of C26H34O8 are, at 100(2) K, orthorhombic, space group 
P212121 – D2
4 (No. 19)[336] with a = 6.1944(1) Å, b = 11.2496(3) Å, c = 35.8673(8) Å, V = 
2499.4(1) Å3 and Z =  4 molecules {dcalcd = 1.261 g/cm
3; a(CuK) = 0.767 mm-1}.   A full set of 
unique diffracted intensities was measured[337] (5711 0.50-wide - or -scan frames with 
counting times of 1–6 seconds) for a single-domain specimen using monochromated CuK 
radiation (= 1.54178 Å) on a Bruker Single Crystal Diffraction System equipped with Helios 
multilayer optics, an APEX II CCD detector and a Bruker MicroSTAR microfocus rotating 
anode x-ray source operating at 45kV and 60mA.  Lattice constants were determined with the 
Bruker SAINT software package using peak centers for 9928 reflections.  A total of 26136 
integrated reflection intensities having 2(CuK)< 127.30 were produced using the Bruker 
program SAINT[338]; 4076 of these were unique and gave Rint = 0.041 with a coverage which was 
99.5% complete. The data were corrected empirically for variable absorption effects using 
equivalent reflections; the relative transmission factors ranged from 0.905 to 1.000.  The Bruker 
software package SHELXTL was used to solve the structure using “direct methods” techniques.  
All stages of weighted full-matrix least-squares refinement were conducted using Fo
2 data with 
the SHELXTL Version 6.10 software package.[339]  
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 The initial structure solution revealed that the 6-membered tetrahydropyran ring was 
disordered with two preferred orientations in the crystal.  A second molecule having this 
conformation was therefore introduced into the model and the structure was refined with “whole 
molecule disorder” by restraining the bond lengths and angles for nonhydrogen atoms of the two 
molecules to have similar values. The major conformation is present 64% of the time and the 
minor conformation is present 36% of the time.  
 The final structural model incorporated anisotropic thermal parameters for all 
nonhydrogen atoms except minor-occupancy carbon atoms C1’ and C26’.  Hydrogen atoms were 
included with fixed isotropic thermal parameters and carbon atoms C1’ and C26’ were included 
with variable isotropic thermal parameters.  Mild restraints were applied to the anisotropic 
thermal parameters for 2 nonhydrogen atoms of the major-ocupancy conformer and 22 
nonhydrogen atoms of the minor-occupancy conformer.  Identical anisotropic thermal 
parameters were used for oxygen atoms O4 and O4’ which refined to essentially the same 
position in the unit cell.  All methyl groups were incorporated into the structural model as rigid 
groups (using idealized sp3-hybridized geometry and a C–H bond length of 0.98 Å) with a 
“staggered” orientation.  The remaining hydrogen atoms were included in the structural model at 
idealized positions (sp2- or sp3-hybridized geometry with C–H bond lengths of 0.95 – 1.00 Å).  
All hydrogen atoms utilized isotropic thermal parameters that were fixed at values 1.20 
(nonmethyl) or 1.50 (methyl) times the equivalent isotropic thermal parameter of the carbon 
atom to which they were covalently bonded.  A total of 598 parameters were refined using 240 
restraints, 4076 data and weights of w = 1/ [
2
(F
2
) + (0.0785 P)
2
 + (0.9339 P)], where P = [Fo
2
 + 
2Fc
2
] / 3.  Final agreement factors at convergence are:  R1(unweighted, based on F) = 0.046 for 
3704 independent absorption-corrected “observed” reflections having 2(CuK)<  127.30 and 
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I>2(I);  R1(unweighted, based on F) = 0.052 and wR2(weighted, based on F2) = 0.126 for all 
4076 independent absorption-corrected reflections having 2(CuK)< 127.30.  The largest 
shift/s.u. was 0.001 in the final refinement cycle.  The final difference map had maxima and 
minima of 0.38 and -0.34 e-/Å
3
, respectively.  Since oxygen was the “heaviest” element present, 
the absolute configuration could not be reliably established using anomalous dispersion of the x-
rays; the “Flack” absolute structure parameter refined to a final value of 0.0(2). 
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CHAPTER 6: DISSERTATION CONCLUSIONS 
 Opioid analgesics are a mainstay in the clinic for the management and treatment of pain.  
The opioid receptor system itself has been implicated in the etiology of depression, mood 
regulation, and drug abuse.  However, there are several important drawbacks associated with 
currently known opioid receptor ligands.  Compounds that are selective agonists for the MOP 
receptor tend to produce constipation, respiratory depression, tolerance, and dependence.  While 
there is an abundance of seemingly structurally diverse MOP ligands, these molecules can 
actually be related to each other through the systematic dismantling of the morphine scaffold.  
Unfortunately, the adverse effects associated with morphine tend to carry through to synthetic 
analogs, despite extensive scaffold manipulation.  Compounds that are selective agonists for the 
KOP receptor can have a dysphoric effect, and selective antagonists of the KOP receptor tend to 
have an unusually long duration of action in vivo making for generally poor candidates for 
pharmacotherapies.  Thus there is a critical need for the identification and development of novel, 
non-morphine-based opioid ligands.  Novel chemical scaffolds that are active at opioid receptors 
have the potential to be biological probes as well as pharmacotherapies that improve upon or 
lack utterly the shortcomings associated with currently known ligands.   
This study was conducted in search of novel, non-morphine-based opioid ligands.  The 
flavonoid structural class was investigated based on literature precedent that molecules 
belonging to this class had been found to have affinity and potency at opioid receptors, as well as 
some receptor subtype selectivity.179  Two flavonoid compounds isolated from the Brazilian vine 
Dioclea grandiflora, dioclein (86) and dioflorin (87), were reported to have antinociceptive 
effects in rodents that were reversed by the opioid antagonist naloxone.200-201  However no in 
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vitro pharmacological evaluation of these compounds had been published.  In order to determine 
if dioclein and dioflorin were indeed opioid ligands and generate some SAR, dioclein and several 
simplified analogs of dioflorin were synthesized and evaluated for affinity and potency using 
radioligand binding assays (opioid receptors), the fluorescent calcium mobilization assay (opioid 
and cannabinoid receptors), and the luminescent -arrestin assay (opioid and GPR-55 receptors).  
Unfortunately, despite extensive investigation of possible biological targets, none of the 
flavonoids in this study appeared to have any activity that could explain the antinocicpetive 
effects reported in rodents.  One possible explanation is that the simplifications made to the 
dioflorin scaffold abolished any receptor activity.  Another possibility is that the compounds 
identified in the literature as the ones responsible for antinociceptive effects were contaminated 
with an undetected impurity that was actually the active constituent.  A third possibility is that 
these compounds exert their antinociceptive effects through a receptor system not examined in 
this report.  In any case, the antinociceptive effects of flavonoids isolated from Dioclea 
grandiflora require confirmation before further analog synthesis and pharmacological evaluation 
can take place. 
The neoclerodane diterpene structural class was also investigated as a source of novel 
opioid ligands.  Salvinorin A (108), a member of this class, is the first non-nitrogenous opioid 
ligand ever reported and is a selective and potent agonist at the KOP receptor.180  Modifications 
to the C-2 acetate of salvinorin A have been reported to change receptor selectivity; herkinorin 
(141), a C-2 benzoyl derivative of salvinorin A, is a selective and potent MOP receptor 
agonist.281  Alkoxy ethers at the C-2 position (e.g. 190 and 191) have been reported to improve 
KOP receptor affinity and potency.322  However, as these ethers have a significant amount of 
rotational flexibility, the structural basis for their improved profile is unknown; for example, it is 
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possible for ethoxymethyl ether 191 to adopt either an extended or an eclipsed conformation 
(Figure 35).  In is also possible that C-2 alkoxy ethers can participate in hydrogen bonding 
interactions not exploited by salvinorin A.  In order to determine the KOP receptor binding mode 
of alkoxy ethers at the C-2 position, a series of analogs was synthesized and evaluated at opioid 
receptors via radioligand binding, the [35S]GTP--S functional assay, and the fluorescent calcium 
mobilization functional assay.   
Analysis of this series of C-2 derivatives revealed several details about the salvinorin A–
KOP receptor binding pocket.  First, there is a stereochemical preference; tetrahydropyranyl 
ligands with the anomeric hydrogen in the  position (e.g. 220 and 231) had better affinity and 
potency than their epimers.  This trend likely carries through to acyclic ligands that are able to 
adopt a conformation similar to 220; ether compound 223a had higher affinity than its epimer 
223b, although the absolute configurations were not determined.  Second, there are steric 
limitations within the binding pocket.  Tetrahydrofuranyl derivatives 222a,b had only modest 
affinity for the KOP receptor and poor potency and, though epimers, were not different from 
each other.  This suggests that their smaller size may fail achieve key interactions within the 
receptor binding pocket that would differentiate them from each other and lead to potent KOP 
receptor activation.  Conversely, brominated ethers 224a,b had no affinity for the KOP receptor, 
suggesting that their increased size precluded binding.  Thirdly, in examining an overlay of the 
crystal structures of salvinorin A and 220 (Figure 42B), it is possible that 220 is able to take 
advantage of binding interactions within the receptor that salvinorin A cannot exploit; the 
tetrahydropyranyl oxygen of 220 occupies a region in space that is not occupied by heteroatoms 
in salvinorin A.  This may explain the affinity and potency of compounds like 220 and 191 as 
well; the KOP receptor binding pocket prefers an eclipsed conformation for these types of 
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ligands.  This hypothesis is supported by examining overlays of the crystal structures of 
salvinorin A, 220, and 231 (Figures 42C and 42D); the extended, methyltetrahydropyranyl ring 
of 231 is flipped and the oxygen is in roughly the same space as the carbonyl oxygen on the C-2 
acetate of salvinorin A, pushing the additional methyl group out into an empty region of space.  
The methyl group of 231 may have unfavorable interactions with the KOP receptor, resulting in 
lower potency relative to 220 and salvinorin A. 
Finally, tetrahydropyranyl compound 220 was evaluated for its ability to effect cocaine-
primed reinstatement of extinguished cocaine-seeking behavior in a rodent model of relapse.  
Compound 220 was able to attenuate drug-seeking behavior at a dose of 1.0 mg/kg,320 
comparable to the effects of 0.3 mg/kg salvinorin A, which was previously reported to attenuate 
reinstatement.289  This represents the first example of a salvinorin A derivative with 
demonstrated anti-addictive capabilities. 
Collectively, these results underscore the importance of continuing to search for novel 
scaffolds that have opioid receptor activity.  Although investigation of compounds in the 
flavonoid structural class from Dioclea grandiflora did not yield any promising molecules for 
biological probes or pharmacotherapies, investigation of the neoclerodane diterpene structural 
class was more fruitful.  Stereochemical and steric preferences of the salvinorin A–KOP receptor 
binding pocket were further elucidated, which will aid further ligand design and SAR 
development.  Further, one analog, tetrahydropyran 220, was found to have potential as a 
pharmacotherapy for drug abuse.  This confirms the utility of the salvinorin A scaffold as a 
source of novel, non-morphine-based opioid ligands. 
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APPENDIX A: 1H NMR SPECTRA 
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